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Stellingen behorende bij het proefschrift 
The many faces of facioscapulohumeral muscular dystrophy: 
opportunities and challenges oan the road to therapies
I. Hoewel het patroon van spierzwakte bij FSHD zeer karakteristiek is, bestaat er vari-
atie in de ernst en verdeling van de spieraantasting tussen families, binnen families, 
binnen verschillende spieren van één patiënt, en zelfs binnen een enkele spier. (Dit 
proefschrift)
II. Klinische variabiliteit kan helpen om het inzicht te vergroten in het pathogenetisch 
mechanisme van een ziekte, maar kan een hindernis vormen bij het ontwerpen van 
klinische trials. (Dit proefschrift)
III. De klinische en genetische variabiliteit bij FSHD wijst erop dat het fenotype het resul-
taat is van een complex samenspel van vele factoren, passend bij een multifactorieel 
ziektemodel. (Dit proefschrift) 
IV. Ondanks dat faciale zwakte het meest karakteristieke symptoom van FSHD is, is er 
zeer weinig bekend over het beloop en de consequenties hiervan. (Dit proefschrift)
V. Bij onderzoek naar FSHD moet er meer aandacht worden besteed aan verschillen in 
het ziektemechanisme en –beloop tussen verschillende spieren en lichaamsregio’s. 
(Dit proefschrift)
VI. Voor het optimaal ontwikkelen en testen van farmacologische therapieën is het nood-
zakelijk om bij iedere stap in het proces klinisch en basaal onderzoek te combineren 
en te integreren. 
VII. Het is niet mogelijk om één optimale uitkomstmaat te ontwerpen die geschikt is voor 
alle studies en alle cohorten, onafhankelijk van de ziekte(ernst), leeftijd en vele andere 
variabelen. 
VIII. Longitudinale natuurlijk beloop studies zijn een essentiële volgende stap op de weg 
naar therapieën voor FSHD.
IX. In today’s world of evidence-based medicine, a clinician’s ability to critique research 
publications, discern the nature and quality of the scientific content and interpret its 
significance is a crucial skill. (F.L. Rosenfeldt et al. 2000)
X. Onderzoekt alles, behoudt het goede. (1 Tessalonicenzen 5:21-22)
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General introduction and outline of the thesis
CLINICAL ASPECTS OF FACIOSCAPULOHUMERAL 
MUSCULAR DYSTROPHY  
A history of clinical variability 
Neuromuscular disorders are a broad group of rare disorders characterized by impaired 
muscle functioning that affect approximately 200,000 individuals in the Netherlands.1 
Until the second half of the 19th century, physicians attributed impaired muscle func-
tioning to pathology of the nerve cells that control the muscle, mainly the anterior horn 
cells. It was Duchenne de Boulogne who in 1868 first presented the concept of primary 
muscle diseases, i.e. diseases caused by pathology of the muscle itself.2 While he became 
most famous for his work on the muscle disorder that now bears his name, Duchenne 
muscular dystrophy, he was also the first to describe a patient with what is now called 
facioscapulohumeral muscular dystrophy (FSHD) (figure 1).3 This was a patient with a 
clearly different phenotype than other known muscle disorders at the time, who presented 
with pronounced facial weakness at a young age and progressive muscle weakness and 
wasting in a descending course along the limbs and the trunk. 
Figure 1. The first image published of an FSHD patient
This picture was published by Duchenne de Boulogne and shows a 13-year old boy with pronounced facial weak-
ness, scapular winging and wasting of the shoulder girdle muscles. Source: www.artandmedicine.com
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In 1885, Landouzy and Dejerine confirmed this phenotype in another patient. That was the 
first report to draw attention to the FSHD phenotype and subsequently FSHD was initially 
called ‘Landouzy-Dejerine disease’. Landouzy and Dejerine were able to perform autopsy 
on their patient and described fatty infiltration of affected muscles and the selective spar-
ing of muscles of, among others, the tongue and the extraocular muscles.4 Additionally, 
they examined the patient’s family and described an autosomal dominant pattern of inher-
itance. Importantly, they were the first to notice the variability in disease severity and age 
at onset, even within families. 
This variability within families turned out to be even larger, when Tyler and Stephens 
reported on a large FSHD kindred in Utah, USA in 1950.5 They identified 159 affected 
family members from one kindred and examined 58 of them. Remarkably, they found that 
24 of these 58 individuals (41%) were asymptomatic by self report, yet (mildly) affected 
by examination. In fact, this was the first report of what we now know as ‘asymptomatic 
gene carriers’.
The modern clinical description of FSHD was provided by Padberg in 1982 in his thesis 
called ‘facioscapulohumeral disease’.6 He examined 107 individuals from 19 families and 
provided a detailed overview of the clinical features, disease course and pattern of inher-
itance. His observations and insights defined the clinical phenotype of FSHD and are 
still considered highly accurate and relevant (box 1).7 Consequently, after more than 35 
years, the Padberg thesis remains one of most frequently cited references on the clinical 
aspects of FSHD. 
Figure 2A. A historical overview of clinical research on FSHD  
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General introduction and outline of the thesis
BOX 1 
Clinical features of facioscapulohumeral muscular dystrophy 
Facioscapulohumeral muscular dystrophy (FSHD) is a chronic progressive most often autosomal domi-
nantly inherited muscle disorder.6 With approximately 2,000 patients in the Netherlands, it is one of the 
most prevalent inherited neuromuscular disorders.8 It is characterized by weakness and wasting of the 
facial, shoulder girdle and upper arm muscles. As the disease progresses, trunk and leg muscles often 
become involved as well. Within patients, there is often a striking asymmetry in muscle involvement. 
While the pattern of muscle involvement is highly characteristic, the degree of involvement is extremely 
variable between individuals ranging from asymptomatic gene carriers to severe generalized weakness, 
with approximately 20% of patients eventually requiring a wheelchair.9-11 In most patients, disease onset 
is between age 15-30 years, although both infantile and late-onset cases occur. Even within affected 
families disease severity, penetrance and age of onset vary widely.7 Extramuscular disease manifestations 
are rare and mostly occur in infantile cases but include sensorineural hearing loss, retinal vasculopathy, 
an increased prevalence of (incomplete) right bundle branch block, restrictive lung disease, and possibly 
cognitive impairment and epilepsy.11,12 Chronic pain and fatigue are frequent complaints.13,14 Currently, 
there is no cure or pharmacological treatment available for FSHD. Treatment is focused at optimizing 
daily functioning and surveillance of extramuscular complications. A comprehensive overview of the 
clinical features of FSHD is provided in the first chapter of this thesis.
Attempts to improve muscle strength 
Until the 1980’s emphasis had been on describing the clinical phenotype. By the 1990’s, 
physicians felt that, despite the exact pathogenic mechanism being still unclear, there was 
a need to develop therapies. Therefore, various clinical trials were conducted all aiming 
to use pharmacological interventions to improve muscle strength and mass. Pilot stud-
ies were performed on prednisone and diltiazem, and randomized, placebo-controlled, 
double-blinded clinical trials on albuterol, creatine and myostatin (MYO-029).15-22 Unfortu-
nately, none of these trials showed clinical benefit and to date, no effective pharmacologic 
interventions that improve strength or slow disease progression in FSHD are available.22
Even though these clinical trials all failed to meet their primary endpoints, they did lead to 
an important step in clinical research on FSHD as they forced researchers to think about 
clinical trial design. This resulted in a standardized testing protocol including measure-
ments of muscle strength (quantitative and manual muscle testing) and functional abilities 
which was tested for reliability.23 Furthermore, researchers realized that natural history 
data is essential for the design of clinical trials, especially in a disease like FSHD with large 
clinical variability and generally slow disease progression. Subsequently, the testing pro-
tocol was applied in a natural history study including 81 patients with a follow-up for up to 
three years.24 After 18 months a small, yet significant, decline in muscle strength by both 
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quantitative and manual muscle testing, was measured. As the decline in strength was 
small and variability large, it was estimated that a two-armed clinical trial with quantitative 
muscle strength as primary outcome would require 160 patients per group and one year 
of follow-up to provide 80% power to detect complete halt of disease progression.25 This 
sample size calculation illustrated some of the challenges that were faced in the design of 
clinical trials in FSHD, i.e. a large sample size and a long follow-up period. 
To help overcome some of these challenges the first FSHD patient registry was established 
in 2000: the United States National Registry of Myotonic Dystrophy and FSHD.26 By collect-
ing patient data and contact information, this registry aimed to assist researchers in the 
recruitment of patients into clinical studies and to provide knowledge on many aspects 
of FSHD. Since 2000, additional national FSHD patient registries were established in 12 
different countries including the Netherlands. 
A paradigm shift in clinical trials
By the beginning of the 21th century, the conceptual framework for clinical trials in FSHD 
started to change. Physicians noted that FSHD comprises more than just muscle weakness 
and realized that the disease burden did not only consist of impaired muscle function. 
Multiple studies showed that factors like mobility, pain, physical activity level, the ability 
to carry out activities, and social participation, are important determinants of the FSHD 
disease burden.13,27,28 Severe fatigue was shown to be common and clinically and socially 
relevant, as it was associated more severe functional impairment in daily life.29
In addition to earlier clinical trials on pharmacological treatments, trials were initiated 
aiming to optimize symptomatic treatment and increase physical activity, self-efficacy and 
nutrition. The concept of exercise as a therapeutic option to prevent or treat a vicious circle 
of inactivity and to preserve functioning, yielded the first two trials with positive results.30,31 
Aerobic exercise and cognitive behavioral therapy (stimulating a physically active lifestyle) 
reduced fatigue and increased physical fitness. Trials on protein supplements and anti-ox-
idants however, did not show beneficial results.31,32 
The therapy of choice was not the only thing that changed in the clinical trials. While both 
in the earlier conducted trials and in the natural history study muscle strength and mass 
were the main outcomes, interest grew in other more clinically meaningful outcomes 
like daily functioning and social participation.33 The rational was that an improvement or 
decline in strength, had no intrinsic meaning in the absence of correlation to quality of life. 
So despite that the validity, reliability and sensitivity of strength measurements and func-
tional tests had been established through the natural history study and the clinical trials, 
drug regulatory agencies such as the FDA (USA) and EMA (European Union) announced 
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General introduction and outline of the thesis
their preference for the use of patient-relevant and preferably patient-reported outcome 
measures for phase III clinical trials.33,34 
Furthermore, modern imaging techniques like muscle CT and MRI became available. Ana-
tomical pictures of skeletal muscle provided detailed information on the specific pattern 
of muscle involvement.35 T1-weighted MRI images showed fatty infiltration and a decrease 
in muscle volume in affected muscles. In some patients, muscles showed hyperintense 
abnormalities on short-T1 inversion recovery (STIR) sequences (T2-weighted sequences 
with nulling of the fat signal), indicative of muscle edema.36 A further advancement was 
the development of MRI methods to quantitatively measure fatty infiltration and remain-
ing muscle tissue in affected muscles.37 With this technique individual muscles or muscle 
groups could be followed over time to measure disease progression and response to 
therapies. Both in the above mentioned clinical trial on aerobic exercise and cognitive 
behavioral therapy and in a natural history study, quantitative muscle MRI was able to 
detect changes in fatty infiltration within 4 and12 months respectively.38,39
Gradually the field of clinical trials in FSHD evolved. The natural history study in the 1990’s 
had already shown the large sample size requirements for clinical trials. Now, new clinical 
outcome measures are required to capture more clinically meaningful outcomes. The 
new imaging techniques provide opportunities to increase the sensitivity to change, but 
their relation to clinical outcome measures still has to be established. All together, the 
shift to the modern framework for clinical trials requires many tools that have to be newly 
developed or refined. Consequently, over the last few years one of the main topics in FSHD 
research has been the concept of ‘clinical trial preparedness’ (box 2). 
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BOX 2 
Clinical trial preparedness in neuromuscular disorders
Drug development in the neuromuscular field has accelerated over the last decade and various thera-
peutic approaches have been approved or are currently in the pipeline. In general, the drug development 
process is a lengthy and costly scientific, medical and regulatory process that takes an average of 14 
years and $2.7 billion for one new compound to reach the market.40 Not only in FSHD, but in most of the 
neuromuscular field, this process faces a number of specific additional challenges:41 
1. Nearly all neuromuscular disorders are rare, which can challenge the enrollment of sufficient 
numbers of patients in clinical trials.42
2. Disease progression is generally slow, requiring clinical trials with a long follow-up period.40
3.  The rate of disease progression is variable between patients, resulting in large sample size require-
ments for clinical trials to establish a treatment effect.43
Because of these challenges optimal preparation for clinical trials is critical. Two major aspects of ‘clinical 
trial preparedness’ are the facilitation of access to patients and the development of proper measurement 
instruments for all clinical trials. However, ‘clinical trial preparedness’ is a much broader concept, that 
also includes an advanced understanding of patient characteristics, natural history and factors that 
contribute to clinical variability. Only with this understanding an optimal selection of patients and clinical 
trial endpoints can be determined. Otherwise, clinical trial results are likely to be inconclusive or even 
misleading. Therefore, research in the neuromuscular field should be aimed both at the development 
of measurement instruments as well as on increasing the understanding of factors contributing to 
clinical variability. 
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UNRAVELING THE GENETIC MECHANISM OF FSHD 
A unifying genetic model
By the end of the 1980’s molecular biology had advanced and genetic research came 
into play. By the early 1990’s, linkage studies, including a large Dutch study on 10 families, 
identified the primary disease locus for FSHD on the subtelomeric region of the long arm of 
chromosome 4 (4q35) (figure 2B).44-46 Shortly after, a tandemly repeated sequence located 
at this region was identified (D4Z4 macrosatellite repeat). The size of the repeat array 
was determined by the number of D4Z4 repeat units that are 3.3 kb each.47 Monosomy 
of chromosome 4 was not associated with FSHD, indicating that at least one D4Z4 repeat 
unit is required.48 The majority of healthy individuals carry a D4Z4 repeat array of 8 or 
more units, while a reduced size of this D4Z4 repeat array (1-10 units) appeared de novo 
in sporadic FSHD patients and segregated with FSHD in the majority of familial cases.49,50 
Despite the central role of the D4Z4 macrosatellite contraction, the overlap in the D4Z4 
repeat array size between healthy individuals and FSHD patients suggested that it was 
merely a predisposing factor.49,47
Indeed, further studies indicated a more complex disease mechanism. A few years later a 
nearly identical D4Z4 repeat array was identified at chromosome 10 (10q26).51 In contrast 
to chromosome 4, contracted repeat arrays on chromosome 10 did not generally cause 
FSHD.52 
At this point, genetic testing for FSHD had become available and phenotype-genotype 
studies were initiated. Multiple studies showed a rough and inverse correlation between 
the number of D4Z4 repeat units and disease severity.53-55 However, variability in disease 
severity was large for all repeat array sizes.
This clinical variability together with the homologous locus on chromosome 10, led to the 
hypothesis that specific DNA sequences adjacent to the D4Z4 repeat array on chromo-
some 4 may render an individual susceptible for FSHD.56 In 2002, a large polymorphism 
was identified immediately distal to the D4Z4 repeat array on chromosome 4, distin-
guishing two main haplotypes that were designated 4qA and 4qB.57 While both 4qA and 
4qB alleles are equally common in the general population, FSHD was associated with 
contractions only on 4qA haplotypes.58 Additional genetic studies revealed that there were 
at least 17 genetic variants of the distal 4q region, but only three were FSHD permissive: 
the common variant 4qA161, and rare variants 4qA159 and 4qA168.59,60 
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Figure 2B. A historical overview of genetic research on FSHD  
Although specific sequence variants seemed causally related to FSHD, the pathogenic 
mechanism was still unknown. As at least one D4Z4 unit was required to develop FSHD, 
researchers focused on the structure of the D4Z4 repeat units. The D4Z4 repeat units 
were found to have a relatively closed chromatin configuration in somatic tissue of healthy 
individuals. In FSHD, the D4Z4 repeat contraction resulted in a more open chromatin 
structure in somatic cells facilitating transcriptional activity. Additionally, the D4Z4 repeat 
array appeared to contain an open reading frame encoding a putative double-homeobox 
transcription factor: DUX4.61,62 DUX4 is a transcription factor, which is normally expressed 
in the luminal cells of the testis but suppressed in somatic cells including muscle cells.63 
A biological role for DUX4 was proposed by recent studies showing that DUX4 is a cleav-
age stage transcription factor involved in zygotic genome activation.64-66 The more open 
chromatin structure in FSHD increases the chance of DUX4 being transcribed in skeletal 
muscle. However, the transcripts originating from the DUX4 gene were unstable in the 
absence of a polyadenylation signal. The identification of a polyadenylation signal imme-
diately distal to the D4Z4 repeat array only on the permissive 4qA haplotypes67, meant a 
breakthrough in genetic research on FSHD. In 2010, a unifying genetic model for FSHD 
was proposed.68 In this model, the D4Z4 repeat array contraction to 1-10 units results 
in chromatin relaxation and subsequently a higher chance of expression of the DUX4 
transcription factor that is encoded within the D4Z4 unit. Only the permissive haplotypes 
provide a polyadenylation signal to stabilize the DUX4 mRNA (figure 3, FSHD1). However, 
exactly how DUX4 expression leads to muscle cell death, is still uncertain. Thus although 
the unifying genetic model was an important step forward, many questions remained 
unanswered. Additionally, approximately 5% of all FSHD patients did not carry a repeat 
contraction and remained genetically unexplained.69 
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Figure 3. Genetic mechanisms of FSHD
In controls the D4Z4 repeat array (triangles) on chromosome 4q varies between 8 and 100 units and adopts a 
repressed chromatin structure in somatic tissue (red wavy lines) characterized by high CpG methylation (me). 
Each D4Z4 repeat contains a copy of the DUX4 gene, without a polyadenylation signal (PAS). Only on 4qA chro-
mosomes (and not on 4qB chromosomes, or chromosomes 10) the last repeat unit is followed by a third exon 
which contains a PAS which can stabilize the DUX4 transcript from the last repeat unit. FSHD is associated with 
chromatin relaxation (green wavy lines) of the D4Z4 repeat array, facilitating the stable expression of DUX4 from 
a 4qA chromosome in skeletal muscle. This chromatin relaxation is marked by, amongst others, reduced CpG 
methylation. FSHD1 is caused by a contraction of the D4Z4 repeat array to a size of 1-10 units. FSHD2 is caused 
by a mutation in a chromatin modifier (SMCHD1 or DNMT3B) in combination with the presence of a chromosome 
4 that contains a DUX4 PAS.
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Discovering genetic variability in FSHD 
While the genetic model proposed for FSHD explained approximately 95% of all FSHD 
patients, the other 5% was still unexplained. A number of patients, so called FSHD2 
patients, showed pan-chromatin relaxation of all D4Z4 repeat arrays and had at least 
one chromosome 4qA, but did not have a D4Z4 repeat contraction.69,70 In 2012, it was 
shown that in these patients mutations in the ‘structural maintenance of chromosomes 
flexible hinge domain containing 1’ (SMCHD1) gene on chromosome 18p can also cause 
the clinical phenotype of FSHD. This was called FSHD2.71 The SMCHD1 gene encodes an 
epigenetic regulator that is able to modify chromatin structure of specific regions in the 
genome, amongst which the D4Z4 repeat array.72,73 In the case of FSHD2, the mutation 
results in D4Z4 hypomethylation and thus a more open chromatin structure of the D4Z4 
repeat array (figure 3; FSHD2). 
Equal to the patients with a D4Z4 repeat contraction (also called FSHD1 patients), a per-
missive 4qA haplotype was required to provide the necessary DUX4PAS to stabilize the 
DUX4 transcript. Due to the required combination of a SMCHD1 mutation on chromo-
some 18 and the DUX4 polyadenylation signal on chromosome 4, FSHD2 is much rarer 
than FSHD1 and has a digenic inheritance pattern. Recently, heterozygous mutations in 
the DNA methyltransferase 3B (DNMT3B) gene were identified in two FSHD families, that 
probably cause FSHD by a similar mechanism as SMCHD1 mutations. These are therefore 
called FSHD2 as well.74 As not all patients with D4Z4 hypomethylation can be explained by 
mutations in SMCHD1 or DNMT3B, there might be more genes involved in FSHD2.
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OPPORTUNITIES AND CHALLENGES 
ON THE ROAD TO THERAPIES
Opportunities to increase the understanding of the disease mechanism
The current knowledge on the disease mechanism only partially explains the large clinical 
variability. A rough inverse correlation between the severity of symptoms and the size of 
the D4Z4 repeat array has been described for FSHD1, but the variability in disease severity 
and penetrance among family members with the same number of repeat units suggests 
a more complex multifactorial pathogenic mechanism.53-55,75,76 Other unidentified disease 
modifying factors could include both genetic, epigenetic and environmental or lifestyle 
factors. One example of an (epi)genetic modifier was found in families with both FSHD1 
and FSHD2 mutations: family members with an SMCHD1 mutation in addition to a D4Z4 
repeat contraction, were more severely affected than those with one of these mutations 
alone (figure 3; FSHD1+2).77 This observation inspired researchers to focus on SMCHD1 
as a potential therapeutic target to decrease DUX4 levels by enhancing SMCHD1 levels.78 
As there are currently no pharmacological treatment options for FSHD, this example 
illustrates the importance of identifying ‘natural modifiers’ for the development of new 
treatment strategies. 
Challenges in clinical trial preparedness 
Although many questions are still unsolved, the recent progress in the understanding of the 
disease mechanism of FSHD offers great opportunities for the development of new ther-
apies within the next years.79 Several pharmaceutical companies have active programs for 
targeted treatments in FSHD, with time-frames for clinical trials expecting to start in the next 
five years. In anticipation of upcoming clinical trials, there are several challenges that need 
to be addressed. As disease progression is generally slow and variability between patients 
large, clinical trials will likely require high numbers of participants and a long follow-up time 
to detect a potential treatment effect.25 Therefore, an ‘FSHD clinical trial toolbox’ consisting 
of patient registries, biomarkers and clinical outcome measures needs to be developed.80,81 
These tools will help tackle the challenges in clinical trial design in FSHD. 
Access to patients is essential for the recruitment of participants for clinical trials. Despite 
being one of the more prevalent neuromuscular disorders, FSHD is a rare disease. Espe-
cially in rare diseases, enrolling a sufficient number of participants can be an important 
bottleneck that slows down clinical trials.80 Patient registries containing clinical and genetic 
information about FSHD patients can provide a valuable tool to quickly identify and con-
tact eligible patients to prevent unnecessary delays in the testing of potential therapies.
As many clinical endpoints are difficult to measure, for example because they require a 
long follow-up time to be sufficiently assessed (e.g. muscle weakness), there is an increas-
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ing interest in biomarkers.40 The term biomarker refers to a biological characteristic that 
can be objectively measured as an indicator of normal biological processes, pathogenic 
processes, or responses to a therapeutic intervention.82 Examples of biomarkers include 
laboratory tests on blood or tissue, but also imaging techniques. Highly responsive bio-
markers with a small variability would permit smaller sample sizes compared to most 
clinical outcome measures. As such, they can be valuable especially in phase I/II trials to 
accelerate to drug development process and to determine what potential treatments are 
worth the effort and resources of a large, well-powered phase III trial.83 
For late phase trials and drug approval clinical outcome measures that reflect how a 
patient ‘feels, functions, or survives’ will be required.83 Useful outcome measures should 
be reliable, valid, highly responsive, and easy to implement across multiple sites. A review 
of the literature showed that over 200 different outcome measures have been used in 
FSHD studies. Most of these were ordinal-based measures of impairment, that were not 
validated for use in FSHD patients.81 Whereas the use of existing scales for patients with 
neuromuscular disorders would be efficient and time-saving, evidence to support their 
suitability to measure functional abilities in FSHD patients should be collected before these 
can be used in clinical trials. 
The development of the components of the FSHD clinical trial toolbox will not only aid the 
design of clinical trials, but will also yield valuable data on many aspects of the disease 
including phenotypic features, natural history, phenotype-genotype correlations and dis-
ease modifying factors. Thus, challenges in clinical research can provide new opportunities 
for unraveling the disease mechanism on a molecular level. 
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AIMS AND OUTLINE OF THE THESIS
This thesis describes the opportunities that the clinical variability in FSHD provides to 
increase the understanding of the disease mechanism (parts I & II), and the challenges 
it presents for the design of clinical trials (part III). 
The first part describes what is already known on the (variability in) clinical features and 
the relation to the (epi)genotype (chapters 1 and 2). The second part focuses on pheno-
type-genotype relations in FSHD and how clinical variability can be used to increase the 
understanding of the pathogenic mechanism (chapter 3). An example of how (epi)genetic 
factors can modify phenotypes is shown in chapter 4, where similar or even identical 
mutations result in two seemingly unrelated disorders: FSHD2 and Bosma arhinia micro-
phthalmia syndrome (BAMS). Chapter 5 shows an example of an exploratory study on a 
potential disease modifier: the influence of the lifetime endogenous estrogen exposure 
on disease severity in female patients with FSHD. 
The third part of this thesis focuses on capturing the clinical variability of FSHD in the 
light of designing the optimal ‘clinical trial toolbox’. Chapter 6 provides a core dataset 
for uniform data collection in FSHD patient registries worldwide. Chapters 7, 8 and 9 
assess three potential biomarkers for structural muscle changes: quantitative muscle MRI, 
quantitative muscle ultrasound and electrical impedance myography. In chapter 10 Rasch 
analysis is used for a critical evaluation of the ‘motor function measure (MFM)’. This is a 
generic outcome measure for neuromuscular disorders, but also used as a clinical out-
come measure for FSHD. Chapter 11 explores the use of quantitative measurements of 
orofacial strength and endurance as an outcome measure, and the relation to swallowing 
and communication difficulties. Finally, an overview and general discussion of all results 
from this thesis is presented and future perspectives are formulated. 
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Variability in FSHD
525558-L-bw-Mul
Processed on: 30-11-2018 PDF page: 32
525558-L-bw-Mul
Processed on: 30-11-2018 PDF page: 33
Karlien Mul, Saskia Lassche, Nicol C. Voermans, George W. Padberg, 
Corinne G.C. Horlings, Baziel G.M. van Engelen 
Practical Neurology 2016 Jun;16(3):201-7
What’s in a name?
The clinical features of 
facioscapulohumeral 
muscular dystrophy
525558-L-bw-Mul
Processed on: 30-11-2018 PDF page: 34
Chapter 1
34
ABSTRACT
Facioscapulohumeral muscular dystrophy (FSHD) is an inherited progressive muscle dis-
order. Although its name suggests otherwise, FSHD comprises not only weakness of the 
facial, shoulder and upper arm muscles, but also of muscles of the trunk and the legs. 
There is great variety in severity and disease course. Especially in early disease stages or 
mild cases recognizing FSHD can be difficult. Knowledge of the subtle signs and symptoms 
of FSHD can lead directly to the correct diagnosis without diagnostic delay and the need for 
multiple diagnostic procedures. This article gives an overview of the signs and symptoms 
of FSHD in severe as well as in mild cases, to facilitate correct and instant recognition of 
this relatively common muscle disorder. 
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1BACKGROUND
Facioscapulohumeral muscular dystrophy (FSHD) is, despite being relatively unknown to 
the general public and perhaps to general neurologists as well, the second commonest 
dominant muscular dystrophy in adults.1 In most cases, this autosomal dominantly inher-
ited disorder is caused by a repeat contraction on chromosome 4.2 As its name suggests, 
it affects muscles of the face, shoulder and upper arm. However, many patients also have 
weakness of the trunk and leg muscles and in some patients these are even the most 
pronounced symptoms. Moreover, some patients develop no or only very mild symptoms. 
This large variability in presenting symptoms and disease course might hinder recognition 
of the disease, especially in early stages. 
When presented to the well-trained eye of a neurologist familiar with the signs and symp-
toms of FSHD, the correct diagnosis is frequently made at the first encounter. However, 
signs and symptoms can be subtle or attributed to other conditions. For example, facial 
weakness - the tell-tale sign of FSHD - is often not recognized by the patient and conse-
quently not explicitly reported as a complaint. Additionally, facial weakness can be very 
mild in up to 25% of cases. As a result, in our neuromuscular clinic we have seen FSHD 
patients present with a myriad of symptoms that would not routinely trigger the search for 
an inherited muscle disorder: unilateral foot drop, shoulder complaints, frequent falling, 
back pain and fatigue. Screening these patients for the sometimes subtle other clinical 
signs of FSHD can lead to a swift diagnosis. 
As FSHD can be diagnosed by clinical observation and DNA testing, prompt recognition of 
FSHD is important to prevent diagnostic delay and unnecessary (often invasive) diagnostic 
procedures. This paper gives an overview of the signs and symptoms of FSHD in severe 
as well as in mild cases, to facilitate the correct recognition of all aspects of this relatively 
common muscular dystrophy for the ‘non-trained’ eye. 
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SYMPTOMS AND SIGNS 
Traditionally FSHD is described as a slowly progressive muscular dystrophy which mani-
fests between age 15-30 with weakness of the facial and shoulder girdle muscles, followed 
by the ankle dorsiflexors and finally the proximal leg muscles. However, many patients do 
not fit this well-known classical FSHD phenotype. Infantile and late-onset cases are not 
uncommon and the severity as well as the sequence of involvement of different muscle 
groups may vary. As a consequence, history and reported symptoms differ from patient 
to patient. Because of the slow progression patients often do not (spontaneously) report 
all of their symptoms or attribute symptoms to other more common disorders, like frozen 
shoulder or shoulder tendon ruptures. Additionally, although it is most often an autosomal 
dominant inherited disorder, a negative family history certainly does not rule out FSHD. 
A high percentage varying from 10 to 30% of cases is caused by de novo mutations3,4 and 
asymptomatic gene carriers are frequently found in FSHD families.5
All together, the diagnosis of FSHD can easily be missed if a physician does not actively 
ask and look for signs and symptoms of FSHD. Patients with FSHD often show multiple 
characteristic signs (figure 1). Some of the signs are highly suggestive of FSHD, whereas 
others can also be observed in other neuromuscular and orthopedic disorders. An over-
view of signs and symptoms of FSHD per body region is given in table 1.
Figure 1. Characteristic signs for FSHD
Poly-hill sign
Facial weakness
and asymmetry
Winging and
overriding scapula
Lumbar
hyperlordosis
Hamstring
weakness
Calf atrophy
Beevor sign
Drop foot
Wasting of humeral
muscles
Horizontal axillary
fold
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1FaceOne of the first and most characteristic signs of FSHD is asymmetrical weakness of the 
facial muscles (figure 2). Most commonly affected facial muscles are the circular muscle 
around the eyes and the mouth, the orbicularis oculi and orbicularis oris respectively, 
and the zygomaticus major. Facial weakness can be very discrete in up to 25% of cases. 
Sometimes it can be visible only as asymmetrical pouting. Patients may not be aware of 
the involvement of the facial muscles and facial weakness goes unnoticed by physicians 
in up to 60% of cases.6 Symptoms of facial weakness are rarely reported by patients 
spontaneously, so physicians should actively ask and look for these symptoms. Patients 
(and relatives) can be asked if they have noticed a change in facial expressions. Some 
patients describe that they are perceived as arrogant, grumpy or tired, because of the 
lack of facial expression. 
Weakness of the orbicularis oculi results in difficulty closing the eyelids. Many patients 
sleep with their eyes partially opened and may have irritated conjunctiva upon awakening. 
When the patient is asked to close the eyes a Bell’s phenomenon can be seen in the more 
advanced cases (fig. 2A). Less pronounced weakness can lead to a ‘signe de cils’; an inability 
to completely bury the eyelashes when the eyes are closed tightly (fig. 2C). 
Due to weakness of the orbicularis oris patients may have an asymmetrical mouth in rest-
ing position (fig. 2B). This asymmetric weakness becomes more visible when the patient 
is asked to prude the lips or blow the cheeks (fig. 2D). Activities like whistling, blowing a 
balloon or drinking through a straw can become more difficult. In some cases the upper 
lips lose mobility. 
Weakness of the zygomaticus muscles results in an inability to raise the corners of the 
mouth. When the patient attempts to smile the mouth moves in a horizontal direction 
producing a so-called ‘transverse smile’, which might impress as a grim. 
In severe cases, other muscles of the face can be involved as well resulting in an unwrinkled 
and expressionless ‘myopathic face’. Extraocular muscles are never affected 7. 
Upper extremities 
In the upper extremities the scapular fixator muscles are often affected, in particular the 
trapezius and serratus anterior. This results in scapular winging, which is often bilateral 
and frequently asymmetrical, which typifies FSHD (figure 3). Mild scapular winging is not 
always visible in resting position. Observing the scapula while the patient slowly lowers the 
arms forward and/or sideward is the most sensitive method to detect scapular winging.8 
Another important sign is the ‘overriding scapula’, upward movement of the scapula due 
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to loss of inferior fixation. Instability of the scapula together with muscle weakness causes 
difficulty in abduction and forward flexion of the arms above shoulder height. Patients 
first complain about difficulty working above shoulder height. As symptoms progress all 
activities requiring lifting of the arms become more difficult, for example combing hair or 
taking off a sweater. 
Figure 2. Facial weakness
Weakness of the orbicularis oculi results in difficulty or inability in closing both eyes (2A) and a ‘signe de cils’ (2C). 
There is an asymmetrical mouth in resting position (fig 2B). Weakness of the orbicularis oris causes difficulty in 
pursing the lips (fig. 2D).
Selective muscle wasting causes some characteristic physical signs that may point to FSHD. 
The so-called ‘Popeye’ arms are caused by the contrast between the atrophied perihu-
meral muscles, especially the biceps, and the sparing and subsequent normal bulk of 
Table 1. Signs and symptoms characteristic for FSHD 
Body region Specific symptoms in history Specific signs in neurological examination Most commonly affected muscles Red flags suggesting other diagnosis
Face • Change in facial expressions
• Difficulty whistling
• Sleeping with eyes open
• Bells phenomenon
• Signe de cils
• Asymmetrical pursing lips or blowing cheeks 
• Transverse smile
• Orbicularis oculi
• Orbicularis oris
• Weakness of extraocular muscles or masseter
Upper extremity 
& shoulder
• Difficulty working above shoulder height 
• Shoulder pain 
• Asymmetrical winging scapula and 
overriding scapula
• Poly-hill sign
• Popeye arms
• Trapezius
• Serratus anterior 
• Proximal part of deltoid 
• Tricpes and biceps brachii
• Weakness of brachioradialis and/or distal arm 
and hand muscles in early stage disease
Trunk • Difficulty coming from supine to sitting 
position
• Loss of balance
• Horizontal axillary fold, often asymmetrical
• Beevor sign 
• Horizontal clavicula
• Prominent abdomen with hyperlordosis
• Pectoralis major (sternal part more than clavicular part)
• Erector spinae
• Rectus abdominis
• Weakness of sternocleidomastoid
• Early respiratory weakness
Lower extremity • Tripping, falling 
• Difficulty walking stairs or rising from a 
chair
• Drop foot
• Trendelenburg’s sign
• Adductor magnus 
• Hamstrings
• Quadriceps femoris 
• Tibialis anterior
• Profound weakness of iliopsoas or 
gastrocnemius in absence of other leg muscle 
weakness
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Table 1. Signs and symptoms characteristic for FSHD 
Body region Specific symptoms in history Specific signs in neurological examination Most commonly affected muscles Red flags suggesting other diagnosis
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• Difficulty working above shoulder height 
• Shoulder pain 
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overriding scapula
• Poly-hill sign
• Popeye arms
• Trapezius
• Serratus anterior 
• Proximal part of deltoid 
• Tricpes and biceps brachii
• Weakness of brachioradialis and/or distal arm 
and hand muscles in early stage disease
Trunk • Difficulty coming from supine to sitting 
position
• Loss of balance
• Horizontal axillary fold, often asymmetrical
• Beevor sign 
• Horizontal clavicula
• Prominent abdomen with hyperlordosis
• Pectoralis major (sternal part more than clavicular part)
• Erector spinae
• Rectus abdominis
• Weakness of sternocleidomastoid
• Early respiratory weakness
Lower extremity • Tripping, falling 
• Difficulty walking stairs or rising from a 
chair
• Drop foot
• Trendelenburg’s sign
• Adductor magnus 
• Hamstrings
• Quadriceps femoris 
• Tibialis anterior
• Profound weakness of iliopsoas or 
gastrocnemius in absence of other leg muscle 
weakness
the muscles of the forearms and relatively sparing of the distal deltiod (figure 4). In more 
severe cases the poly-hill sign can be seen (figure 5).9 This results from selective wasting 
of muscles: the first hill arises from atrophy of the trapezius muscle in combination with 
upward movement of the superior angle of the scapula. More laterally, the second hill is 
caused by displacement of the acromio-clavicular joint. Next, the proximal deltoid muscle 
is wasted while its distal part forms a bulk (third hill) and the biceps brachii again is wasted. 
Often the supraspinatus and infraspinatus muscles appear fairly intact.
Trunk
Abdominal muscle weakness is an early and prominent though often underrecognized 
feature of FSHD. Patients often have difficulty rising from a supine to a sitting position, for 
example when they are getting out of bed. As the weakness progresses, turning from one 
side to the other in supine position becomes more difficult. On physical examination the 
(asymmetrically) protruding abdomen can be mistaken for abdominal fat instead of muscle 
weakness. More specifically for FSHD, a positive Beevor sign may be present: an upward 
movement of the umbilicus on flexing the neck in supine position. Because the proximal 
part of the rectus abdominis muscle is weaker than the distal part, the umbilicus gets 
pulled upward. Abdominal muscle weakness also contributes to lumbar hyperlordosis, 
which is found in the majority of patients. 
Other trunk muscle that are often affected in FSHD are the erector spinae muscles of the 
back and the major pectoral muscle on the chest. Weakness of the erector spinae muscles 
may, in rare cases, result in bent spine syndrome (camptocormia).10 Combined weakness 
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of abdominal and back muscles is an important contributor to the loss of balance and 
subsequent falling.11 Atrophy of the major pectoral muscle results in an, often asymmet-
rical, extra anterior axillary fold (figure 6). 
Figure 3. Scapular winging
Asymmetrical bilateral scapular winging (right more evident than left) becoming visible on forward lowering of 
the arms.
Lower extremities
Although the disease is called facioscapulohumeral muscular dystrophy, the vast majority of 
patients has weakness in the lower extremities. In one observational study including 122 
patients, 20% even presented with lower limb weakness.14 The sequence of involvement 
of the leg muscles differs between patients. A classic feature of FSHD is weakness of the 
tibialis anterior muscle eventually causing foot drop. Footdrop is prevented for a long 
time by hypertrophy of the extensor digitorum brevis which is often cited as a feature 
distinguishing the myopathy from a neuropathy. 
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1Weakness of the hamstrings is very common, but usually does not lead to functional limitations in daily life. The calf and quadriceps muscles may also be affected (figure 7). 
Trendelenburg’s sign is not specific for FSHD, but is frequently present in the advanced 
cases when walking stairs becomes difficult. 
Figure 4. ‘Popeye’ arms 
Horizontal axillary folds, protuberant abdomen and overriding scapula. Also note the proximal wasting of the 
deltoid muscle with an intact distal part and the wasting of the humeral muscles with a normal bulk of the 
muscles of the forearm. 
Respiratory muscles are not involved in the disease process. However, weakness of the 
trunk muscles, including accessory respiratory muscles, and chest wall deformities can 
cause difficulty in breathing, which in rare cases requires ventilatory assistance.12,13
Pain and fatigue
Approximately 75% of patients with FSHD experience moderately severe chronic pain, 
which is mostly located in the lower back, legs, shoulder region and neck.15,16 Around 60% 
experiences severe fatigue17, which is related to multiple perpetuating factors including 
pain, sleep disturbances, physical activity and impairment.18
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Figure 5. Poly-hill sign (dorsal view)
Arrow 1: wasting of trapezius; arrow 2: superior angle of the scapula; arrow 3: displaced acromio-clavicular joint; 
arrow 4: atrophied proximal deltoid; arrow 5: normal bulk of distal deltoid 
Systemic involvement 
Cardiac involvement includes an increased prevalence of (incomplete) right bundle branch 
block without cardiac symptoms or progression to clinically relevant cardiac arrhythmias.19 
FSHD does not cause cardiomyopathy. The presence of cardiomyopathy should warrant 
investigations into other disorders.
Retinal vasculopathy is associated with FSHD. This is mostly subclinical but can, mostly 
in severely affected early onset cases with very short repeat sizes, progress to Coat’s 
syndrome.20 Coat’s syndrome is a treatable condition characterised by retinal vascular 
abnormalities and leakage that can lead to exudative retinal detachment and blindness. 
High-frequency hearing loss has been described in patients with FSHD, but appears to be 
subclinical in most cases. Severely affected early onset patients may suffer from hearing 
loss requiring hearing aids. 
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Figure 6. Trunk muscle weakness
On the trunk a horizontal anterior axillary fold is seen on both sides. The abdomen is protruding asymmetrically. 
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A frequently found chest wall deformity is pectus excavatum which is found in approxi-
mately 5-16% of patients with FSHD and can occasionally be severe.21 There are a few case 
reports describing mental retardation and/or epilepsy in severely affected FSHD patients. 
Figure 7. Atrophy of the right calf muscles
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1DIAGNOSTIC INVESTIGATIONS
History and physical examination are the keystones in diagnosing FSHD. In case of high 
clinical suspicion for FSHD, the diagnosis can be confirmed by direct DNA testing. Muscle 
biopsy does not show specific findings that lead to a diagnosis of FSHD neither do labora-
tory tests. The serum creatine kinase (CK) level is normal or slightly elevated (never more 
than five times of normal). 
FSHD1 can be diagnosed genetically by assessing the size of the repeat contraction on 
chromosome 4. A size of ≤10 repeat units on a 4qA allele is consistent with the diagnosis 
of FSHD. FSHD1 is the most common type of FSHD and accounts for 95% of the patients. 
Repeat size is reported as EcoRI band, in which fragments ≤38kb are consistent with 
FSHD1. The reported EcoRI/BlnI band is used only to confirm that the repeat contraction 
is located on chromosome 4 and not on a similar repeat array on chromosome 10. In case 
of a repeat contraction on chromosome 4, the EcoRI/BlnI band is 3 kb shorter than the 
EcoRI band. Because FSHD1 is caused by a repeat contraction, current high-yield genetic 
sequencing like exome sequencing techniques fail to detect FSHD1.
In case of a negative test (fragment size >38kb) and a high clinical suspicion for FSHD, 
FSHD2 can be tested for. FSHD2 accounts for 5% of patients who have heterozygous 
mutations in the SMCHD1 gene, leading to a clinical phenotype indistinguishable from 
FSHD1.22.There are reports of very severe FSHD patients who carry mutations for FSHD1 
as well as for FSHD2.23 A small group of patients with an FSHD phenotype tests negative 
for FSHD1 and FSHD2 and cannot be explained genetically at this moment. In case of neg-
ative genetic testing for FSDH1 and/or FSHD2, other diagnoses should be considered.24 A 
more detailed description of genetic testing lies beyond the scope of this paper and can 
be found elsewhere.25,26
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COUNSELING AND MANAGEMENT
FSHD is an autosomal dominantly inherited disorder. Muscle weakness is typically slowly 
progressive, although there is a high variability in disease severity between and within 
families. When compared to other muscular dystrophies, FSHD may show a more stepwise 
disease progression, sometimes with years of stabilization of progression, followed by a 
period with relatively fast progression of muscle weakness. Therefore, it is at present not 
possible to predict individual disease course. Approximately one in five patients becomes 
wheelchair dependent by age 50.27 Factors that are associated with a more severe pheno-
type are early onset of symptoms and very short repeat sizes (10-20kb).28 Life expectancy is 
generally not reduced.29 Patients should be referred for genetic counseling for information 
regarding recurrence risk. Preimplantation genetic diagnosis is technically very difficult for 
FSHD, because of the large amount of DNA that is required to perform the Southern blot 
analysis. In large families proximal flanking makers can be used, but this technique has a 
5% chance of false result because the FSHD repeat lies distally on chromosome 4q and 
because this area knows a high recombination frequency. 
Currently there is no cure or medicinal treatment available for FSHD. Treatment is focused 
on improvement of functional limitations and maintenance of an optimal physical con-
dition. Therefore, for all patients who experience functional limitations, a rehabilitation 
consult is recommended.24 Several studies have focused on symptomatic treatment of 
physical limitations and fatigue. Aerobic exercise has a beneficial effect on chronic fatigue, 
physical activity and fitness.30,31 Cognitive behavioral therapy was beneficial for chronic 
fatigue as well, through tackling fatigue-perpetuating factors.30 
An evidence-based guideline regarding management and screening for complications in 
FSHD was recently developed.28 It is advised to obtain baseline pulmonary function tests 
on all patients with FSHD, especially in severely affected patients (wheelchair bound and/
or with chest wall deformities). Routine cardiac screening is not recommended. 
Routine assessment for retinal vasculopathy and hearing loss is not necessary, except in 
severe infantile cases using dilated indirect ophthalmoscopy and screening audiometry. In 
case of elective surgery, patients with FSHD should always undergo pre-operative screen-
ing, which at least should include assessment of respiratory function. 
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1CONCLUSION
FSHD is an inherited progressive muscle disorders that - despite its name - comprises 
more than just weakness of the facial, scapular and humeral muscles. Awareness of the 
signs and symptoms of FSHD, which may be subtle, leads to prompt diagnosis resulting 
in reduction of diagnostic delay and (often invasive) diagnostic procedures. The diagnosis 
can be confirmed genetically. Treatment is currently based on improvement of functional 
limitations.
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ABSTRACT
Purpose of review: This review gives an overview of the currently known key clinical and 
(epi)genetic aspects of facioscapulohumeral muscular dystrophy and provides perspec-
tives to facilitate future research. 
Recent findings: Clinically, imaging studies have contributed to a detailed characterization 
of the FSHD phenotype and a model is proposed with five stages of disease progression. 
A number of clinical trials has been conducted regarding exercise and diet aiming to 
reduce symptoms. Genetically, at least two different mechanisms (FSHD1 and FSHD2) 
lead to DUX4 expression in skeletal myocytes which is expected to be necessary for the 
pathology. Disease severity is most likely determined by a combination of the D4Z4 repeat 
size and its epigenetic state. 
Summary: Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common 
muscular dystrophies and is characterized by a typical distribution of muscle weakness. 
Progress has been made on clinical as well as on (epi)genetic aspects of the disease. 
Currently, there is no cure available for FSHD. For successful development of new treat-
ments targeting the disease process, integration of clinical and pathogenetic knowledge 
is essential. A clinical trial toolbox that consists of patient registries, biomarkers and clinical 
outcome measures will be required to effectively conduct future clinical trials. 
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INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) a chronic progressive muscular disorder 
which is characterized by weakness and wasting of facial and shoulder girdle muscles ini-
tially, followed by the leg and trunk muscles.1,2 In most cases the disease has an autosomal 
dominant pattern of inheritance with incomplete penetrance. 
Over the past decade, our knowledge on FSHD has increased significantly from a clinical 
as well as from a genetic point of view. Currently, in clinical research, imaging studies are 
contributing to a detailed characterization of the patterns of muscle weakness and insights 
on different disease stages. At the same time (epi)genetic studies continue to make sig-
nificant progress in unraveling the primary pathogenic mechanism. 
Currently there is no medicinal treatment for FSHD. However, interest has grown in 
optimizing symptomatic treatment and improving quality of life resulting in clinical trials 
regarding life style interventions and treatment guidelines. Additionally, with advances 
made in our understanding of the pathomechanism, studies investigating therapeutic 
approaches that target the disease process are emerging. For the development and test-
ing of new treatment strategies it is essential to aim future research at integration of 
clinical and pathophysiological knowledge. Moreover, a ‘toolbox’ for conducting trials will 
be required, including patient registries, imaging and laboratory biomarkers and clinical 
outcome measures. 
In this review we discuss recent advances made in clinical and (epi)genetic research, and 
provide future perspectives for integrating clinical and genetic aspects of FSHD. 
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CLINICAL ASPECTS AND DISEASE MANAGEMENT
FSHD is one of the most common forms of muscular dystrophy. Since the introduction of 
DNA testing for FSHD, its prevalence was found to be on average 5 per 100.000. A recent 
study in the Netherlands, however, suggests a prevalence of 12 per 100.000, which is 
more than twice as high as previously thought.3 There are two genetic forms of FSHD, 
called FSHD1 and FSHD2, that share many of the same clinical characteristics and are 
described below as ‘FSHD’. 
Clinical features
FSHD is characterized by a typical distribution of muscle weakness.2 In most cases, FSHD 
presents with weakness of facial muscles and/or shoulder girdle and upper arm mus-
cles. As the disease progresses muscles of the trunk and lower extremities may become 
involved as well. Age at onset is typically in the second decade of life, but varies from 
early childhood to onset beyond age 60. The weakness is often asymmetrical and slowly 
progresses over life, but life expectancy is generally not reduced. Severity and rate of pro-
gression are largely variable, ranging from isolated facial weakness to severe generalized 
weakness, with approximately 20% of patients eventually requiring a wheelchair.4 There 
is a high percentage (20-30%) of asymptomatic or minimally affected gene carriers. Even 
within the same family, large differences in disease severity can occur. In most cases family 
history is positive, but 10-30% of cases is caused by de novo mutations, which often occur 
post-fertilization and result in somatic mosaicism.5 
Systemic involvement is rare but can include retinal vasculopathy, sensorineural hearing 
loss, restrictive lung disease and (incomplete) right bundle branch block, although all are 
mostly subclinical.6 Patients with early onset severe disease are most at risk of developing 
symptomatic extramuscular manifestations. 
Imaging
Imaging studies have added detailed information on the specific pattern of muscle involve-
ment in FSHD (table 1). Axial muscles were found to be involved in FSHD and play an 
important role in posture and gait, but are easily overlooked during clinical examination.7-9
Imaging studies have also provided new insights on the course and disease stages of 
FSHD. First, the degree of fatty infiltration of muscle tissue per muscle was found to have 
a rather dichotomous distribution: 85% of all muscles was either normal or minimally 
fatty infiltrated or had a high degree of fatty infiltration, but only approximately 15% had 
an intermediate degree.10,11 This dichotomous distribution suggests that the intermediate 
phase of muscle replacement occurs rapidly in FSHD. In the leg muscles, fatty infiltration 
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was located mostly distally in mildly affected muscles while in more severely affected 
muscles the fatty infiltration was also located proximally indicating that in leg muscles the 
disease progresses from distal to proximal.10
In some patients, muscles showed hyperintense abnormalities on STIR sequences 
(T2-weighted sequences with nulling of the fat signal). These hyperintensities are inter-
preted as indicative of muscle edema as a marker for inflammation, although the latter 
requires further experimental validation.12 It is assumed that STIR positive areas are more 
likely to rapidly progress to fatty infiltration compared to STIR negative areas.13,10,14,15 In 
cross-sectional studies only 4-7% of all scanned muscles showed STIR positive areas, most 
often in patients with moderate severity.16 Additionally, part of the STIR positive muscles is 
normal on T1 sequences, showing no signs of fatty infiltration (yet). Thus STIR positivity has 
been proposed as an early sign of muscle involvement and a marker for disease activity.14,16 
Based on the MRI findings described above, a model is proposed with five stages of dis-
ease progression (table 2).14 In these stages, normal muscle tissue progresses to an active 
stage with muscle inflammation and then rapidly progresses to end-stage fatty infiltrated 
tissue. Longitudinal studies involving large cohorts are required to confirm this model and 
to study its clinical implications. 
All together, this suggests that FSHD is a multifocal myopathy with various muscles in dif-
ferent stages of pathology. MRI can be used as a biomarker for disease progression and 
-activity and provides new insights into the pathophysiological mechanism. 
Table 1. Muscles found in literature to be frequently affected and spared in FSHD
Body region Frequently affected Frequently spared
Upper extremities Pectoralis major
Serratus anterior
Subscapularis
Infraspinatus
Trunk Paraspinal muscles
Abdominal muscles 
Lower extremities Hamstrings, especially semimembranosus 
Rectus femoris
Iliopsoas 
Internal and external obturator
Management 
A cure for FSHD is not yet available, but a few clinical trials have recently been conducted 
regarding life style interventions, such as exercise and diet. A Cochrane review concluded 
that moderate-intensity strength training in FSHD appears to do no harm, but there is 
insufficient evidence to conclude that it offers benefit.17 Two newly conducted clinical trials 
showed beneficial effects of aerobic exercise.18,19 The first trial compared aerobic exercise 
with cognitive-behavioral therapy and a nonintervention control group in order to lessen 
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chronic fatigue.19 Both interventions proved effective in reducing fatigue and increasing 
physical activity. Cognitive behavioral therapy additionally increased sleep quality and 
social participation. 
Table 2. Proposed stages of disease progression on MRI
Stage number MRI findings
0 No fatty infiltration, STIR negative
1 No fatty infiltration, STIR positive
2 Partial fatty infiltration, STIR positive
3 Partial fatty infiltration, STIR negative 
4 Complete fatty infiltration, STIR negative 
The second trial compared aerobic exercise with or without post-exercise protein sup-
plement with nonintervention controls.18 Aerobic exercise improved fitness, workload 
and walking speed. The addition of protein supplements did not further improve perfor-
mances. 
Regarding diet, a clinical trial was conducted on supplementation of the antioxidants 
vitamin C, vitamin E, zinc gluconate and selenomethionine.20 Rational for this trial was that 
oxidative stress may contribute to FSHD pathology21 and that antioxidants might help in 
maintaining muscle function. One of the primary outcomes, the two-minute walking test, 
did not differ significantly between groups after supplementation. However, both maximal 
voluntary contraction and endurance of the quadriceps muscles increased significantly 
more with antioxidant supplementation. Since this was a preliminary trial involving small 
numbers of patients, additional studies are required.
One of the hallmarks of FSHD disease management is monitoring complications.6 It is 
advised to obtain baseline pulmonary function tests for all patients, but certainly in those 
who are wheelchair bound and/or have chest wall deformities. For most other complica-
tions monitoring is only required in high-risk patients: dilated indirect ophthalmoscopy 
for retinal vasculopathy in patients with small residual D4Z4 repeat sizes, audiometry for 
childhood-onset patients, because undetected hearing loss may impair language devel-
opment, and cardiac screening only in patients with cardiac symptoms. 
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GENOTYPE AND PATHOPHYSIOLOGY
FSHD is associated with chromatin relaxation of the D4Z4 repeat on chromosome 4 in 
somatic cells and expression of the DUX4 gene, of which a copy is located in each D4Z4 
unit. This chromatin relaxation is associated with reduced levels of CpG methylation and 
H3K9me3 at D4Z4.22,23 FSHD is specifically linked to contractions on the 4qA disease-per-
missive haplotype, which contains a polymorphic DUX4 polyadenylation signal, facilitating 
the stabilization of the DUX4 transcript in somatic cells.24 Two genetic forms of FSHD 
have been discovered, which are clinically indistinguishable.25 In the most common form, 
FSHD1, D4Z4 chromatin relaxation and DUX4 expression are associated with a contrac-
tion of the D4Z4 repeat to an array of 1-10 units.26 This repeat varies between 8-100 
units in the healthy control population.27,28 FSHD2 is characterized by D4Z4 chromatin 
relaxation of both 4q chromosomes as well as the very homologous D4Z4 repeats on 
chromosome 10, but without repeat contraction. However, the average size of the shortest 
permissive allele in FSHD2 patients is 16 units, which is smaller than the average size in 
the control population (28 units).25,29 Heterozygous mutations in the chromatin modifier 
structural maintenance of chromosome flexible hinge domain containing 1 (SMCHD1) gene 
have been identified as the most common cause of FSHD2.29-35 SMCHD1 is involved in 
the establishment and/or maintenance of CpG methylation at specific loci.36-38 SMCHD1 
binds directly to D4Z4 and this binding is reduced in FSHD2.30 Knockdown of SMCHD1 
activates or increases DUX4 expression in control and FSHD1 myotubes, respectively.30,31 
SMCHD1 levels decrease during muscle cell differentiation, suggesting that muscle might 
be more susceptible to D4Z4 derepression.39 Collectively, this indicates that SMCHD1 has 
an important role in silencing the D4Z4 repeat in somatic cells. 
Recently, heterozygous mutations in the DNA methyltransferase 3B (DNMT3B) gene were 
identified in two FSHD2 families without SMCHD1 mutation.40 These DNMT3B mutations 
segregate with D4Z4 hypomethylation and increased FSHD penetrance in both fami-
lies. Since not all patients with D4Z4 hypomethylation can be explained by mutations in 
SMCHD1 or DNMT3B, there might be more genes involved in FSHD2. 
DUX4 expression in skeletal myocytes is common to both forms of FSHD and is expected 
to be necessary for the pathology. DUX4 is a transcription factor, which is normally 
expressed in the luminal cells of the testis, but suppressed in somatic tissue.41 Because 
of the D4Z4 chromatin changes, sporadic expression of DUX4 can be detected in a small 
and variable percentage of myonuclei from FSHD patients and also in a very low percent-
age of control muscle biopsies.41,42 How DUX4 expression leads to muscle weakness is 
under active investigation, but ectopic expression in myocytes leads to a complex cascade 
of events eventually leading to muscle cell death.43 Since DUX4 is a transcription factor, 
525558-L-bw-Mul
Processed on: 30-11-2018 PDF page: 58
Chapter 2
58
multiple studies analyzed the transcriptional consequences of DUX4 expression. Identified 
genes include both direct targets of DUX4, as indicated by DUX4 ChIP-seq peaks, as well 
as indirect targets.44,45,43The transcriptional consequences of DUX4 expression include 
activation of germline genes, suppression of the innate immune response and disruption 
of RNA metabolism.44,43,45 Alternative splicing, which is seen in DUX4 expressing myoblasts, 
might be related to the inhibition of nonsense-mediated-decay (NMD) by DUX4, since its 
expression triggers the degradation of a central component of NMD (UPF1).46,43 Addition-
ally to DUX4, other genes proximal to D4Z4, such as FRG1, FRG2 and FAT1 might also be 
deregulated in FSHD either by DUX4 directly (FRG1 and FRG2) or independently (FAT1).47-
49 Their clinical relevance to pathology warrants further investigation since some FSHD 
families genetically exclude a direct role for proximal 4qter genes.50 
Phenotype-(epi)genotype relation
The high clinical variability in FSHD raises the question whether (epi)genetic factors influ-
ence disease severity. Indeed, in FSHD1 there is a rough inverse correlation between 
remaining repeat size and disease severity, which was recently confirmed in Korean and 
Chinese cohorts.51,52 Individuals with D4Z4 repeats of 7-10 units have milder disease or 
remain non-penetrant and have lower pathology grades for their muscle biopsies.53,54 
Additionally, D4Z4 repeats of 7-10 units on disease permissive 4qA chromosomes are 
found in 1-3% of the control population, indicating the reduced penetrance of these 
alleles.27,28 However, unaffected carriers exist for smaller repeat sizes (1-3 units) as well, 
indicating that repeat size is not always predictive for disease severity.55 Furthermore, in 
some FSHD1 families with borderline repeat sizes and D4Z4 hypomethylation, SMCHD1 
mutations were identified that modify disease severity. While carriers of both an FSHD1 
sized allele and an SMCHD1 mutation were severely affected, familial carriers of only one 
of these conditions were more mildly affected.31,33
The relevance of the epigenetic state of the repeat for disease severity was shown in 
multiple studies that found a difference in D4Z4 methylation levels between affected and 
unaffected carriers of an FSHD1 allele.29,56,57 This suggests that affected carriers are epige-
netically more susceptible to disease presentation. Indeed, DUX4 expression in myocytes 
from FSHD1 affected individuals was more responsive to treatment with compounds that 
relieve epigenetic repression compared to non-manifesting relatives.57 Possibly, expres-
sion levels of or polymorphisms in chromatin modifiers, such as SMCHD1, could influence 
this epigenetic susceptibility. 
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For FSHD2 D4Z4 methylation attributed to the smallest permissive allele correlates with 
disease severity, with lower methylation being related to higher severity.29 The nature of 
the SMCHD1 mutation influences the extent of hypomethylation with open reading frame 
(ORF) preserving mutations resulting in significantly lower D4Z4 methylation than ORF 
disrupting mutations.29 SMCHD1 forms homodimers through its hinge domain58,59 and 
open reading frame preserving mutations might result in malfunctioning dimers, which 
could explain why these mutations have a more severe effect on methylation. Additionally, 
the size of the smallest permissive repeat is also expected to contribute to the epigenetic 
susceptibility to disease presentation.29 All together this suggests that for both FSHD1 and 
FSHD2 a combination of the D4Z4 repeat size and its epigenetic state influence disease 
severity.
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FUTURE PERSPECTIVES 
Therapeutic approaches that specifically or aspecifically target the disease process are 
emerging. Because of the central role of DUX4 in the pathological mechanism, down-reg-
ulation of DUX4 expression or counteracting its downstream effects are considered as 
potential therapeutic strategies. Laboratory studies have been performed with molecules 
that target DUX4 mRNA directly or target the D4Z4 chromatin structure and have shown 
beneficial effects in cell and animal models.60-63
For optimal development of more therapeutic strategies, integrating knowledge of clinical 
features and the (epi)genetic mechanism is essential. Because of the large clinical and 
genetic variability of FSHD, it will most likely be necessary to select specific patient groups 
for (testing of) specific therapies. Moreover, because of the different disease stages in vari-
ous muscles, the timing of a treatment in the disease course could be of great importance. 
An example of a clinical trial that is using selected patients in a specific disease stage is 
a multinational phase Ib/II clinical trial that is currently underway testing Resolaris (his-
tidyl-tRNA synthetase, aTyr Pharma, Inc., San Diego, CA, USA). Histidyl-tRNA synthetase 
autoantibodies are associated with inflammatory myositis and in animal models his-
tidyl-tRNA synthetase reversed immune cell invasion of muscle tissue. This therapy is 
specifically being tested in patients with STIR positive muscles on MRI, i.e. in patients with 
active muscle inflammation. 
In order to effectively recruit patients for future clinical trials, patient registries are required. 
These registries along with biomarkers, imaging, and clinical outcome measures form the 
clinical trial toolbox (figure 1).64,14 Whereas biomarkers and muscle imaging might detect 
the effect of therapeutic interventions on disease activity and progression, reliable clinical 
outcome measures are needed to detect clinically relevant effects for the patients daily 
functioning. Developing a reliable and sensitive clinical outcome measure has proven 
difficult. In 125 papers on clinical research over 200 different clinical outcome measures 
were used mostly measuring levels of impairment, especially strength, instead of measur-
ing patient functioning. Additionally, the majority of outcome measures was not validated 
nor assessed for their clinimetric properties, emphasizing the need for new valid, relevant 
and sensitive clinical outcome measures. A number of new outcome measures is currently 
being developed or validated.14
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Figure 1. Future perspectives for research on FSHD 
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CONCLUSION
Over the last decade progress has been made on clinical as well as on pathophysiological 
aspects of FSHD. Imaging studies suggest that FSHD is a multifocal myopathy with various 
muscles in different stages of pathology. Clinical trials have shown beneficial effects of 
aerobic exercise. (Epi)genetic studies are further unraveling the pathogenic mechanism 
and are paving the way for the development of new potential disease-specific therapies. 
In order to successfully develop and test new treatment strategies it is important to merge 
clinical and genetic knowledge. 
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ABSTRACT 
To determine how much of the clinical variability in facioscapulohumeral muscular dys-
trophy type 1 can be explained by the D4Z4 repeat array size, D4Z4 methylation and 
familial factors, we included 152 carriers of an FSHD1 allele (23 single cases, 129 familial 
cases from 37 families) and performed state-of-the-art genetic testing, extensive clinical 
evaluation and quantitative muscle MRI. Familial factors accounted for 50% of the variance 
in disease severity (FSHD clinical score). The explained variance by the D4Z4 repeat array 
size for disease severity was limited (approximately 10%), and varied per body region 
(facial muscles, upper and lower extremities approximately 30%, 15% and 3%, respec-
tively). Unaffected gene carriers had longer repeat array sizes compared to symptomatic 
individuals (7.3 vs 6.0 units, p=0.000) and slightly higher Delta1 methylation levels (D4Z4 
methylation corrected for repeat size, 0.96 vs -2.46, p=0.048). 
The D4Z4 repeat array size and D4Z4 methylation contribute to variability in disease 
severity and penetrance, but other disease modifying factors must be involved as well. The 
larger effect of the D4Z4 repeat array on facial muscle involvement suggests that these 
muscles are more sensitive to the influence of the FSHD1 locus itself, whereas leg muscle 
involvement seems highly dependent on modifying factors. 
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INTRODUCTION 
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common inherited 
muscle disorders.1 It is characterized by progressive and typically asymmetrical weakness 
and wasting of facial, shoulder girdle and upper arm muscles, and often also trunk and 
leg muscles.2 The degree of muscle involvement and the rate of disease progression are 
highly variable both between and within families.3, 4 
FSHD is caused by the expression of the DUX4 transcription factor that is normally sup-
pressed in somatic cells.5, 6 A copy of the DUX4 gene is located within each unit of the D4Z4 
repeat array on chromosome 4q35 and a complete DUX4 gene in the most distal D4Z4 unit. 
In the normal population this repeat array varies between 8-100 units, whereas in FSHD1, 
the most common form of FSHD, it is contracted to 1-10 D4Z4 units.7, 8 This contraction leads 
to a more open D4Z4 chromatin structure, resulting in a higher chance of DUX4 expression 
in skeletal muscle. In FSHD2, the rarer form of FSHD, the more open D4Z4 chromatin struc-
ture is caused by a pathogenic variant in the SMCHD1 or DNMT3B gene instead of a repeat 
contraction.9, 10 Both gene products are necessary to establish or maintain a repressive D4Z4 
chromatin structure in somatic tissue. Both in FSHD1 and FSHD2 the mutations only lead to 
disease if they are present on specific haplotypes that provide the necessary polyadenylation 
signal (DUXPAS) to stabilize the DUX4 transcript.7, 11 A small number of FSHD patients cannot 
be genetically explained by these two mechanisms.
For FSHD1 a rough and inverse correlation between the number of D4Z4 repeat units 
and disease severity has been repeatedly described.3, 12-15 The majority of patients with 
1-3 repeat units has a severe phenotype, while patients with 7-10 repeat units tend to be 
more mildly affected.16, 17 However, variability in disease severity is large for all repeat array 
sizes. Within families with repeat array sizes of 7-10 units, asymptomatic or non-penetrant 
gene carriers are found frequently (up to 30% of family members).15, 18 These longer sized 
repeat arrays are also found in 1-2% of the healthy Caucasian population, indicating that 
they are disease permissive, but not always pathogenic.19, 20 
Since the discovery of the disease mechanism for FSHD2, it is becoming increasingly clear 
that not only the D4Z4 repeat size, but also the epigenetic state of the D4Z4 locus con-
tributes to the disease severity and penetrance. Observations that pathogenic variants 
in SMCHD1 aggravate disease severity in FSHD1 families suggested that D4Z4 chromatin 
modifiers influence DUX4 expression in skeletal muscle.21 This hypothesis was supported 
by the lower CpG methylation level that was found in symptomatic individuals with 7-10 
repeat units compared to asymptomatic and non-penetrant gene carriers with the same 
repeat size.22
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Still, with the current knowledge on the disease mechanism we cannot adequately 
explain the large clinical variability, even within families. Most likely, disease severity and 
penetrance are determined through a complex interplay of genetic, epigenetic and envi-
ronmental and/or lifestyle factors. Two of the contributing factors are the D4Z4 repeat 
array size and D4Z4 chromatin structure (reflected by the methylation level), although it is 
unclear how much of the clinical variability can be explained by these factors. Additionally, 
because of the characteristic pattern of muscle involvement, the influence of the genetic 
defect and disease modifying factors may differ between body regions or muscle groups.
 
In this study, we combine state of the art genetic testing for FSHD with extensive clinical 
data in a large cohort of FSHD1 patients to assess how much of the clinical variability can 
be explained with our current knowledge on the (epi)genetic mechanism. We use family 
data to estimate the influence of familial factors on disease severity and include a detailed 
description of clinical features to further refine phenotype-genotype correlations. 
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METHODS
Patients
We recruited patients through the Neurology department of the Radboud University Med-
ical Center, the national referral center for FSHD patients in the Netherlands between 
2014-2015. We performed genetic testing on individuals aged 18 years or older and 1) 
with an FSHD phenotype, or 2) without an FSHD phenotype, but with at least one affected 
first degree family member. All individuals who tested positive for FSHD1 (D4Z4 repeat 
array size 1-10 units on a DUX4PAS containing haplotype) were included.11, 19 Exclusion 
criteria were the presence of pathogenic variants in SMCHD1 or DNMT3B and somatic 
mosaicism for the D4Z4 repeat array contraction. Asymptomatic mutation carriers were 
defined as individuals aged 25 years and older who did not report symptoms of FSHD on 
history taking, but who showed signs of FSHD on physical examination. Non-penetrant 
mutation carriers were aged 25 years and older, reported no symptoms and had no signs 
of FSHD on physical examination.
Genetic testing
For all samples we isolated blood-derived genomic DNA (gDNA), which was analyzed for 
D4Z4 repeat size and haplotype on chromosomes 4q and 10q, as previously described.11 
Southern blot analysis of gDNA after digestion with the methylation sensitive restriction 
enzyme FseI was used to determine the CpG methylation at the D4Z4 repeats on chromo-
somes 4 and 10. The Delta1 score as measure for the degree of D4Z4 hypomethylation 
was calculated as previously described.22 D4Z4 CpG methylation is repeat size dependent 
and the Delta1 score indicates the differences between the expected D4Z4 CpG meth-
ylation based on the number of repeat units, and the observed methylation.22 Detailed 
protocols are freely available from the Fields Center website (www.urmc.rochester.edu/
fields-center).
Clinical outcome measures
Multiple clinical scores were obtained by a trained clinician (KM): the clinical severity score 
by Ricci et al. is a 10-point for overall disease severity in which 0 indicates no symptoms and 
10 indicates wheelchair dependency14; the FSHD clinical score assesses disease severity 
by assigning severity scores to six body regions and ranges from 0 to 15 in which higher 
scores indicate more severe muscle weakness23; the 32-item motor function measure 
(MFM) tests for functional abilities in neuromuscular diseases and is expressed as a per-
centage where a score of 100% implies no motor deficits.24 Additionally, manual muscle 
testing was graded using a 6-point Medical Research Council (MRC) scoring system25 for 
the following muscle groups: neck flexors and extensors, shoulder ab- and adductors 
and exorotators, elbow flexors and extensors, wrist flexors and extensors, hip flexion, 
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knee flexion and extension, foot dorsal and plantar flexion. Facial weakness was graded 
bilaterally on a self-designed 4-point scale (facial score) for seven different tasks (closing 
the eyes gently and firmly, raising the eyebrows, frowning, pursing the lips, showing the 
teeth and puffing of the cheeks). A sumscore ranging from 14-56 was calculated in which 
lower scores indicate more severe facial weakness. 
Muscle MRI 
Ninety patients also participated in a large quantitative muscle MRI study on FSHD.26 Scan-
ning protocol and data processing are described in detail elsewhere.26 The MR imaging 
was performed on a 3-Tesla MR system (TIM Trio; Siemens, Erlangen, Germany). Briefly, 
the legs were scanned using a Dixon 2.0 sequence. Slice thickness was set at 5 mm. The 
Dixon sequence fat fraction map was used to draw a region of interest for each of the leg 
muscles. Muscle fat fractions were calculated per region of interest. Fat fractions below 
15% are considered normal.27
Protocol approval
This study was conducted according to the principles of the Declaration of Helsinki (version 
October 2013) and in accordance with the Medical Research Involving Human Subjects 
Act (WMO). The study protocol was approved by the regional medical ethics committee 
(CMO region Arnhem-Nijmegen). All participants signed informed consent.
Statistical analyses 
Statistical analyses were performed using SPSS Statistics version 22 and R Studio version 
3.2. Descriptive statistics (mean, standard deviation, range and frequency) were calculated 
for each variable. The relationship between the age-corrected FSHD clinical score (FSHD 
clinical score divided by age at examination) and the D4Z4 repeat array size was studied 
visually by a scatter plot and a best fitted trend line based on the least squared method. 
Next, nested linear regression models were fitted to study the fraction of variance in dis-
ease severity (FSHD clinical score, dependent variable) explained by each of the variables 
age, sex, D4Z4 repeat array size and Delta1 methylation score (independent variables). 
This was done by adding the independent variables stepwise to the model to assess 
the additional explained variance by each of the added variables. Since we were mainly 
interested in the additional value of D4Z4 repeat array size and Delta1 methylation score, 
the “baseline model” contained the variables age and sex (Model 1). The variables D4Z4 
repeat array size and Delta1 methylation score were each added separately (Model 2a and 
Model 2b) and together to the baseline model (Model 3). The procedure was repeated for 
all clinical outcomes that were collected.
525558-L-bw-Mul
Processed on: 30-11-2018 PDF page: 77
Phenotype-genotype relations in FSHD1
77
3
To study which percentage of the remaining variance can be explained by familial factors, 
a random intercept for family was added to the full fixed effects model (Model 4). The 
percentage of interest was estimated as the variance of the random effect divided by 
the total variance of the outcome (corrected for the fixed effects). In all linear models the 
variable D4Z4 repeat array size is included in the model as a linear continuous variable, 
but also transformations of the variable were considered.
To test for differences in outcomes between the sexes and between symptomatic and 
asymptomatic/non-penetrant mutation carriers independent samples t-tests were used 
for continuous measures and χ2 for frequencies. For all statistical tests p-values of < 0.05 
were considered statistically significant. For analyses on asymptomatic and non-penetrant 
gene carriers, two individuals aged younger than 25 years without signs or symptoms of 
FSHD were left out of the analyses. 
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RESULTS
Patient characteristics 
We performed genetic testing on 188 individuals. Thirty-six individuals were excluded. Five 
were excluded because of somatic mosaicism for the D4Z4 repeat array contraction, 2 
carried a pathogenic variant in SMCHD1 (FSHD2), 22 were unaffected family members of 
FSHD1 mutation carriers with negative genetic testing for FSHD. Seven other individuals 
tested negative for FSHD1 and FSHD2, 5 of which in retrospect had a phenotype incon-
sistent with FSHD. Two individuals from one family had a typical FSHD phenotype and are 
still genetically unexplained. This resulted in a cohort of 152 FSHD1 gene carriers. There 
were 23 single cases and 129 familial cases from 37 different families, with the number of 
participating family members ranging from 2 to 12. Baseline characteristics are shown in 
table 1. There was a small overrepresentation of females (55.3%). No significant differences 
between females and males were found in age, disease duration, clinical outcomes and 
genetic testing results. 
Table 1. Patient characteristics 
Total cohort n =152 Females n = 84 Males n = 68
Age in years 
(mean ± SD [range])
51.1 ±16.67[18-84] 50.0 ±17.1 [18-84] 52.4 ±16.1 [18-76]
Disease duration in years* 
(mean ± SD [range])
25.6 ±17.10[0-64] 26.5 ±17.75[0-59] 24.7 ±16.5 [0-64]
D4Z4 repeat units (mean ± SD [range]) 6.2 ±1.5 [3-9] 6.3 ±1.6 [3-9] 6.2 ±1.5 [3-9]
Delta1 methylation score 
(mean ± SD [range])
-1.9 ±8.4 [-23-24] -2.8 ±8.6 [-23-24] -0.8 ±8.4 [-18-22]
Haplotype (n)
A161 147 82 65
A159 5 2 3
Clinical condition¶ (n)
Symptomatic 127 69 58
Asymptomatic 14 9 5
Non-penetrant 9 6 3
Clinical severity score (Ricci score) 
(mean ± SD [range])
5.4 ±2.9 [0-10] 5.3 ±2.9 [0-10] 5.4 ±3.0 [0-10]
FSHD clinical score (mean ± SD [range]) 6.4 ±4.6 [0-15] 6.2 ±4.7 [0-15] 6.7 ±4.5 [0-15]
*only for symptomatic patients n = 123; ¶two male individuals aged < 25 years without signs or symptoms of FSHD 
were excluded from the analyses. No significant differences between females and males were found.
Explained variance in disease severity 
Figure 1 shows a scatter plot of the age-corrected disease severity (FSHD clinical score) 
against the D4Z4 repeat array size. Patients with 7-9 D4Z4 repeat units were less severely 
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affected than patients with 3-6 D4Z4 repeat units (age-corrected FSHD clinical score 9.7 vs 
16.2, p = 0.000). For the Delta1 methylation score no significant association with age-cor-
rected disease severity was found (figure 2). The Delta1 methylation score decreased with 
an increase in the D4Z4 repeat array size (table 2). The explained variance (coefficient of 
determination R2) for the various nested linear regression models are given in table 3. 
Within model 1, the fraction of additionally explained variance was 0.3% for sex (R2 = 
0.003). Next, we added a random intercept for family to the full fixed effects model (model 
3), this yielded model 4. The explained variance by the random family factor was approx-
imately 40%. By leaving out the variable D4Z4 repeat size from the model, the family 
component absorbed the degree of explanatory power of the variable D4Z4 repeat array 
size and the explained variance by the random intercept grew to 50% (after correcting for 
the fixed effects except D4Z4 repeat size). This indicates that the D4Z4 repeat array size 
only accounts for 10% of the explained variance in model 4. 
Several transformations of the variable D4Z4 repeat size were considered, but a linear 
association with the outcome seemed most appropriate. Within families the Delta1 score 
did not explain differences in disease severity. There were two outliers from one family 
with 5 D4Z4 repeat units with a very severe phenotype (age-corrected FSHD clinical scores 
58 and 65) who had Delta1 scores of -8 and -6. Excluding them from the analyses did not 
change the results.
Disease penetrance
This study included 14 asymptomatic and 9 non-penetrant gene carriers, excluding two 
individuals aged younger than 25 years without signs or symptoms of FSHD. Asymptomatic 
gene carriers were aged 26-79 years (mean 49 years) and non-penetrant gene carriers 
33-69 years (mean 47 years), and their mean age did not differ from the symptomatic 
individuals. There was no difference in the proportion of asymptomatic and non-penetrant 
individuals between males and females. The asymptomatic and non-penetrant gene car-
riers had a significant longer D4Z4 repeat array compared to symptomatic patients (7.3 
vs 6.0 units, 95%-CI of the difference -1.929 to -0.601, p = 0.000). All asymptomatic and 
non-penetrant carriers had ≥5 D4Z4 repeat units and 18 (78%) had ≥ 7 repeat units. The 
Delta1 score was slightly higher in asymptomatic and non-penetrant gene carriers than in 
symptomatic patients with ≥ 5 D4Z4 repeat units (0.96 vs -2.46, 95%-CI of the difference 
-7.08 to -0.04, p = 0.048). There were no differences in D4Z4 repeat array size or Delta1 
methylation score between asymptomatic and non-penetrant gene carriers. 
525558-L-bw-Mul
Processed on: 30-11-2018 PDF page: 80
Chapter 3
80
Figure 1. The age-corrected FSHD clinical score shows a moderate inverse correlation with the number of 
D4Z4 repeat units 
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Explained variance in disease severity per body region 
We further refined the phenotype-genotype relations by applying the nested linear models 
(models 1-3) on various outcome measures for three body regions: the face, the upper 
extremities and the lower extremities (table 3). We found that approximately 30% of the 
variance in the involvement of the facial muscles (facial score) was accounted for by D4Z4 
repeat size (ΔR2 0.313). Severe facial weakness (facial score < 23) was observed only in 
patients with ≤ 5 D4Z4 repeat units. The variance explained by the D4Z4 repeat array 
size was very limited for the lower extremities (ΔR2 0.006-0.066) and intermediate for 
the upper extremities (ΔR2 0.110-0.183). We also performed these analyses for each of 
the leg muscles separately (MRI fat fraction of single muscles) and found an influence of 
the repeat array size ranging from only 1 to 4% on the degree of fatty infiltration in the 
individual muscles.
The additional variance explained by the Delta1 methylation score was very limited for all 
body regions (ΔR2 0.009-0.043). 
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Figure 2. Delta1 methylation score per repeat array size in units for more mildly and more severely affected 
individuals (age-corrected FSHD clinical score < 15 and ≥ 15 respectively)
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Table 2. Disease severity and Delta1 methylation score decrease when the number of D4Z4 repeat units 
increases
Number of D4Z4 
repeat units
Number 
of participants
Age-corrected FSHD 
clinical score
Delta1 methylation 
score
3 5 25.1 ±5.0 -1.0 ±14.2
4 10 17.8 ±9.9 -1.1 ±4.4
5 49 16.4 ±12.8 -1.7 ±8.4
6 15 11.4 ±4.7 -2.1 ±8.2
7 43 11.1 ±7.1 -2.1 ±9.6
8 16 9.0 ±8.0 -1.6 ±4.3
9 14 6.4 ±6.1 -4.0 ±11.1
525558-L-bw-Mul
Processed on: 30-11-2018 PDF page: 82
Chapter 3
82
Table 3. Results of nested linear regression analyses for disease severity and outcome measures per body 
region, showing the largest influence of the D4Z4 repeat array size on the facial muscles
Model 1 
(age, sex)
Model 2a 
(age, sex, 
D4Z4 repeat array) 
Model 2b 
(age, sex, 
Delta1 score) 
Model 3
(age, sex, D4Z4 
repeat array, 
Delta1 score) 
R2 ΔR2 from model 1 ΔR2 from model 1 ΔR2 from model 1
Overall disease severity
FSHD clinical score 0.128 0.118 0.013 0.131
Face
Facial score 0.025 0.313 0.043 0.356
Upper extremities
MFM upper extremity items 0.065 0.110 0.009 0.120
MRC-sum score upper 
extremity
0.047 0.183 0.014 0.197
Lower extremities
MFM lower extremity items 0.215 0.046 0.008 0.053
MRC-sum score lower 
extremity
0.151 0.066 0.009 0.074
Quantitative MRI fat fraction 
leg muscles (n = 87)
0.303 0.006 0.009 0.015
In each model independent factors were added to assess the additional explained variance from model 1 (ΔR2)
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DISCUSSION
The high clinical variability in FSHD raises the question which factors contribute to disease 
severity and penetrance. This study showed that the D4Z4 repeat array size (mainly) in 
the range from 5-9 repeat units accounted for only approximately 10% of the variance in 
disease severity of FSHD, even though asymptomatic and non-penetrant gene carriers 
showed significantly longer repeat array sizes than symptomatic individuals. All other famil-
ial factors, including shared genetic factors other than the FSHD1 mutation and shared 
environmental factors within families, explained an additional 40% of the clinical variability 
in disease severity. Although unaffected gene carriers showed higher Delta1 methylation 
levels, suggesting that chromatin modifiers acting on the D4Z4 methylation level are prob-
ably involved, there was no significant correlation between Delta1 methylation scores and 
clinical severity. The identification of two outliers with a very severe phenotype without 
an SMCHD1 pathogenic variant nor extremely low Delta1 scores (-6 and -8), suggest that 
additional modifiers acting through other pathways than the D4Z4 chromatin structure 
must be involved. 
Our results suggest that currently unknown disease modifying factors acting on an indi-
vidual level are involved. These factors probably include a combination of additional (epi)
genetic factors as well as organismal, environmental and lifestyle factors. Research on 
the latter is limited. In the current study we found no influence of sex on disease severity. 
Possible protective effects of antioxidants and female reproductive hormones are still 
under active investigation, but results are contradictory.28-30 One study on aerobic exercise 
in FSHD showed that it slows down disease progression in leg muscles.31 
The characteristic pattern of muscle involvement in FSHD prompted us to assess whether 
the influence of genetic and epigenetic factors differs per body region or muscle group. 
Indeed, the D4Z4 repeat array size had a stronger influence on the degree of facial weak-
ness than on the upper and lower extremity involvement. This is in line with previous 
studies showing that patients with a facial-sparing phenotype generally have repeat array 
sizes of > 30 kb (approximately 7 units).32-40 In contrast to the facial muscles, leg muscle 
involvement was influenced by age, but hardly by D4Z4 repeat array size. Remarkably, 
there was no difference in the influence of the D4Z4 repeat array size and methylation 
between frequently involved and frequently spared leg muscles.26, 41 
These findings raise the question whether the facial muscles, that represent the most 
characteristic and often first symptom of FSHD, are more sensitive to (differences in) DUX4 
expression levels than other muscles. There is no data on a histological or molecular level 
of the facial muscles in FSHD since they cannot be biopsied, and also on a clinical level 
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knowledge is lacking. However, given the recent studies suggesting a functional relation-
ship between DUX4 and the myogenic Pax3 and Pax7 homeodomain transcription factors, 
but not with other related homeodomains such as Pitx2 and Tbx1, it is tempting to spec-
ulate that facial muscles are more susceptible to DUX4 damage during development.42, 43 
The small influence of the D4Z4 repeat array size on the degree of leg muscle involvement 
suggests that these muscles are more sensitive to modifying factors, or that compensa-
tion by other myogenic homeobox proteins takes place. Since all patients with leg muscle 
involvement also had some degree of facial- and/or shoulder girdle muscle involvement, 
DUX4 expression is likely to be required as a trigger to induce disease activity in the leg 
muscles. This could indicate that the involvement of leg muscles is results from a complex 
interplay of downstream effects of DUX4 together with various modifying factors. Possibly, 
the influence of physical activity is larger for the lower extremity muscles, as the level of 
activity is more variable for the leg muscles than for the facial muscles. Additional research 
is required to test this hypothesis. 
A limitation of this study was the low proportion of individuals with very short repeat array 
sizes (1-3 units). Generally, patients with 1-3 D4Z4 repeat units have a severe phenotype. 
The statistical models used include the assumption that the relation between age and 
disease severity is linear. Although on an individual level disease progression is likely to be 
stepwise instead of gradually progressive, this assumption probably is correct on a group 
level. Another limitation was the presence of families with a limited number of participating 
family members. Although we included large families with up to 12 participating family 
members, there were also families with only two included cases that were less suited to 
study the contribution of familial factors. Finally, it is likely that some of the asymptomatic 
or non-penetrant gene carriers were still presymptomatic and will develop symptoms 
at a later age, even though their mean age was high (49.8 years) and we excluded those 
aged under 25 years. A longitudinal study would not only shed light on this question, but 
would also provide information on the relation between (epi)genetic findings and disease 
progression.
Although the D4Z4 repeat array sizes contributes to differences in disease severity and 
penetrance, other unidentified factors must play an important role. These modifying fac-
tors include chromatin modifiers acting on D4Z4 methylation, but could include (epi)
genetic as well as organismal, environmental or lifestyle factors as well. Additionally, there 
are probably differences in the sensitivity to the influence of the D4Z4 locus itself and to 
various modifiers between different muscle groups. 
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ABSTRACT 
Objective: This study aims to determine whether congenital arhinia/Bosma arhinia micro-
phthalmia syndrome (BAMS) and facioscapulohumeral muscular dystrophy type 2 (FSHD2), 
two seemingly unrelated disorders both caused by heterozygous pathogenic missense 
variants in the SMCHD1 gene, might represent different ends of a broad single phenotypic 
spectrum associated with SMCHD1 dysfunction.
Methods: We examined and/or interviewed 14 FSHD2 patients and 4 unaffected family 
members with N-terminal SMCHD1 pathogenic missense variants to identify BAMS 
sub-phenotypes.
Results: None of the FSHD2 patients or family members demonstrated any congenital 
defects or dysmorphic features commonly found in patients with BAMS. One patient 
became anosmic after nasal surgery and one patient was hyposmic; one man was infertile 
(unknown cause) but reported normal pubertal development.
Conclusions: These data suggest that arhinia/BAMS and FSHD2 do not represent one 
phenotypic spectrum and that SMCHD1 pathogenic variants by themselves are insuffi-
cient to cause either of the two disorders. More likely, both arhinia/BAMS and FSHD2 are 
caused by complex oligogenic or multifactorial mechanisms which only partially overlap 
at the level of SMCHD1.
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INTRODUCTION
The ‘structural maintenance of chromosomes flexible hinge domain containing 1’ (SMCHD1) 
gene on chromosome 18p encodes an epigenetic regulator that is thought to repress 
gene transcription through DNA methylation, histone tail modification, and association 
with long non-coding RNAs (e.g., XIST on the X-chromosome).1 The SMCHD1 protein con-
tains two functionally conserved domains, an N-terminal ATPase domain (aa 111-365) 
and a C-terminal hinge domain (aa 1688-1875), which powers chromatin re-modeling or 
mediates homodimerization and DNA binding, respectively.2 Physiologically it is, among 
other functions, involved in X chromosome inactivation in females.3
Recent genetic studies showed that identical heterozygous mutations in SMCHD1 are 
associated with two seemingly unrelated disorders: (1) facioscapulohumeral muscular 
dystrophy type 2 (FSHD2) 4 and (2) congenital arhinia, often with co-morbid reproductive 
and ocular defects, a triad called Bosma arhinia microphthalmia syndrome (BAMS).5-7
FSHD2 is a rare form of muscular dystrophy, characterized by slowly progressive and 
asymmetric weakness of muscles of the face and shoulder girdle, and in later stages 
the trunk and leg muscles. FSHD2 has a complex digenic and epigenetic etiology, that 
involves both the SMCHD1 locus (18p11.32) and the D4Z4 macrosatellite repeat array on 
chromosome 4 (4q35).4 Under normal conditions in somatic cells (including muscle cells), 
SMCHD1 binds to the D4Z4 repeat array where it functions as a chromatin repressor and 
suppresses transcription of the DUX4 retrogene. Heterozygous missense, insertion, dele-
tion, splicing and truncating variants in SMCHD1 identified in patients with FSHD2 patients 
are associated with hypomethylation of the D4Z4 repeat array, consistent with a loss-of-
function mechanism. Loss of SMCHD1 repressive activity leads to partial relaxation of the 
D4Z4 chromatin structure and de-repression of DUX4. When this occurs in the presence 
of a specific (‘permissive’) 4q35 haplotype, a poly-adenylation signal (DUX4 PAS) tags and 
stabilizes the DUX4 mRNA and DUX4 protein accumulates, triggering muscle cell death. 
8,4 The more common genetic FSHD variant is FSHD type 1 (FSHD1), where contraction of 
the D4Z4 repeat array to a critical number between 1 and 10 units also leads to a partial 
relaxation of the locus and derepression of the DUX4 gene.8
BAMS is an extremely rare syndrome that is defined by the triad of arhinia, colobomatous 
microphthalmia, and hypogonadism.7 In contrast to FSHD2, where missense and loss-of-
function variants are distributed along the entire SMCHD1 locus, in BAMS patients, the 
variants are all missense and are clustered within or immediately downstream of the 
ATPase domain.6,5 While D4Z4 hypomethylation akin to FSHD2 is seen in BAMS patients 
with SMCHD1 mutations, suggesting a loss-of-function mechanism5, a gain of function 
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mode of action has also been proposed.6 Given the digenic etiology of FSHD2 and the 
extremely low frequency of damaging SMCHD1 mutations in the general population, it is 
not entirely surprising that only one patient with both arhinia and FSHD2 and one multiplex 
family with one of the two conditions present in different members have been reported to 
date.5 However, because the discovery of SMCHD1 mutations in FSHD2 patients preceded 
the same discovery in arhinia patients, there has yet to be a systematic investigation of 
BAMS-associated features in patients with FSHD2. To this end, we performed phenotypic 
and genotypic studies in 14 members of our FSHD2 cohort and 4 of their family members, 
who harbor missense mutations in the N-terminal region of SMCHD1 to identify potential 
areas of overlap.
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MATERIALS AND METHODS
Patients
We identified 23 FSHD patients with heterozygous pathogenic missense variants near 
the ATPase domain of SMCHD1 in the FSHD genetic database in the Human Genetics 
department of the Leiden University Medical Center. Family members of one patient were 
recruited through a cohort-study (FSHD-FOCUS study) by the Neurology department of the 
Radboud University Medical Center, Nijmegen. Another 10 sporadic cases were recruited 
for participation by referring clinicians from the USA, France, United Kingdom and the 
Netherlands. 
Genetic testing
DNA was extracted from blood samples and analyzed for D4Z4 repeat size, chromosome 
4q and 10q haplotypes, as described previously9, and for SMCHD1 pathogenic variants 
by Sanger sequencing.4 CpG methylation at the D4Z4 repeat was determined by South-
ern blot and the methylation sensitive restriction enzyme FseI. Detailed protocols are 
freely available from the Fields Center website (www.urmc.rochester.edu/fields-center). 
The Delta1 score, a measure of the degree of D4Z4 hypomethylation, was calculated as 
described previously.10 The Delta1 threshold for FSHD-associated SMCHD1 pathogenic 
variants lies below -21%. 
Clinical assessment
All participants were interviewed regarding nasal and olfactory abnormalities, puber-
tal development, fertility, eye anatomy and vision, history of maxillofacial surgery, and 
presence of cleft lip/palate. Photographs were available for 10 participants, which were 
independently assessed by three clinicians. 
In addition, ten members of one FSHD family were examined in person for (subtle) signs 
of arhinia or associated comorbidities by a clinical geneticist (MK) who was blinded to 
mutation status. Olfactory function was assessed using the Sniffin’ Sticks Screening Test 
(Burghart, Medizintechnik, GmbH, Wedel, Germany) which assigns a sex and age-adjusted 
olfactory score. One family member was examined using Skype. 
Ethical approval 
This study was conducted according to the principles of the Declaration of Helsinki (version 
October 2013) and in accordance with the Medical Research Involving Human Subjects 
Act (WMO). Participants were consented under a protocol approved by the local ethics 
committee of the Radboud University Medical Center, Nijmegen.
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RESULTS
Genetic results
In the large Euro-Caucasian FSHD family, 8 family members carried a pathogenic missense 
variant in SMCHD1 (c.320T>C; p.Leu107Pro) (figures 1 and 2, table 1). Importantly this 
pathogenic variant was previously reported in an unrelated, African-American female with 
BAMS.5 All pathogenic variant carriers showed profound hypomethylation at the D4Z4 
locus on chromosome 4q with Delta1 scores below -26%.10 The 5 affected individuals had 
the FSHD-permissive, 4qA haplotype that contains the somatic DUX4 PAS.9 In addition, 
four of them had a D4Z4 repeat array of 9 units, compatible with an additional molecular 
diagnosis of FSHD18, but also found in 1-2% of the Caucasian control population.11-13 
The three unaffected individuals were homozygous for the 4qB haplotype, which is not 
FSHD-permissive because of the absence of a somatic DUX4 PAS. One family member that 
tested negative for the SMCHD1 pathogenic variant, did carry a 9 unit repeat on a 4qA 
haplotype. Her Delta1 score was -9%. 
We identified 23 other sporadic FSHD2 patients in the FSHD genetic database with a 
pathogenic missense variantin close proximity to or identical to those previously iden-
tified in patients with arhinia or BAMS (6,5, Shaw, unpublished observation). All FSHD2 
patients had a permissive haplotype and D4Z4 hypomethylation (table 2). Seventeen of 
the 20 pathogenic variants in these FSHD2 patients involved the same SMCHD1 exon as 
in arhinia patients and three pathogenic variants were identical to those found in arhinia 
patients (figure 3). We also identified one family with a heterozygous 3-bp deletion in exon 
6 (c.729_731delCTT; p.Phe244del) resulting in the deletion of a single amino acid just two 
positions downstream of an amino acid affected in BAMS patients.
Clinical characteristics
In the large FSHD family, six individuals with an N-terminal SMCHD1 pathogenic mis-
sense variant were examined (individuals II:1 and II:4 were deceased at the time of the 
study). None of them had microphthalmia, congenital cataracts, coloboma, nasolacrimal 
duct atresia, mid-face hypoplasia, or cleft lip/palate (table 3). Several family members had 
narrow nares and/or hypoplastic alae nasi (rounded prominence of nostril) but these 
features did not segregate with the SMCHD1 pathogenic variant, suggesting they were 
unrelated, familial traits. One family member with FSHD1 and 2 (II-3) developed anosmia 
shortly after surgery for a deviated nasal septum. A second affected patient with both 
FSHD1 and 2 (III-3) was hyposmic (Sniffin’ Sticks Screening Test result below the 10th per-
centile). All family members who were questioned reported normal pubertal timing and 
denied infertility. 
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Figure 1. Pedigree for FSHD2 multiplex family with pathogenic variant (p.L107P) in SMCHD1
Shaded symbols represent family members meeting clinical criteria for FSHD2. Genetic information is listed below 
each family member: top box is mutation status (SMCHD1 variant present or WT- wild type), lower boxes indicate 
the 4q35 haplotype (A or B) and D4Z4 repeat length (units) for each allele.
Figure 2. Sequence track of the SMCHD1 pathogenic variant in the FSHD2 family and in a control sample
The position of the variant in exon 3 is indicated above the sequence traces and is highlighted in yellow. The 
genomic position is based on reference genome hg19 and the transcript and protein position on accession 
number NM015295 and NP056110, respectively.
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Table 1. Genetic characteristics of FSHD family members
ID Fig 1 Sex Age 4q35 locus SMCHD1 variant and D4Z4 methylation (%) At risk for FSHD
      4q_1 units 4q_1 haplotype 4q_2 units 4q_2 haplotype FseI methylation Delta1 methylation SMCHD1  
II-1 F † 20U 4B163 23U 4B163 3% -42% +/- No
II-2 M 80y 27U 4A161 28U 4B163 58% 12% +/+ No
II-3 F 75y 9U 4A161 20U 4B163 4% -33% +/- FSHD1+2
II-4 M † 9U 4A161 20U 4B163 n/a n/a +/- FSHD1+2
II-5 M † 20U 4B163 23U 4B163 25% -16% +/+ No
III-1 F 52y 20U 4B163 28U 4B163 11% -34% +/- No
III-2 M 61y 39U 4A161 45U 4B168 n/a n/a +/+ No
III-3 F 51y 9U 4A161 27U 4A161 6% -35% +/- FSHD1+2
III-4 M 47y 20U 4B163 28U 4B163 7% -39% +/- No
IV-1 F 21y 18U 4B163 66U 4A161 22% -29% +/- No
IV-2 F 18y 9U 4A161 45U 4B168 36% -9% +/+ FSHD1
IV-3 M 16y 9U 4A161 39U 4A161 16% -26% +/- FSHD1+2
IV-4 M 19y 28U 4B163 40U 4B168 52% 6% +/+ No
IV-5 F 14y 20U 4B163 40U 4B168 47% 3% +/+ No
M: male; F: female; n/a: not available; 4q_1 and 4q_2 represent the two alleles on chromosome 4q35; †: deceased; 
U: units. IDs correspond to those in the pedigree (Figure 1).
Table 2. Genetic characteristics of FSHD2 patients
ID Fig 3 Sex 4q35 locus SMCHD1 variant and D4Z4 methylation (%)
    4q_1 units 4q_1 haplotype 4q_2 units 4q_2 haplotype FseI 
methy-lation
delta1
methy- lation
SMCHD1 cDNA 
(NM_015295.2) 
SMCHD1 variant 
(NP_056110.2)
Position relative to known 
BAMS mutation
exon
2   see Table 1 see Table 1 c.320T>C p.Leu107Pro identical to p.Leu107Pro 3
7 M 13 A 33 B 12 -28 c.580C>T p.Leu194Phe 23 aa distal to p.Phe171Val 5
8 M 11 A 39 B 5 -33 c.610A>G p.Lys204Glu 33 aa distal to p.Phe171Val 5
10a M no genotype data (no DNA) 3 n/a c.729_731delCTT p.Phe244del 2 aa distal to p.Ala242Gly 6
10b F no genotype data (no DNA) NA n/a c.729_731delCTT p.Phe244del 2 aa distal to p.Ala242Gly 6
10c M no genotype data (no DNA) NA n/a c.729_731delCTT p.Phe244del 2 aa distal to p.Ala242Gly 6
12 F 13 A n/a n/a 5 n/a c.848A>G p.Tyr283Cys 41 aa distal to p.Ala242Gly 7
14 M 17 A 47 A 9 -41 c.1058A>G p.Tyr353Cys 5 aa distal to p.His348Arg 9
15 F 14 A 15 A 1 -37 c.1273G>A p.Gly425Arg 5 aa distal to p.Asp420Val 10
18 M 11 A 35 B 7 -29 c.1474T>C p.Cys492Arg 19 aa distal to p.Glu473Gln 12
19 F 17 A 18 A 11 -31 c.1556T>C p.Phe519Ser 1 aa distal to p.Lys518Glu 12
M: male; F: female; n/a: not available; nl: normal; 4q_1 and 4q_2 represent the two alleles on chromosome 4q35. IDs correspond to the mutation number in
figure 3.
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Table 1. Genetic characteristics of FSHD family members
ID Fig 1 Sex Age 4q35 locus SMCHD1 variant and D4Z4 methylation (%) At risk for FSHD
      4q_1 units 4q_1 haplotype 4q_2 units 4q_2 haplotype FseI methylation Delta1 methylation SMCHD1  
II-1 F † 20U 4B163 23U 4B163 3% -42% +/- No
II-2 M 80y 27U 4A161 28U 4B163 58% 12% +/+ No
II-3 F 75y 9U 4A161 20U 4B163 4% -33% +/- FSHD1+2
II-4 M † 9U 4A161 20U 4B163 n/a n/a +/- FSHD1+2
II-5 M † 20U 4B163 23U 4B163 25% -16% +/+ No
III-1 F 52y 20U 4B163 28U 4B163 11% -34% +/- No
III-2 M 61y 39U 4A161 45U 4B168 n/a n/a +/+ No
III-3 F 51y 9U 4A161 27U 4A161 6% -35% +/- FSHD1+2
III-4 M 47y 20U 4B163 28U 4B163 7% -39% +/- No
IV-1 F 21y 18U 4B163 66U 4A161 22% -29% +/- No
IV-2 F 18y 9U 4A161 45U 4B168 36% -9% +/+ FSHD1
IV-3 M 16y 9U 4A161 39U 4A161 16% -26% +/- FSHD1+2
IV-4 M 19y 28U 4B163 40U 4B168 52% 6% +/+ No
IV-5 F 14y 20U 4B163 40U 4B168 47% 3% +/+ No
M: male; F: female; n/a: not available; 4q_1 and 4q_2 represent the two alleles on chromosome 4q35; †: deceased; 
U: units. IDs correspond to those in the pedigree (Figure 1).
Table 2. Genetic characteristics of FSHD2 patients
ID Fig 3 Sex 4q35 locus SMCHD1 variant and D4Z4 methylation (%)
    4q_1 units 4q_1 haplotype 4q_2 units 4q_2 haplotype FseI 
methy-lation
delta1
methy- lation
SMCHD1 cDNA 
(NM_015295.2) 
SMCHD1 variant 
(NP_056110.2)
Position relative to known 
BAMS mutation
exon
2   see Table 1 see Table 1 c.320T>C p.Leu107Pro identical to p.Leu107Pro 3
7 M 13 A 33 B 12 -28 c.580C>T p.Leu194Phe 23 aa distal to p.Phe171Val 5
8 M 11 A 39 B 5 -33 c.610A>G p.Lys204Glu 33 aa distal to p.Phe171Val 5
10a M no genotype data (no DNA) 3 n/a c.729_731delCTT p.Phe244del 2 aa distal to p.Ala242Gly 6
10b F no genotype data (no DNA) NA n/a c.729_731delCTT p.Phe244del 2 aa distal to p.Ala242Gly 6
10c M no genotype data (no DNA) NA n/a c.729_731delCTT p.Phe244del 2 aa distal to p.Ala242Gly 6
12 F 13 A n/a n/a 5 n/a c.848A>G p.Tyr283Cys 41 aa distal to p.Ala242Gly 7
14 M 17 A 47 A 9 -41 c.1058A>G p.Tyr353Cys 5 aa distal to p.His348Arg 9
15 F 14 A 15 A 1 -37 c.1273G>A p.Gly425Arg 5 aa distal to p.Asp420Val 10
18 M 11 A 35 B 7 -29 c.1474T>C p.Cys492Arg 19 aa distal to p.Glu473Gln 12
19 F 17 A 18 A 11 -31 c.1556T>C p.Phe519Ser 1 aa distal to p.Lys518Glu 12
M: male; F: female; n/a: not available; nl: normal; 4q_1 and 4q_2 represent the two alleles on chromosome 4q35. IDs correspond to the mutation number in
figure 3.
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Table 3. Clinical findings in FSHD family with a pathogenic SMCHD1 variant
ID Fig 1 Sex Age (y) SMCHD1 variant Signs of FSHD Interview and assessment of dysmorphic features Pubertal 
development
Sniffin’ 
sticks test
Other
II-1 F † +/- n/a (not at risk) n/a n/a n/a
II-2 M 80 +/+ n/a (not at risk) n/a nl; fertile n/a
II-3 F 75 +/- severe FSHD, wheelchair bound narrow nares; high nasal bride; hypoplastic alae nasi; 
bilateral cataracts at age 73y; dystopia canthorum; 
elongated philtrum
nl; fertile anosmia anosmia after nasal 
septum surgery
II-4 M † +/- severe FSHD, wheelchair bound n/a n/a n/a
II-5 M † +/+ n/a (not at risk) narrow nares; hypoplastic alae nasi nl n/a assessment using 
photographs
III-1 F 52 +/- nl (not at risk) hypoplastic alae nasi; unilateral epicanthal fold; glasses 
(-0.25 and -4.25)
nl; fertile n/a assessment using 
Skype
III-3 F 51 +/- severe FSHD, able to walk a few steps with support narrow nares and nose; high nasal bridge; hypoplastic 
and asymmetrical alae nasi; micrognatia
nl; fertile hyposmia 
III-4 M 47 +/- nl (not at risk) high nasal bridge; asymmetrical alae nasi; long philtrum nl; fertile normosmia
IV-1 F 21 +/- nl (not at risk) asymmetrical alae nasi nl normosmia
IV-2 F 18 +/+ mild facial weakness tendency to hypertelorism; short philtrum nl normosmia
IV-3 M 16 +/- facial weakness coarse facial features; thick and asymmetrical alae nasi; 
strabism; tendency to hypertelorism; retrognatia
nl normosmia mild learning 
disability
IV-4 M 19 +/+ nl (not at risk) none nl normosmia
IV-5 F 14 +/+ nl (not at risk) midline raphe nl normosmia
F: female; M: male; †: deceased; y: years; n/a: not available; nl: normal. IDs correspond to those in the pedigree 
(Figure 1).
Table 4. Clinical findings in sporadic FSHD2 patients as determined by interview and photographs
ID Fig 3 Sex BAMS-associated phenotypes BAMS-associated phenotypes Photographs
    Smell Nasal 
abnormalities
Nasal surgery Open nostrils Vision Eye anatomical 
abnormalities
Tear production Pubertal 
development
Fertility Cleft lip/ palate  
7 M nl no no yes nl no nl nl nl no n/a
8 M nl no adenoid 
removal
yes glasses no nl nl nl no n/a
10a M nl no no yes Astigmatism, 
hypermetropy
no nl nl nl no n/a
10b F nl no no yes nl no nl nl nl no n/a
10c M nl no no yes nl no nl nl nl no n/a
12 F nl no no yes nl no nl n/a n/a no n/a
14 M nl Difficulty 
clearing 
secretions
no yes glasses no Decreased 
(Schirmer’s test 
score 4)
Decreased body 
hair
Infertile no no 
abnormalities
15 F nl no no yes nl no nl nl nl no n/a
18 M nl no no yes nl no nl nl nl no n/a
19 F nl no no yes glasses no nl nl nl no no 
abnormalities
n/a: not available; nl: normal. IDs correspond to the mutation number in Figure 3.
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Table 3. Clinical findings in FSHD family with a pathogenic SMCHD1 variant
ID Fig 1 Sex Age (y) SMCHD1 variant Signs of FSHD Interview and assessment of dysmorphic features Pubertal 
development
Sniffin’ 
sticks test
Other
II-1 F † +/- n/a (not at risk) n/a n/a n/a
II-2 M 80 +/+ n/a (not at risk) n/a nl; fertile n/a
II-3 F 75 +/- severe FSHD, wheelchair bound narrow nares; high nasal bride; hypoplastic alae nasi; 
bilateral cataracts at age 73y; dystopia canthorum; 
elongated philtrum
nl; fertile anosmia anosmia after nasal 
septum surgery
II-4 M † +/- severe FSHD, wheelchair bound n/a n/a n/a
II-5 M † +/+ n/a (not at risk) narrow nares; hypoplastic alae nasi nl n/a assessment using 
photographs
III-1 F 52 +/- nl (not at risk) hypoplastic alae nasi; unilateral epicanthal fold; glasses 
(-0.25 and -4.25)
nl; fertile n/a assessment using 
Skype
III-3 F 51 +/- severe FSHD, able to walk a few steps with support narrow nares and nose; high nasal bridge; hypoplastic 
and asymmetrical alae nasi; micrognatia
nl; fertile hyposmia 
III-4 M 47 +/- nl (not at risk) high nasal bridge; asymmetrical alae nasi; long philtrum nl; fertile normosmia
IV-1 F 21 +/- nl (not at risk) asymmetrical alae nasi nl normosmia
IV-2 F 18 +/+ mild facial weakness tendency to hypertelorism; short philtrum nl normosmia
IV-3 M 16 +/- facial weakness coarse facial features; thick and asymmetrical alae nasi; 
strabism; tendency to hypertelorism; retrognatia
nl normosmia mild learning 
disability
IV-4 M 19 +/+ nl (not at risk) none nl normosmia
IV-5 F 14 +/+ nl (not at risk) midline raphe nl normosmia
F: female; M: male; †: deceased; y: years; n/a: not available; nl: normal. IDs correspond to those in the pedigree 
(Figure 1).
Table 4. Clinical findings in sporadic FSHD2 patients as determined by interview and photographs
ID Fig 3 Sex BAMS-associated phenotypes BAMS-associated phenotypes Photographs
    Smell Nasal 
abnormalities
Nasal surgery Open nostrils Vision Eye anatomical 
abnormalities
Tear production Pubertal 
development
Fertility Cleft lip/ palate  
7 M nl no no yes nl no nl nl nl no n/a
8 M nl no adenoid 
removal
yes glasses no nl nl nl no n/a
10a M nl no no yes Astigmatism, 
hypermetropy
no nl nl nl no n/a
10b F nl no no yes nl no nl nl nl no n/a
10c M nl no no yes nl no nl nl nl no n/a
12 F nl no no yes nl no nl n/a n/a no n/a
14 M nl Difficulty 
clearing 
secretions
no yes glasses no Decreased 
(Schirmer’s test 
score 4)
Decreased body 
hair
Infertile no no 
abnormalities
15 F nl no no yes nl no nl nl nl no n/a
18 M nl no no yes nl no nl nl nl no n/a
19 F nl no no yes glasses no nl nl nl no no 
abnormalities
n/a: not available; nl: normal. IDs correspond to the mutation number in Figure 3.
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Figure 3. Schematic of pathogenic missense variants in the N-terminal region of SMCHD1 associated with 
FSHD2 and/or arhinia/BAMS 
Pathogenic variants in the FSHD2 cohort in the current study are in bold (see also table 2), and the pathogenic 
variants that have been implicated in both FSHD2 and BAMS are underlined.
Four family members had symptoms of FSHD: the two older individuals (50 years and 
older) displayed severe muscle weakness and were wheelchair-dependent, whereas the 
two younger individuals had facial weakness, an early sign of FSHD. Three of them had 
both FSHD1 and 2, and one of the younger individuals only had FSHD1. 
The 10 sporadic FSHD2 patients who were phenotyped did not have physical features 
consistent with arhinia/BAMS (table 4). One male reported normal pubertal development 
but had infertility of unknown etiology. He denied other signs of hypogonadism such as 
cryptorchidism or micropenis and had never required testosterone replacement. Photo-
graphs of this patient revealed no signs of a craniofacial defect.
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DISCUSSION
We assessed FSHD patients with pathogenic missense variants in the N-terminal region of 
SMCHD1, which were recently shown to cause arhinia/BAMS, to determine whether FSHD2 
and BAMS might represent the opposite ends of one broad, phenotypic spectrum or if 
each condition is caused by SMCHD1 dysfunction in the presence of a genetic background 
unique to each condition. Only one patient with arhinia has been identified thus far who 
meets clinical and genetic criteria for FSHD25, and until now, FSHD2 patients had never 
been specifically assessed for BAMS-like features. 
Detailed examination of a large FSHD family with an SMCHD1 pathogenic variant identical 
to one found in BAMS patients did not uncover any congenital defects or dysmorphic 
features commonly found in patients with BAMS. We identified one patient in this family 
who developed cataracts in her 70’s and lost olfaction after nasal surgery. These findings 
are unlikely to be related to BAMS as cataracts are very common with aging secondary 
to cumulative photo-oxidative insults (e.g. ultraviolet-B) and she did not have congenital 
anosmia as occurs in BAMS patients; rather she lost olfactory function after nasal surgery 
which is a recognized, albeit rare, potential side effect of septoplasty.14,15 We also observed 
several family members with nasal hypoplasia. The power of our combined genetic and 
phenotypic approach, however, allowed us to confidently classify this phenotype as a 
familial rather than SMCHD1-related trait as it did not segregate with the SMCHD1 patho-
genic variant. 
All other FSHD2 patients included in this study reported normal olfaction, no craniofacial 
or ocular abnormalities and normal pubertal development and those of reproductive age 
were fertile with the exception of one male patient with infertility of unknown cause. Thus, 
we find no evidence for phenotypic overlap in FSHD2 and BAMS patients.
 The phenotyping protocol for this study was intentionally simple and non-invasive in 
design such that all study procedures could be performed by patients from afar. Although 
we performed detailed, structured interviews to collect phenotypic data on the sporadic 
cases, it is possible that patients were not fully aware of any subtle BAMS-associated fea-
tures. Future studies will be required to confirm our findings in a larger number of FSHD 
patients using more sophisticated tools such brain imaging to assess the integrity of the 
olfactory bulbs and tracts, dilated eye exams, and reproductive hormone testing.
Our data support the hypothesis that arhinia/BAMS and FSHD2 represent two distinct 
oligogenic disorders. In both conditions, SMCHD1 dysfunction appears to be necessary 
but not sufficient to cause disease. In FSHD2, a permissive 4q35 haplotype is one known 
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requirement, but the variability in muscle weakness that is seen among family members 
with the same SMCHD1 pathogenic variant (and D4Z4 repeat size) suggests that there are 
other genetic or environmental modifiers yet to be discovered. Incomplete penetrance 
of SMCHD1 variants in the form of nasal hypoplasia or isolated anosmia has also been 
observed in multiplex arhinia/BAMS families.5 Modifier genes have not been identified in 
arhinia but SMCHD1 binding partners and/or downstream targets are rational candidates. 
Thus, in the extremely rare chance that a patient has an N-terminal SMCHD1 pathogenic 
variant and meets the genetic requirements unique to arhinia/BAMS and to FSHD2, he/
she can demonstrate both conditions. 
Pathogenic variants in the N-terminal region of SMCHD1 play a critical role in the pathogen-
esis of both FSHD2 and arhinia/BAMS and. The complete absence of phenotypic overlap 
between these two disorders, however, suggests that these variants are, by themselves, 
insufficient to cause either disorder. The current study instead supports an oligogenic or 
multifactorial disease mechanism for both FSHD2 and arhinia/BAMS. 
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ABSTRACT
Facioscapulohumeral muscular dystrophy (FSHD) is characterized by large variability in 
disease severity, that is only partly explained by (epi)genetic factors. Clinical observations 
and recent in vitro work suggest a protective effect of estrogens in FSHD. The aims of this 
study were to assess whether the lifetime endogenous estrogen exposure contributes to 
the variability in disease severity in female patients, and whether female patients experi-
ence changes in disease progression during periods of hormonal changes. We calculated 
the lifetime endogenous estrogen exposure by subtracting periods with high progester-
one levels (in which estrogens are counteracted) from the reproductive life span. Multiple 
linear regression in 85 patients did not show a contribution of the lifetime endogenous 
estrogen exposure to disease severity (B = 0.063, p = 0.517, ΔR2 = 0.003). The majority 
of women reported an unchanged rate of disease progression through periods of hor-
monal changes, like menarche, pregnancy or menopause. Women that noticed differences 
reported accelerations as well as decelerations. These results indicate that differences in 
estrogen exposure do not have a clinically relevant modifying effect on disease severity. 
However, a clinically relevant protective effect of greater differences in estrogen levels, or 
a protective effect caused by a more complex interplay with other reproductive hormones, 
cannot be ruled out.
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INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) is an inherited muscular dystrophy that 
initially affects the facial-, shoulder and upper arm muscles, followed by the trunk and leg 
muscles.1 It is caused by chromatin relaxation of the D4Z4 repeat array on chromosome 
4q35, resulting in the misexpression of the DUX4 transcription factor in myogenic cells, 
that finally leads to muscle cell death.2 In its most common form, FSHD1, the chromatin 
relaxation is caused by a repeat contraction to 1-10 D4Z4 repeat units. In FSHD2, chro-
matin relaxation is in most cases the result of heterozygous mutations in the SMCHD1 
(Structural Maintenance of Chromosomes flexible Hinge Domain containing-1) gene in 
the absence of a repeat contraction.3 
One of the clinical hallmarks of FSHD is its large variability in disease severity, ranging from 
asymptomatic and minimally affected gene carriers to wheelchair-bound individuals.1 Even 
within the same family, large differences in disease severity can occur, despite carrying 
an identical D4Z4 repeat array. Most variability is observed in families with longer sized 
repeat arrays (seven repeat units and more), in which asymptomatic gene carriers are 
common.4-6 This unexplained variability strongly suggests that other, not yet identified, 
modifying factors must be involved in this disease. 
One of the longstanding questions in FSHD is whether sex-related modifiers could be iden-
tified that influence disease severity. Sex differences in disease severity in FSHD patients 
have been observed in different studies, consistently reporting a higher proportion of 
women among asymptomatic gene carriers.5-9 Additionally, cases have been reported 
of women experiencing a persistent worsening of symptoms following pregnancies, 
early menopause or anti-estrogenic therapy.10-12 However, limited work has been done 
to systematically assess changes in disease progression during periods of pronounced 
hormonal changes. Recently, in vitro studies showed that estrogens antagonize DUX4 
activity and improve the differentiation properties of FSHD-derived myoblasts.10 These 
findings suggest a protective effect of estrogens on disease severity in FSHD. We therefore 
hypothesized that a higher estrogen exposure in female patients could act as a disease 
modifying factor, resulting in less severe symptoms. In this study we assessed whether the 
lifetime endogenous estrogen exposure contributes to the variability in disease severity in 
female patients with FSHD. In addition, we evaluated whether female patients experienced 
subjective changes in the rate of disease progression during periods of hormonal changes. 
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METHODS
Patients
Data were collected in a large cohort study on FSHD (FSHD-FOCUS study) at the Neurology 
department of the Radboud University Medical Center, Nijmegen, the Netherlands from 
2014 to 2015. The cohort consisted of 203 patients aged 18 years and older, including 
105 female patients. All patients were genetically confirmed, including determination of 
the number of D4Z4 repeat units.2 Women who underwent hysterectomy or ovariectomy 
were excluded, because of uncertainty of time of menopause and thus uncertainty of 
total estrogen exposure. 
Ethical approval 
This study was conducted according to the principles of the Declaration of Helsinki (version 
October 2013) and in accordance with the Medical Research Involving Human Subjects 
Act (WMO). The study protocol was approved by the regional medical ethics committee. 
All patients signed informed consent.
Disease severity
Disease severity was determined using the FSHD clinical score. This is a fifteen-point sum-
score that evaluates severity of involvement of different muscle groups with zero indicating 
no symptoms and fifteen severe involvement of all muscles groups.13
Lifetime estrogen exposure 
Data on reproductive history were collected using a questionnaire. The lifetime estrogen 
exposure was calculated as previously reported.14,15 We calculated the reproductive life 
span by subtracting the age at menarche from age at menopause or from age at examina-
tion in pre-menopausal women. Next, we subtracted all periods with high progesterone 
levels from the reproductive life span, since progesterone counteracts the effects of estro-
gens. To calculate the unopposed estrogen exposure, the following periods with high 
progesterone levels were subtracted: pregnancies (including miscarriages), periods of 
oral contraceptive use and (post-menopausal) hormone replacement therapy, periods of 
breast feeding and the post-ovulation part of the menstrual cycle. The latter was calculated 
by taking fourteen days for every menstrual cycle (luteal phase), with the number of men-
strual cycles being determined based on the woman’s cycle length. Duration of pregnancy 
at a miscarriage was not recorded and we therefore subtracted three months for each 
of the 15 reported miscarriages as 80% of miscarriages occur in the first twelve weeks of 
pregnancy.14 For ten out of 179 children, the duration of breast feeding child was unknown 
and we subtracted four months, the average time of breast feeding, for these children. 
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Subjective influence of hormonal changes
A second questionnaire addressed subjective changes in the rate of disease progression 
during periods of hormonal changes. Participants were asked to indicate whether their 
rate of disease progression accelerated, decelerated, or remained constant during men-
arche, menopause, oral contraceptive use and during and after pregnancies. 
Statistical analyses 
Statistical analyses were performed using SPSS version 22. Descriptive statistics were cal-
culated for both disease related and reproductive factors. Mean and standard deviation 
are reported unless stated otherwise. 
Multiple linear regression analysis was used to assess the influence of the lifetime endog-
enous estrogen exposure on FSHD disease severity. The FSHD clinical score, a measure 
for disease severity, was the dependent variable. Independent variables were entered 
hierarchically. Block 1 contained variables known to influence disease severity, i.e. age and 
repeat length. In the second block, the calculated years of lifetime endogenous estrogen 
exposure was entered. B and P-values are reported, statistical significance is defined as p 
< 0.05. R2 values were calculated to assess the additional variance that was explained by 
the lifetime endogenous estrogen exposure.
A sensitivity analysis was performed using G*Power statistical software16 to calculate the 
effect size this study should be able to detect with the sample size of 85 women, with a 
power of 0.8 and α of 0.05. Effect size is given as Cohen’s f 2, the proportion of variance 
uniquely accounted for by the lifetime endogenous estrogen exposure, in which f 2 ≥ 0.02, 
f 2 ≥ 0.15, and f 2 ≥ 0.35 represent small, medium and large effect sizes respectively.17 
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RESULTS
Patient characteristics 
Eighty-five women were included in this study. Of the 105 women participating in the 
cohort study, 103 returned the questionnaire. Thirteen women were excluded because 
they underwent hysterectomy and/or ovariectomy. Five women were excluded because 
age at menarche was missing. Baseline characteristics are presented in table 1. None of 
the patients had received anti-estrogenic therapy.
Table 1. Patient characteristics 
Characteristic N=85
Age 47.8 years ±16.7 [18-84]
Post-menopausal n=39 (45.9%)
FSHD type FSHD1 n=83
FSHD2 n=2
Repeat units (FSHD1) 6.1 ±1.8 [1-9]
BMI 24.8 ±5.2 [15.4-40.7]
FSHD clinical score 6.7 ±4.8 [0-15]
Years of estrogen exposure 10.4 years ±5.6 [0-22.4]
Influence of lifetime estrogen exposure 
Multiple linear regression revealed that age and repeat length are significantly associated 
with FSHD disease severity and explained approximately 29% of variance in disease sever-
ity (table 2). Lifelong endogenous estrogen exposure was not significantly associated with 
FSHD disease severity and did not yield any additional predictive value over block one. 
Similar results were found for the association between duration of the reproductive life 
span (time from menarche to current age or menopause) and disease severity (B = 0.082, 
p = 0.339, ΔR2 = 0.009).
To exclude the possibility that a small effect of estrogen exposure was obscured by the 
large effect of age on disease severity, we stratified the patients into three different 
age groups and repeated the analyses. The effect of age indeed cancelled out, but 
estrogen exposure did not influence disease severity (table 3). Subgroup analysis on 
39 post-menopausal women only, yielded similar results ((B = -0.178, p = 0.284, ΔR2 
= 0.028).
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Since variability seems larger in patients with larger repeat sizes4, modifying factors may 
play a bigger role in these patients. We therefore also analyzed subgroups with shorter 
(≤ 6 repeat units, n = 42) and larger (≥ 7 repeat units, n = 41) repeat sizes. Again, in both 
subgroups no effect of estrogen exposure on disease severity was found (≤ 6 repeat unit 
B = 0.203, p = 0.246, ΔR2 = 0.025; ≥7 repeat unit = 0.036, p = 0.826, ΔR2 = 0.001).
Table 2. Results of multiple linear regression analyses 
B β P-value
Block 1
Constant 7.589 0.000
Age (years) 0.127 0.454 0.000
Repeat units (n) -1.191 -0.461 0.000
Block 2
Constant 7.534 0.000
Age (years) 0.114 0.406 0.001
Repeat units (n) -1.181 -0.457 0.000
Lifetime endogenous estrogen exposure (years) 0.063 0.074 0.517
R2 block 1: 0.290; ΔR2 block 2: 0.003 (P>0.05)
Sensitivity analysis
The sensitivity analysis revealed that using this cohort of 85 women, an effect size of f2 
= 0.09 could be detected with a power of 0.8. This indicates that the study would have 
been able to detect a small effect (f 2 between 0.02 and 0.15) of the lifetime endogenous 
estrogen exposure on disease severity.17 
Subjective influence of hormonal changes
Most women reported that their rate of disease progression remained constant through 
periods of hormonal changes (table 4). For those who reported differences, both acceler-
ations as well as decelerations occurred for all periods, except for oral contraceptive use 
that only resulted in a decelerated rate of progression. 
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Table 3. Results of multiple linear regression analyses stratified into different age groups 
Age 18-40 years 
n=29
Age 41-60 years 
n=35
Age 61 years and older 
n=21
B β p-value B β p-value B β p-value
Block 1
Constant 10.91 0.004 11.06 0.131 16.67 0.234
Age (years) -0.108 -0.153 0.510 0.094 0.109 0.515 -0.012 -0.015 0.947
Repeat units (n) -0.692 -0.386 0.104 -1.324 -0.515 0.004 -1.105 -0.309 0.185
Block 2
Constant 11.37 0.006 11.10 0.137 22.33 0.188
Age (years) -0.138 -0.197 0.454 0.101 0.117 0.505 -0.020 -0.026 0.911
Repeat units (n) -0.710 -0.397 0.103 -1.326 -0.515 0.005 -1.321 -0.369 0.152
Endogenous estrogen 
exposure (years)
0.105 0.085 0.700 -0.029 -0.032 0.849 -0.258 -0.160 0.523
R2 block 1: 0.252; 
ΔR2 block 2: 0.005 (p>0.05)
R2 block 1: 0.244; 
ΔR2 block 2: 0.001 (p>0.05)
R2 block 1: 0.095; 
ΔR2 block 2: 0.022 (p>0.05)
Table 4. Subjective changes in rate of disease progression during periods of hormonal changes
Period of hormonal changes Rate of disease progression
Accelerated Decelerated Constant 
During menarche (n= 85) 5 1 79
During menopause (n= 39) 10 7 22
During oral contraceptive use (n= 64) 0 11 53
During pregnancy (n= 56) 6 10 40
After pregnancy (n= 56) 9 8 39
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DISCUSSION 
This study is the first to report a clinical approach to the influence of estrogen exposure 
on disease severity in female FSHD patients. Our results did not show a contribution of 
the lifetime endogenous estrogen exposure to disease severity among female patients. 
This finding suggests that differences in estrogen exposure alone are not sufficient to 
modify disease severity. However, the variation in estrogen exposure between women is 
small. Possibly, to have a clinically relevant effect on disease severity, greater differences in 
estrogen exposure are required. Preliminary in vitro work suggests a diminished toxicity of 
DUX4 in cells treated with supra-physiological doses of estrogens.18 This is also in line with 
earlier reports of a higher proportion of female asymptomatic gene carriers compared 
to males, since differences in estrogen levels between the sexes are much larger than 
differences between women. Furthermore, cases have been reported of female patients 
having an accelerated rate of disease progression after sudden dramatic drops in estrogen 
levels, such as anti-estrogen therapy in breast cancer patients or very early menopause.10 
Our cohort did not include such cases. 
This study focused on the effects of estrogen exposure and did not assess the influence 
of other reproductive hormones. For testosterone or progesterone, preliminary in vitro 
work also suggested a possible protective effect on DUX4 toxicity.18,19 However, in this 
study the absence of an additional influence of the length of the reproductive life span 
(time from menarche to current age or menopause), argues against an effect of the lifetime 
progesterone exposure, on disease severity. 
The most important limitation of this study was the retrospective design, which carries an 
inevitable risk of recall bias, that we tried to reduce by using a structured questionnaire. 
Since this study was cross-sectional, we cannot rule out temporary effects of changes 
in estrogen levels on the rate of disease progression, for example in naturally occurring 
periods of more pronounced hormonal changes like the menopause. However, subgroup 
analyses for women in different age groups and thus in different hormonal phases, and 
for pre- and postmenopausal women, showed no influence of total endogenous estrogen 
exposure on disease severity. 
Because of the continuously changing levels in reproductive hormones in females, hor-
monal influence on disease severity is a difficult topic to study in vivo. Measuring levels of 
reproductive hormones in the blood would render results that are highly dependent on 
the moment in the menstrual cycle at which the samples were taken and may therefore 
be difficult to interpret. 
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In conclusion, this study did not find a clinically relevant modifying effect of the lifetime 
endogenous estrogen exposure on disease severity in women with FSHD. However, we 
cannot rule out that greater differences in estrogen levels produce a clinically relevant 
protective effect, or that a protective effect in women is caused by a more complex inter-
play with other reproductive hormones. 
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INTRODUCTION 
On 18-20 November 2016 the 225th ENMC Workshop on ‘A global FSHD Registry framework’ 
took place in Heemskerk, the Netherlands. Twenty-two participants from 11 different 
countries gathered, including clinicians, researchers, policy makers and representatives 
from patient advocacy groups and industry. 
Facioscapulohumeral muscular dystrophy (FSHD) is an inherited muscle disorder, char-
acterized by weakness of the facial and shoulder girdle muscles followed by the leg and 
trunk muscles.1,2 There is a large variability in the severity of symptoms, ranging from 
asymptomatic to wheelchair bound individuals. 
Approximately 95% of FSHD patients carry one allele with a reduced number (1-10) of D4Z4 
repeat units on chromosome 4q35 associated with specific haplotypes (FSHD1).3 Of the 
remaining 5% of patients with FSHD phenotype (FSHD2), most cases have been explained 
by heterozygous mutations in the SMCHD1 (Structural Maintenance of Chromosomes flexible 
Hinge Domain containing-1) gene.4 These two different (epi)genetic mechanisms lead to 
chromatin relaxation of the D4Z4 repeat in somatic tissue and subsequent expression of 
the DUX4 gene in myogenic cells. DUX4 is thought to be the major contributor to FSHD 
pathology, although the exact pathophysiological mechanism is still largely unknown.5 
Expansion of our knowledge on the (epi)genetic mechanism underlying FSHD has led to 
advances in identifying (targeted) therapeutic strategies. Consequently it is now important 
to develop a ‘clinical trial toolbox’, consisting of patient registries, biomarkers and clinical 
outcome measures, to ensure resources are utilized effectively.6 The wide phenotypic 
expression in rare diseases such as FSHD, means that patient registries are particu-
larly important for clinical trial readiness. The aims of this workshop were to analyze the 
experience and results of the existing FSHD patient registries, update the Treat-NMD rec-
ommended dataset for FSHD, increase collaboration among established research groups 
and patient advocacy organizations and to create the foundation on which to establish a 
global registry for FSHD. 
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SESSION 1: FSHD OVERVIEW
Rossella Tupler started with an overview on the adult FSHD phenotype. The first description 
of FSHD was of an infantile onset case in 1884 by Landouzy and Dejerine. Even in this first 
report the wide spectrum of clinical presentation was evident, describing familial cases 
with later onset and without facial weakness. Phenotypic variability was further expanded 
upon in a case report of a large family in Utah in the 1950’s that included the observation 
of minimally affected individuals. In the 1980’s Padberg examined multiple large FSHD 
families and established diagnostic criteria for individuals to be included in linkage analyses 
(table 1) setting the gold standard for FSHD.1,7 This led to the discovery of the D4Z4 repeat 
contraction as the cause of FSHD1 in 1992, enabling highly sensitive and specific genetic 
testing for FSHD.8 A rough inverse correlation between the number of D4Z4 repeat units 
(1-10) and clinical severity has been proposed.9
Table 1. Padberg and Brouwer clinical criteria for diagnosing (infantile) FSHD
Main criteria for clinical diagnosis of FSHD by Padberg et al.7 
1. Onset of the disease in facial or shoulder girdle muscles; sparing of the extra-ocular, pharyngeal and lingual 
muscles and the myocardium
2. Facial weakness in more than 50% of the affected family members
3. Autosomal dominant inheritance in familial cases
4. Evidence of myopathic disease in EMG and muscle biopsy in at least one affected member without biopsy 
features specific to alternative diagnosis 
Main criteria for clinical diagnosis of infantile FSHD by Brouwer et al.10 
1. Signs and symptoms of facial weakness by the age of five 
2. Shoulder girdle weakness by the age of ten
In recent studies on patients included in the Italian FSHD registries, again wide variability in 
disease severity, including among members of the same family, has been demonstrated. 
The ‘comprehensive clinical evaluation form’ was introduced as a novel tool for catego-
rizing patients and their relatives based on typical and/or atypical features for the FSHD 
phenotype.11 A number of videos with examples of different FSHD phenotypes was shown 
during the presentation. 
In the first workshop discussion session it was agreed to first focus on discriminating 
typical from atypical phenotypes, because this distinction seems most relevant for future 
clinical trials on therapeutic approaches. Additionally, atypical phenotypes are rare and 
potential modifiers of the phenotype are still largely unknown. 
525558-L-bw-Mul
Processed on: 30-11-2018 PDF page: 125
A global FSHD registry framework
125
6
Angela Berardinelli presented an overview of the infantile form of FSHD, starting with the 
criteria for infantile FSHD set by Brouwer and Padberg: signs and symptoms of facial 
weakness by the age of five and shoulder girdle weakness by the age of ten (table 1).10
In the literature the infantile form is considered as a very severe and rapid form of FSHD. It 
makes up a small proportion (around 4%) of the total FSHD population.10 Within this group, 
disease course is reported to be more homogeneous. One remarkable characteristic of 
this group is that the onset of pelvic girdle weakness can occasionally precede the shoul-
der girdle weakness by 1.5-2 years. The infantile form is also more frequently associated 
with extra-muscular manifestations such as mental retardation, epilepsy, severe exuda-
tive retinopathy, hearing loss and severe respiratory problems in some cases requiring 
(non-invasive) ventilation. This severe form is often associated with very short D4Z4 repeat 
fragments of 1-3 repeat units. 
Results were shown of a multicenter retrospective study aiming to investigate the prog-
nostic significance of very short 4q35 alleles of 1-3 repeat units.12 A total of 66 index cases 
(40 de novo and 26 familial cases) was included through the Italian National Consortium 
for FSHD. 
In this cohort of patients carrying 1-3 repeat units there was wide clinical variability in the 
severity of symptoms. Additionally, infantile onset of symptoms did not always predict a 
very severe clinical outcome. In this retrospective study, no evidence of pre- or perinatal 
onset of the disease was found. The results indicate that the presence of a very short 
repeat fragment does not always associate with a severe phenotype, thus supporting the 
hypothesis that additional factors other than the repeat size must contribute to FSHD 
disease severity. 
In the workshop discussion that followed other clinicians noted that in their experience 
young onset FSHD is not necessarily predictive of a very severe disease course. In retro-
spect quite a proportion of FSHD patients may have had unnoticed mild facial weakness 
at young age. 
Nicole Voet presented the results of a clinical trial on aerobic exercise and cognitive behav-
ioral therapy to reduce chronic fatigue in FSHD through tackling fatigue perpetuating 
factors.13 After 16 weeks of intervention and 12 weeks of follow-up, both treatments were 
effective in reducing chronic fatigue. Additionally, MRI imaging of the upper leg muscles 
showed a significantly smaller increase in the percentage of fatty infiltration in the muscles 
of patients in the interventions groups compared to a control group.14
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In the workshop discussion that followed it was agreed that physical activity or exercise 
could potentially be a modifier of disease severity, which may be of particular relevance 
in the design of future clinical trials. 
Silvère van der Maarel summarized what is currently known on FSHD on a molecular 
level and elucidated current knowledge in the context of his extensive experience in the 
molecular characterization of the disease. Briefly, 95% of all FSHD patients carry a repeat 
contraction of the D4Z4 repeat on chromosome 4q35, whereas most of the other 5% 
have a mutation in the SMCHD1 gene. Both mechanisms result in chromatin relaxation of 
the D4Z4 repeat in somatic tissue and subsequent expression of the DUX4 transcription 
factor in skeletal muscle. Only specific 4qA haplotypes provide the necessary polyad-
enylation signal to stabilize the DUX4 transcript and are thus disease-permissive. An 
exception is the 4qA166 haplotype, which for unknown reasons appears to be less likely 
to be disease-causing than other 4qA haplotypes. DUX4 is a transcription factor normally 
expressed in the luminal cells of the testis and suppressed in somatic cells. The exact 
pathways by which DUX4 expression leads to muscle weakness is currently unknown, but 
it is believed to influence, amongst others, pathways involved in apoptosis, expression of 
stem cell genes, alterations of RNA processing in muscle atrophy and inhibition of muscle 
regeneration. 
Because of the observation that in individuals with shorter repeat sizes the disease is more 
likely to be symptomatic, an oligogenic model is proposed in which individuals with longer 
repeat sizes are more dependent on additional modifiers for the disease to become symp-
tomatic. This oligogenic model could also explain the variability in onset and progression 
of FSHD and the high frequency of non-penetrant mutation carriers in the population. 
Modifiers could be environmental factors or (epigenetic) factors working in cis, such as 
the repeat length or the polyadenylation signal, or in trans, like SMCHD1. Recently, a new 
trans-acting factor was found through the identification of two FSHD families with a muta-
tion in the DNMT3B gene.15 Research continues on finding additional modifiers. 
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SESSION 2: CURRENT LANDSCAPE
Betsy Bogard introduced different registry models from the perspective of the industry as 
well as from patient advocacy groups. She explained the “original” registry model in rare 
diseases: a longitudinal registry, focused on one disease and owned by a drug company. 
These registries have historically been clinician-centered, with data input only through 
clinicians and no or limited feedback directly to the participating patients. Over the last 5-7 
years ‘patient-driven’ registries have evolved. These are more frequently cross-sectional, 
patient-reported and provide direct feedback to patients. An example of a global ‘one 
registry’ for fibrodysplasia ossificans progressiva (FOP) was shown. In this registry example, 
there is input by both clinicians and patients through different portals of the same registry. 
In general, it was pointed out to be aware of de-centralized registry ownership, because 
it can lead to registry fragmentation and thus complicate data consolidation. Although 
registries provide valuable information, no registry could replace natural history studies 
and clinical trials. 
Armelle Richiardi outlined the relevance of patient registries for the industry. From an 
industry perspective, registries are mostly used in the setting of clinical trials for obtain-
ing disease knowledge (clinical trial endpoints, long term disease progression, treatment 
impact) and patient knowledge (patient profile and identification for clinical trials, post 
marketing surveillance). An example of a successful collaboration of the industry with 
a registry was given: a registry and natural history study for early onset FSHD including 
patients from twelve different hospitals worldwide. Longitudinal data on this cohort will 
be collected in the upcoming years. 
June Kinoshita presented an overview of the existing FSHD patient registries from an 
international perspective. Currently, there are FSHD registries in 13 different countries 
comprising data on over 3000 patients. While the current registries include a large number 
of patients, this is still only a fraction of the total number of FSHD patients worldwide. Fur-
thermore, of those registered, data is not uniformly collected and is consequently difficult 
to aggregate or compare. Therefore, it is critical for the FSHD community to establish a 
global core dataset that collects patient-reported information in a way that it can be ano-
nymized, aggregated and analyzed. There is still a number of logistic issues to be solved 
before establishing a global federated registry. 
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SESSION 3: THE REGISTRY PARADIGM
Five different national FSHD registries and their results so far were discussed. 
Baziel van Engelen presented the Dutch FSHD registry, a patient-centered online regis-
try that currently contains 275 participants. Patients register themselves online, sign an 
informed consent form to collect genetic data and then fill out online questionnaires. In 
addition to the standardised and internationally agreed Treat-NMD core data set (table 
2), a number of validated questionnaires is included, for example on fatigue, depression, 
pain and quality of life. These additional questionnaires serve as patient reported outcome 
measures (PROMS) to enable researchers to learn more about the impact of the disease. 
The Dutch registry envisions a two-way registry, in which patients not only provide input 
but also receive feedback about their successive data over time or in comparison to the 
total group. Additionally, the registry is structured to enable participants to make sug-
gestions with regard to researched items. This registry has already proven useful in the 
recruitment of patients for a recent clinical trial.
Teresinha Evangelista presented the UK (United Kingdom) FSHD patient registry. The UK 
FSHD Patient Registry is an online patient-initiated registry combining patient reported 
outcomes with clinically verified details.16 Genetic confirmation is obtained through a cli-
nician specialist or directly from the laboratory that is performing the test. The registry 
contains the Treat-NMD core data set and a set of additional questionnaires for example 
on pain, quality of life and scapular fixation. Since 2013 over 700 participants have reg-
istered, 576 of whom have a confirmed genetic diagnosis. Longitudinal data is collected 
through annual updates. The registry has proven its utility with the recruitment of patients 
for a natural history study of infantile onset FSHD and the validation of a newly developed 
Rasch-built patient reported outcome measure. 
The US (United States) national patient registry was presented by Rabi Tawil. It is the 
oldest FSHD registry established in 2000 as a combined registry for FSHD and myotonic 
dystrophy.17 Participants sign a consent form that allows the registry to obtain medical 
records for review. There are currently 876 patients registered and 88 unaffected family 
members. Paper questionnaires are filled out by the participants and all medical records 
are reviewed by one clinician and participants are categorized by diagnostic certainty. All 
data is then entered into an electronic data base. About 60% of all participants are genet-
ically confirmed. There is a yearly follow-up to track disease progression and longitudinal 
data up to 14 years is available. The registry captures hard endpoints such as age at first 
use of assistive devices and use of wheelchair and includes a functional questionnaire that 
allows tracking of disease progression.18 Newsletters and recruitment letters about studies 
525558-L-bw-Mul
Processed on: 30-11-2018 PDF page: 129
A global FSHD registry framework
129
6
are sent out regularly by the registry to participants. Researchers utilize the registry to 
either to help recruit patients for clinical studies or to analyze anonymized data. To date, 
the registry has received application for 19 applications. 
Rossella Tupler presented the Italian FSHD registry; it is a multi-center clinician reported 
registry. Fourteen neuromuscular clinics and two diagnostic laboratories participate in 
the ‘Italian National Registry for FSHD’. The registry includes a standardized clinical exam-
ination and molecular testing of index cases and relatives. The registry now includes 
1093 index cases with 2131 D4Z4 carrier relatives and 399 single cases. The patients are 
categorized based on the phenotype into classical and atypical or complex phenotypes.11 
The registry has been used for a prospective observational study of 246 subjects with a 
follow-up period of five years. Over those five years the mean FSHD score19 increased from 
4.4 ±3.7 SD to 5.6 ± 4.3 SD and 4% of patients lost ambulation. Approximately a quarter of 
the 45% asymptomatic relatives became symptomatic during the five years of follow-up, 
decreasing the percentage of asymptomatic relatives to 34%. 
Sabrina Sacconi introduced the French FSHD registry, which includes a total of 682 patients. 
It is a combined patient- and doctor-reported registry with a self-reported form and a clin-
ical evaluation form respectively. Patients and doctors can view data for a specific patient 
online by using a personal patient identification number. More recently, the motor function 
measure has been included as an outcome measure in the registry. 
After these five registries were presented, the workshop participants discussed some of 
the challenges faced by current registries. The proportion of registered patients is still 
low compared to the total number of potential participants. The inclusion rates could be 
improved by actively involving patients and patient advocacy groups, improving accessi-
bility of the registries and actively inviting patients to be involved, for example at the time 
of diagnosis. Since no registry will be able to capture data on every aspect of the disease, 
a core dataset with optional additional data collection on specified topics is desired. Data 
collection needs to be standardized to enable assembly of data globally. Additionally, 
different topics could be addressed in different registries to complement one another. 
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SESSION 4: EXAMPLES FROM OTHER DISEASE AREAS 
Hugh Dawkins shared the experiences from the federated global registry for Duchenne 
muscular dystrophy (DMD). The Duchenne Foundation, in close partnership with Aus-
tralian umbrella neuromuscular disease patient organisations, initiated a nationwide 
campaign for a National DMD Registry to collate clinical and genetic data. Patients and 
patient advocacy groups have been involved in the development of the registry throughout 
the entire process. This ‘patient voice’ has helped to get policymakers engaged and thus 
accelerate registry design. Because accuracy of the data was considered as a critical 
success factor, a clinician-centered registry was chosen. The Treat-NMD core dataset was 
the starting point for data collection. After successfully rolling out a DMD registry, other 
registries for neuromuscular diseases were developed as well, resulting in an overarching 
neuromuscular disease registry structure that is open source, secured and interoperable 
with other registries. The Australian Duchenne registry is now also participating in a global 
registry supported by Treat-NMD, which is a federated global registry of multiple national 
registries. 
Jacqui van Rens summarized experiences from the European Cystic Fibrosis Society 
Patient Registry. Since its initiation in 2003, the registry has included over 40.000 genet-
ically confirmed patients in 30 countries, including longitudinal data since 2008. It is a 
highly secured web-based and open-source registry containing anonymized data. Data 
is collected through cystic fibrosis centers as well as through national registries. Patient 
encounters are entered into the registry and annual summaries are sent to the federated 
European registry. It is possible to extract reports per patient, center or country, which 
enables comparisons over time or between centers or countries. Applications for aggre-
gated data can be made by researchers, patient organizations and industry. Important 
lessons learned include: aim for clear definitions, start with a pilot study, organize funds, 
share online data-collection platform and collaborate with existing (inter)national registries 
and patient advocacy groups.
In a workshop discussion that followed this session it was emphasized that anonymized 
(aggregated) data should be easily accessible wherever possible, to facilitate and accel-
erate research projects. 
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SESSION 5: BEYOND THE DATASET
June Kinoshita reported the results of a survey conducted by the FSH Society on patients’ 
views and priorities with regard to registries. 326 patients responses were received. The 
main outcomes indicated that patients often misunderstand the purpose and/or intention 
of registries and have difficulty discriminating between registries and other research stud-
ies. Additionally, registry participants appreciate some forms of interaction or feedback in 
return for their efforts. Regular communication from registries and active involvement of 
patients and patient advocacy groups will help to keep them engaged.
Chad Heatwole presented the design of the FSHD Health Index (FSHD-HI), a disease-specific 
patient-reported outcome measure intended to measure a patient perception of the total 
disease burden. It was developed based on the Food and Drug Administration (FDA) guide-
lines starting from qualitative interviews of patients followed by a national cross-sectional 
validation study. The questionnaire contains 116 questions in 14 subscales that can be 
answered in approximately 15 minutes. The FSHD-HI was tested and compared to tradi-
tional outcome measures in a 12-month longitudinal study including 41 participants. The 
questionnaire showed good reliability and correlation with traditional outcome measures 
like the FSHD clinical score, 6-minute walking test and manual muscle testing. Further 
analyses will be performed regarding responsiveness and minimally clinically important 
differences. 
Betsy Bogard emphasized the value of registries for the pharmaceutical industry in a drug 
development process. Briefly she explained how the role of a registry evolves along the 
drug development path. It starts with gathering disease and patient knowledge, connecting 
patients and researchers and identifying patients for clinical trials in the preclinical devel-
opment phase and the clinical trial phase. Later in the process, in the regulatory approval 
phase and the commercial phase, registries can support post-marketing commitments, 
provide data supportive of trial findings, support label expansion and advance the under-
standing of treatment response. 
The existing Treat-NMD core dataset for international FSHD registries was introduced by 
Rabi Tawil and Baziel van Engelen. The dataset currently comprises five mandatory items 
and ten highly encouraged items, including personal data, genetic data and data on clin-
ical aspects. It includes one column with items in medical terms and another one with 
the same items in layman terms to be included in patient-reported registries. All items 
were introduced and discussed shortly in preparation for the final core dataset in the 
discussion session. 
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SESSION 6: STRUCTURED DISCUSSIONS 
ON AREAS OF THE DATASET
For the first part of the discussion the workshop participants were separated into three 
groups: clinicians, patient advocates and geneticists. Conclusions of each group were dis-
cussed and key issues and recommendations were crystallized during the plenary session. 
The clinicians discussed the diagnostic criteria for FSHD as formulated by Padberg et al. in 
19917; they agreed that these criteria are still accurate and continue to be highly relevant 
(table 1). Although pharyngeal and tongue muscles can be involved in very severe forms 
of FSHD, involvement of these particular muscles was considered so rare that the cur-
rent criteria were presumed to apply to practically all FSHD patients. In the future, when 
longitudinal (registry) data become available, the criteria may be revised or expanded. 
Additionally, the criteria by Brouwer et al. for infantile FSHD were still supported by the 
group.10
In relation to the core dataset for international FSHD registries the workshop participants 
confirmed that all the current data items were considered highly relevant. The infantile 
form should be considered a severe form in the total spectrum of FSHD and it was agreed 
that most of the current items capture data that is also applicable to infantile cases. 
Regarding extra-muscular manifestations of FSHD, the workshop participants agreed that 
it would be useful to add items on the involvement of the central nervous system. Based 
on existing the literature it was decided to add two items about epilepsy and cognitive 
delay as highly encouraged items (table 2). 
The patient advocates reviewed the design and formulation of the Treat-NMD common 
dataset for FSHD. All participants agreed on a number of textual changes to make item 
descriptions more clear and to remove any ambiguity. Conceptual changes were made so 
that for every item, the drop down or radio-button lists for responding to the options start 
with the least severe symptoms /characteristics first (table 2). An expansion of the per-
sonal data elements was suggested to enable the possibility of Privacy-Preserving Record 
linkage, that could include the need to assign patients a unique global identifier code, thus 
opening up possibilities for the data to be used in a global dataset. Again it was empha-
sized that additional questionnaires can be used along with the core dataset in national 
registries. All agreed that further iterations of the group, followed by industry engagement 
and wider FSHD testing and feedback are desired to design an optimal dataset. 
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The geneticists proposed a genetic testing workflow for diagnosing FSHD (figure 1). For a 
molecular diagnosis of FSHD, the number of D4Z4 repeat units should be determined. A 
range of 1-10 repeat units is compatible with FSHD1, but only on a DUX4 polyadenylation 
signal containing chromosome, usually the 4qA haplotype. In the absence of this polyad-
enylation site, homozygous 4qB haplotypes typically exclude the diagnosis of FSHD. 
For FSHD2 repeat size should be in the range of 1-20 D4Z4 units, although some patients 
have been reported with repeat sizes that exceed the 20 units. Again, a 4qB haplotype is 
not compatible with FSHD and the haplotype should always be determined. A mutation 
in the SMCHD1 gene confirms the diagnosis. Assessment of hypomethylation is strongly 
encouraged, but not essential for the genetic diagnosis of FSHD, although this may render 
the interpretation of SMCHD1 variants cumbersome.
Figure 1. Graphical representation of currently known genetic mechanisms used in molecular diagnosis of 
FSHD1 and FSHD2 
FSHD1 FSHD2
1-10 D4Z4
repeat units
1-20 D4Z4
repeat units
4qA haplotype
(homozygous 4qB haplotype excludes FSHD)
SMCHD1 mutation
present
Genetically confirmed fiagnosis
Highly encouraged:
hypomethylation
< -21%
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CONCLUSIONS
FSHD is a rare condition for which potential interventions and targeted therapies are 
on the near horizon. Patient registries are valuable instruments to efficiently recruit 
patients for clinical trials and also to provide knowledge on many aspects of FSHD to 
doctors, researchers and patients. A global registry would allow for a greater number of 
participants and subsequently bigger data sets. Since there are already multiple national 
registers for FSHD in place, the most suitable way would be to create a one federated 
global registry consisting of different national registries. Such a federated registry should 
have a common general data set, but should also leave room for national registries to 
expand and have their own approaches. Along these lines, the existing common data 
set by Treat-NMD was updated. Additionally, two items were added concerning central 
nervous system involvement, especially relevant for early onset cases. 
Accurate diagnosis is essential for the patients to receive best care and for capturing useful 
genotype-phenotype data. The clinical diagnostic criteria as proposed by Padberg et al. 
were still considered highly relevant and accurate. A genetic test flow for genetic diagnosis 
for FSHD1 and FSHD2 was designed. 
Patient empowerment, as well as engagement of industry and policy makers was consid-
ered critical for optimal design and use of patient registries. 
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FUTURE PLANS
During the meeting the ‘FSHD Consortium’ was formed to initiate and maintain an interna-
tional effort to initiate and maintain one federated global FSHD registry. The consortium 
will be formalized and a charter will be written. The first consortium goal will be a pilot 
study to collect curated data of the minimal core dataset of the existing 13 national reg-
istries towards the global registry. The global registry could be used to further define the 
FSHD phenotype and genotype, and to collect longitudinal data. The registry could also be 
used as a basis for international surveys and research into the benefit of exercise and cog-
nitive behavioral therapy, the use of pharmaceutical and other (non-prescription) drugs, 
pregnancy-related issues, and to evaluate and deploy patient reported outcome measures 
like the FSHD-HI. Further iteration of the registry design and especially of the content of 
the common minimal data set will be required, not only by clinicians and researchers, but 
also by industry and patient advocates. 
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Table 2. Updated treat-NMD core dataset for FSHD 
Item Self-report example
Mandatory items
1a. Personal data
Biological sex at birth
First name 
Middle name
Last name 
Date of birth
City of birth
Country of birth 
Current Address Zip/post code Country 
Telephone 
Email 
Your* personal data
Biological sex at birth
First name 
Middle name
Last name 
Date of birth
City of birth
Country of birth 
Current Address Zip/post code 
Country 
Telephone 
Email 
* Or FSHD patient’s, if you are a parent/guardian or caregiver registering on behalf of a patient
1b. Alternative contact
Next of kin
First name
Last name
Current address
Zip/post code
Country
Telephone
Email
Alternative contact should you be unavailable
Next of kin
First name
Last name
Current address
Zip/post code
Country
Telephone
Email
1c. Diagnosing physician
First name
Last name
Medical institution
Address
Zip/post code
Country
Telephone
Email
Physician who diagnosed you with FSHD
First name
Last name
Medical institution
Address
Zip/post code
Country
Telephone
Email
2. Genetic test result
• Confirmed FSHD1 (D4Z4 contraction 1-10 
repeats + 4qA) 
• FSHD2 (no contraction + 4qA + SMCHD1 
mutation)
• Not FSHD (homozygous for 4qB)
• Result pending
• Not tested
What is your genetic test result?
• I have been told I have genetically confirmed 
FSHD and I can provide a copy of my genetic 
test result [UPLOAD]
• I have been told I have genetically confirmed 
FSHD but I do not have my genetic test result. 
[FOLLOW-UP: OBTAIN GENETIC TEST REPORT 
FROM DIAGNOSING PHYSICIAN]
• I have been tested but I haven’t received the 
result yet
• I have not been tested but wish to be tested
• I have not been tested and do not wish to be 
tested
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Table 2. Continued
Item Self-report example
3. Clinical diagnosis
• Facial weakness
• Periscapular shoulder weakness
• Foot dorsiflexor weakness
• Hip girdle weakness
• Asymptomatic (patients has no complaints, but 
physician detects signs)
• Non-penetrant (no signs)
Which of these symptoms do you have? (Select 
all that apply)
• Facial weakness
(weakness of muscles in the face causing e.g. 
inability to smile, to whistle, or to close your eyes 
fully at night)
• Shoulder weakness
(weakness of the muscles around the shoulder 
blades causing
e.g. shoulder blades to protrude; inability to 
raise your arms sideways above the level of your 
shoulder).
• Foot or ankle weakness
(weakness of the muscles that help you lift your 
feet up, causing e.g. foot drop (where the foot 
tends to hang with the toes pointing down), 
steppage gait (lifting the feet high when walking), 
or frequent tripping)
• Hip girdle weakness
(weakness of the muscles of the pelvis and top 
of the legs, causing e.g. difficulties in going up 
stairs or ladders, rising from a chair or getting 
up from the floor)
• I have none of the signs or symptoms described 
above
4. Current best motor function
• Ambulatory (unassisted)
• Ambulatory (assisted)
• Non-ambulatory
Which of the following options describes the 
best motor function you are currently able to 
achieve? 
• I can walk unaided always
• I can walk unaided most of the time
• I can walk with an assistive device for some 
distance
• I can walk with an assistive device for a short 
distance
• I cannot walk
5. Wheelchair use
• No
• Part-time (start date year)
• Full-time (start date year)
Do you use a wheelchair? (please select all that 
apply)
• I don't use a wheelchair.
• I started using an assistive device from [YEAR]
• I started using a wheelchair part-time from 
[YEAR]
• I use a wheelchair all the time since [YEAR]
525558-L-bw-Mul
Processed on: 30-11-2018 PDF page: 139
A global FSHD registry framework
139
6
Table 2. Continued
Item Self-report example
6a. Pulmonary function test
• No
• Yes 
Has your respiratory capacity ever been 
evaluated (for example pulmonary function 
testing)? 
• No
• Yes 
• I don’t know 
Do you regularly use a non-invasive (mask) 
ventilation device?
• No, never
• Yes, but only part-time, e.g. at night, since 
[YEAR])
• Yes, all day since [YEAR]
6b. Non-invasive ventilation
• None 
• Part-time (start date year) 
• Full-time (start date year)
Do you regularly use a non-invasive (mask) 
ventilation device?
• No, never
• Yes, but only part-time, e.g. at night, since 
[YEAR])
• Yes, all day since [YEAR]
6c. Invasive ventilation
• None 
• Part-time (start date year) 
• Full-time (start date year)
Do you use invasive ventilation (requiring 
surgery, e.g tracheostomy)? 
• No
• Yes, part-time since [YEAR] 
• Yes, full-time since [YEAR]
7. Age of onset for selected FSHD symptoms 
(taken from question 3)
• Facial weakness (start date year)
• Periscapular shoulder weakness (start date year)
• Foot dorsiflexor weakness (start date year)
• Hip girdle weakness (start date year)
At what age did you first notice symptoms 
related to your FSHD? Give approximate year 
for all that apply
• Facial weakness, first occurred in [YEAR]
• Shoulder weakness, first occurred in [YEAR]
• Ankle/foot weakness, first occurred in [YEAR]
• Hip girdle weakness, first occurred in [YEAR]
8. Retinal vascular disease attributable to FSHD
• No
• Yes (start date year)
• Unknown
Have you been diagnosed with retinal problems 
or abnormal blood vessels at the back of your 
eye that your doctors think may be related to 
your FSHD? (“Coat’s disease,” retinal vascular 
disease) 
• No
• Yes, first occurred in [YEAR], but with no visual 
impairment
• Yes, first occurred in [YEAR], and has caused 
visual impairment
• I don’t know
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Table 2. Continued
Item Self-report example
9. Hearing loss
• No
• Yes (start date year)
• Unknown
Do you have hearing loss?
• No
• Yes, first occurred in [YEAR], but I don’t use a 
hearing aid
• Yes, first occurred in [YEAR], and I use a hearing 
aid
• I don’t know
10. Scapular fixation
• No 
• Yes, unilateral (surgery date year)
• Yes, bilateral (surgery dates year)
Have you had scapular fixation (an operation to 
fix your shoulder blade to your ribcage)?
• No
• Yes, in one shoulder [LEFT/RIGHT], operated in 
[YEAR]
• Yes, both shoulders,  operated in [YEAR] and 
[YEAR]
11. Pregnancy (only females)
• No
• Yes
• Number of pregnancies
(For women only) Have you ever been 
pregnant? Select all that apply.
• No
• Yes, ____ time(s) in [YEARS]
12. Family history
• Affected mother
• Affected father
• Affected offspring
• Affected sibling(s)
• Other affected relative
• No
• Unknown
Has anybody else in your family been diagnosed 
with FSHD (select all that apply)?
• Yes, mother
• Yes, father
• Yes, one or more children
• Yes, one or several of my siblings (brothers and 
sisters) 
• Yes, further relatives (other than parents and 
siblings)
• No
• I don’t know
13. Epilepsy
• No
• Yes
Do you have a history of seizures/convulsions?
• No
• Yes
14. Mental retardation
• No
• Yes
Do you have a history of delayed cognitive 
development or cognitive impairment?
• No
• Yes
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Table 2. Continued
Item Self-report example
Non-Mandatory
15. Ethnic origin
• Pulldown menu [SPECIFIC TO EACH COUNTRY’S 
REQUIREMENTS?]
• Other
• Declined to answer
How would you describe your ethnic origin?
• Pulldown menu [SPECIFIC TO EACH COUNTRY’S 
REQUIREMENTS]
• Other
• I choose not to answer this question
16. Other registry
• Yes (specify...)
• No
• Unknown
Have you signed up for any other FSHD registry 
or studies?
• Yes (if yes, please specify: PULLDOWN MENU or 
OTHER)
• No
• I don’t know
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ABSTRACT
Objective: Adding quantitative muscle MRI to the clinical trial toolbox for FSHD by cor-
relating it to clinical outcome measures in a large cohort of genetically and clinically 
well-characterized FSHD patients comprising the entire clinical spectrum. 
Methods: Quantitative MRI scans of leg muscles of 140 FSHD1 and FSHD2 patients were 
assessed for fatty infiltration and TIRM hyperintensities and were correlated to multiple 
clinical outcome measures.
Results: The mean fat fraction of the total leg musculature correlated highly with the 
Motor Function Measure, FSHD clinical score, Ricci score and 6-minute walking test (cor-
relation coefficients -0.845; 0.835; 0.791; -0.701 respectively). Fat fraction per muscle 
group correlated well with corresponding muscle strength (correlation coefficients up to 
-0.82). The hamstring muscles, adductor muscles, rectus femoris and the gastrocnemius 
medialis were affected most frequently, also in early stage disease and in patients without 
leg muscle weakness. Muscle involvement was asymmetrical in 20% of all muscle pairs and 
fatty infiltration within muscles showed a decrease from distal to proximal of 3.9%. TIRM 
hyperintense areas, suggesting inflammation, were found in 3.5% of all muscles, with and 
without fatty infiltration. 
Conclusions: We show a strong correlation between quantitative muscle MRI and clinical 
outcome measures. Muscle MRI is able to detect muscle pathology before clinical involve-
ment of the leg muscles. This indicates that quantitative leg muscle MRI is a promising 
biomarker that captures disease severity and motor functioning and can thus be included 
in the ‘FSHD trial toolbox’. 
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INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) is one of the commonest forms of adult 
muscular dystrophy.1 It is characterized by slowly progressive weakness of the facial and 
shoulder girdle muscles, followed by leg and trunk muscles.2 Disease course and sever-
ity are highly variable, even within families, ranging from asymptomatic gene carriers to 
wheelchairbound patients. 
Since the discovery of the (epi)genetic origin of the disease new therapeutic strategies are 
being developed and clinical trials are at the horizon. Consequently, there is an urgent 
need for a ‘clinical trial toolbox’, including patient registries, biomarkers and clinical out-
come measures.3 While clinical outcome measures provide direct measures of patient 
functioning or ability, they may not be sensitive enough to capture changes in this slowly 
progressive disorder. Especially for early phase clinical trials, biomarkers that detect subtle 
changes in muscle pathology are required. Quantitative muscle MRI may provide such a 
biomarker4, however evidence of its correlation to clinical outcome measures still has to 
be established. Previous studies on this correlation have mostly used qualitative or ordinal, 
and thus non-linear, MRI data.5-11 Studies that have used quantitative MRI comprised small 
cohorts with a maximum of 50 patients and none of them included patients across the 
entire FSHD clinical spectrum.12-16 
We enrolled a large cohort of genetically confirmed and clinically heterogeneous FSHD 
patients. This study presents baseline data on quantitative MRI of the leg muscles and its 
correlation to multiple clinical outcome measures to determine the value of muscle MRI 
as component of the ‘FSHD trial toolbox’. 
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METHODS
Patients
We included genetically confirmed FSHD patients of 18 years and older at the Neurol-
ogy department of the Radboud University Medical Center, Nijmegen, the Netherlands, 
between 2014-2015. Asymptomatic gene carriers (individuals who reported no symptoms, 
with or without signs of FSHD on clinical examination) with at least one affected family 
member were also included. We included FSHD1 and FSHD2 patients to compare both 
groups. Exclusion criteria were contraindications for MRI (e.g. claustrophobia or metallic 
implants). The study protocol was approved by the regional medical ethics committee. All 
patients signed informed consent.
Clinical outcome measures
In all patients multiple clinical outcome measures were scored. The motor function mea-
sure (MFM) is a 32-item scale assessing the severity of the motor deficit in neuromuscular 
diseases; outcomes range from 0-100% in which 100% implies no motor deficits.17 The 
six minute walking test (6-MWT) is used to evaluate functional capacity in neuromuscular 
disorders and indicates the maximum distance that a patient is able to walk in six min-
utes.18,19 The clinical severity score by Ricci et al. (‘Ricci score’) indicates clinical severity on 
an 10-point scale in which 0 indicates no muscle weakness and 10 indicates wheelchair 
dependency.20 The Ricci score assumes a fixed sequence of muscle involvement and is 
less suitable for patients with an atypical disease course. We therefore included the FSHD 
clinical score that evaluates strength and functionality of six muscle regions separately.21 
This score ranges from 0 to 15, where 0 indicates no muscle weakness and 15 severe 
muscle weakness in all muscle groups. Manual muscle testing was scored using a 6-point 
MRC (Medical Research Council) gradation ranging from 0 (no muscle contraction) to 5 
(maximal muscle strength) for hip flexion, hip abduction, knee flexion, knee extension, foot 
dorsal flexion and foot plantar flexion.22 The maximum isometric contraction of the knee 
extensors was assessed using fixed dynamometry, scored in Newtons. All clinical scores 
were obtained by one trained physician (KM).
MRI acquisition 
All MRI exams were performed on the same 3-Tesla MR system (TIM Trio; Siemens, Erlan-
gen, Germany) using a scanning protocol adapted from previous studies.15,14 Participants 
were placed feet first supine in the scanner. Scout images were made in 3 orthogonal 
directions to position imaging slices for subsequent scans. A transverse Dixon sequence 
was acquired around the upper- and lower leg (field of view 271x435 mm, matrix size 
200x320, repetition time 10 ms, echo time 2.45/3.675 ms, number of slices 144, slice 
thickness 5 mm, slice gap 0 mm, FA 3°). For the TIRM sequence, the inversion time was 
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selected to null the fat signals (field of view 271x435, matrix size 160x256, repetition time 
4000ms, echo time 40ms, inversion time 220ms, number of slices 72, slice thickness 5mm, 
slice gap 5mm, FA 150°). 
MRI analysis 
The water and fat image of the Dixon sequence were used to create a fat fraction map 
using Matlab according to the following equation:
𝐹𝐹𝐹𝐹𝐹𝐹
𝐹𝐹𝐹𝐹𝐹𝐹 +𝑊𝑊𝐹𝐹𝐹𝐹𝑊𝑊𝑊𝑊
 
 
 
⅚ 
 
. The fat fraction map was used 
to draw region of interest (ROI’s) per muscle using ImageJ software (figure 1).23 All drawn 
ROIs were checked by a second clinician, and interrater variability was assessed on a 
subset of ten scans (380 muscles). Muscle cross-sectional area and fat fractions were 
calculated per ROI. We evaluated twelve upper leg muscles, and seven lower leg muscles 
(figure 1). ROI’s were drawn at two different slices using the localizer sequences: in the 
upper leg at one third and two thirds of the distance between the spina iliaca anterior 
superior and the upper edge of the patella. In the lower leg we used slices at two thirds 
and ⅚ of the distance between the lateral malleolus and the lower edge of the patella for 
the gastrocnemius, and one third and two thirds of the distance between these landmarks 
for the other lower leg muscles. 
TIRM images were visually assessed for the presence of signal hyperintensity in each 
muscle by a radiologist and the first author (KM). When there was discrepancy between 
the two scores, another author (CH) also assessed the image. 
Figure 1. Example of transverse DIXON fat fraction map of upper leg muscles of the right leg
A. DIXON fat fraction map of upper leg muscles without fatty infiltration. B. Regions of interest per muscle. C. 
Examples of different degrees of fatty infiltration per muscle. VM: m. vastus medialis; VI: m. vastus intermedius; 
VL: m. vastus lateralis; S: m. sartorius; BFS: m. biceps femoris short head; BFL: m. biceps femoris long head; AM: 
m. adductor magnus; G: m. gracilis; ST: m. semitendinosus; SM: m. semimembranosus
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Statistical analyses
All statistical analyses were performed using IBM SPSS Statistics (SPSS Inc. Chicago, IL, 
USA), version 22. Spearman rho analyses were used to calculate bivariate correlations, 
independent t-test to compare means. A χ² test was used to search for an association 
between TIRM positivity and sex. Simple linear regression analyses were used for the rela-
tion between duration of symptoms and mean fat fraction and clinical outcome measures. 
Interrater variability was assessed using intraclass correlation coefficient. P-values ≤ 0.05 
were considered statistically significant. 
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RESULTS
Patients
One-hundred and forty genetically confirmed FSHD patients participated in this study. 
Patient characteristics are listed in table 1. 
Table 1. Patient characteristics
Total cohort 
n = 140
Male 
n = 79
Female 
n = 61
Age in years (mean ± SD [range]) 50.2 ±14.9 [18-81] 52.9 ±13.0 [20-75] 46.8 ±16.5 [18-81]
Disease duration in years 
(mean ± SD [range])
25.0 ±15.0 [1-59] 25.3 ±14.3 [1-59] 24.5 ±16.1 [1-59]
Symptomatic patients (n)
Asymptomatic patients (n)
131
9
73
6
58
3
BMI (mean ± SD [range]) 25.3 ±4.1 [17.0-37.6] 25.5 ±3.4 [19.4-37.6] 25.1 ±4.8 [17.0-35.6]
FSHD type (n)
FSHD1
FSHD2
FSHD1+2
130
8
2
73
6
0
57
2
2
Repeat units (n)
1-3
4-7
8-10
5
88
30
2
51
15
3
37
15
Ricci score (n)
0 
1-3
4-6
7-10
5
37
43
54
3
21
24
31
2
16
19
23
FSHD clinical score (n)
0
1-5
6-10
11-15
4
55
50
31
3
29
32
15
1
26
18
16
6-minute walking test in meters* 
(mean ± SD)
464.9 ±108.5 475.0 ±108.8 450.1 ±107.7
Motor function measure (mean ± SD) 82.2 ±19.4 83.1 ±16.8 81.2 ±22.3
* Out of 140 participants, 111 were capable of performing the 6-MWT (66 male, 45 female) 
Clinical correlations
The mean fat fraction correlated highly and statistically significantly with all clinical outcome 
measures (figure 2). MFM showed the strongest correlation (CC= -0.845). MRC scores of 
knee flexion, knee extension and foot dorsal flexion correlated highly with the mean fat 
fraction of the corresponding muscle groups (CC right leg -0.74, -0.77, -0.69 respectively; 
and left leg -0.74, -0.58, -0.76 respectively, all p < 0.001). The correlation for the plantar 
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flexors was weak (CC right leg -0.38, left leg -0.43, p < 0.001), as was the correlation 
between quantitative isometric knee extensor strength and corresponding fat fraction of 
quadriceps muscles (right leg CC -0.42, left leg -0.37, p < 0.001). 
Notably, the rectus femoris was often fatty infiltrated, while the rest of the quadriceps 
muscles were normal. Knee extension strength was tested in the seated position. In this 
position knee extension is primarily driven by the vastus muscles, because the rectus 
femoris is already shortened. We therefore also correlated knee extension strength to the 
mean fat fraction of the three vastus muscles, leaving out the rectus femoris. Correlation 
coefficients then increased for manual muscle testing (right leg -0.82, left leg -0.79, p < 
0.001) and quantitative muscle testing (right leg -0.51, left leg -0.46, p < 0.001). 
Nine asymptomatic gene carriers were included. Four had no signs of FSHD on exam-
ination, two had mild scapular winging, two a combination of mild scapular winging and 
minimal facial weakness, and one had unilateral mild hamstring weakness. Two asymp-
tomatic gene carriers with signs of FSHD showed fatty infiltration of leg muscles: one had 
a rectus femoris muscle with a fat fraction of 23.5%, another had elevated fat fractions 
in the rectus femoris, adductor longus and soleus muscles of 36.2%, 67.0% and 23.3% 
respectively.
In patients without any functional involvement of the leg muscles (Ricci scores < 2.5, n = 43) 
specific muscles showed elevated mean fat fractions: semimembranosus (19.7% ±19.5), 
rectus femoris (16.3%, ±19.0), adductor longus (13.9%, ±14.7), tibialis anterior (11.7%, 
±8.4), adductor magnus (11.1%, ±8.6). Three patients had mild weakness of the dorsiflex-
ors of the ankle on manual muscle testing and and one 32-year old female patient showed 
knee extensor weakness on quantitative muscle assessment (227 N). Excluding these 
patients from the analyses did not change the results. Regression analysis was performed 
to assess associations between disease duration and clinical measures. In this cohort, 
ten years longer disease duration was associated with 7.5% (95%-CI 5.9-9.1) higher mean 
fat fraction for the total legs, 7.7% (95%-CI 5.8-9.5) lower score on the MFM, 44.8 (95%-CI 
32.2-57.5) meters less on the 6-MWT, and 1.7 (95%-CI 1.3-2.1) and 0.8 (95%-CI 0.6-1.1) 
points higher on the FSHD clinical score and Ricci score, respectively. 
Pattern of muscle involvement 
Fat fraction per muscle ranged from 2-98%. Of all 5,243 leg muscles 46.4% showed hardly 
any fatty infiltration (fat fractions < 10%). About a quarter (23.5%) was severely fatty infil-
trated (fat fractions > 60%). Strong interrater agreement was found for the assessment 
of fatty infiltration (ICC 0.992, p < 0.01). 
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Figure 2. Correlation coefficient (CC) between mean fat fraction and clinical outcome measures. Each dot rep-
resents the score of one patient. Note; 6-minute walking test could only be performed by 111 of 140 patients.
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The most often and most severely affected muscles were the semimembranosus (mean 
fat fraction 41.8%, ±27.6), adductor magnus (33.8%, ±27.4), rectus femoris (31.5%, ±26.9), 
gastrocnemius medialis (31.4%, ±27.9), semitendinosus (31.0%, ±27.7) and adductor longus 
(29.6%, ±27.8). The tibialis posterior, peroneus and gastrocnemius lateralis were least 
severely affected (mean fat fractions 8.7% ±9.2, 16.1% ±15.6, and 16.9% ±21.0 respectively). 
Mean fat fractions for other muscles are included in table 2. Fat fractions of all muscles 
sorted on duration of symptoms show that in this cohort the muscles that are most severely 
affected in later disease stages, are also the ones that are affected early (figure 3). 
Asymmetric involvement in at least one muscle pair, defined as a difference of > 10% in 
fat fractions between sides, was found in 80.7% (113/140) of all patients. However, most 
muscles were symmetrically affected; i.e. 20.1% of all muscle pairs showed asymmetry in 
fat fraction between sides. Of those muscle pairs with asymmetry, there was right-sided 
preference in 53.0%. 
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Table 2. Mean fat fraction per muscle and number of TIRM positive muscles
Muscle Mean fat fraction Number of patients with TIRM 
positivity
right leg left leg right leg left leg
Upper leg
Semimembranosus 42.6% ±27.3 41.3% ±27.8 5 4
Adductor longus 34.3% ±30.1 29.4% ±29.2 1 0
Adductor magnus 33.6% ±27.0 34.3% ±27.8 4 3
Rectus femoris 31.5% ±26.7 31.5% ±27.1 2 1
Semitendinosus 31.1% ±27.7 31.3% ±27.8 2 4
Biceps femoris long head 28.5% ±26.2 29.4% ±27.5 7 2
Biceps femoris short head 24.9% ±22.1 24.3% ±22.3 0 1
Gracilis 23.3% ±23.6 24.2% ±23.6 0 4
Vastus medialis 21.8% ±23.4 21.0% ±22.8 3 3
Sartorius 21.5% ±21.1 22.6% ±21.2 3 0
Vastus intermedius 19.3% ±20.8 19.0% ±21.0 7 2
Vastus lateralis 17.5% ±18.6 17.4% ±18.2 19 6
Lower leg
Gastrocnemius medialis 32.0% ±28.2 31.7% ±27.6 18 15
Tibialis anterior 28.5% ±21.8 28.0% ±22.4 26 10
Soleus 25.0% ±22.5 23.8% ±22.2 0 3
Extensor digitorum longus 20.0% ±18.5 20.4% ±20.7 14 5
Peroneus 16.9% ±15.9 15.3% ±15.3 0 1
Gastrocnemius lateralis 16.1% ±20.3 17.6% ±21.8 6 5
Tibialis posterior 8.7% ±9.2 8.7% ±9.3 0 0
FSHD2
In eight FSHD2 patients we found a similar pattern of muscle involvement and asymmetry 
compared to FSHD1. Most severely affected were semimembranosus, rectus femoris, 
adductor longus, adductor magnus, gastrocnemius medialis and tibialis anterior. Two 
individuals with combined FSHD1 and FSHD2 had a very severe phenotype with mean fat 
fraction of 65.5% and 73.0%, which was much higher than the mean total fat fraction of 
23.8% of the FSHD1 patients and 31.6% of the FSHD2 patients. 
TIRM hyperintensity
In 68 out of 140 patients (48.6%) we found at least one muscle with a hyperintense signal 
on TIRM sequence (TIRM positive). 5,240 muscles were assessed for TIRM hyperintensity 
and 186 were positive (3.5%) (figure 3). The muscles that were positive most frequently 
were the tibialis anterior (12.9%), gastrocnemius medialis (11.8%) and vastus lateralis 
(8.9%). The tibialis posterior, peroneus, adductor longus rarely displayed TIRM hyperinten-
sity (0-0.4%). The presence of TIRM hyperintensity per muscle is given in table 2. 
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Figure 3. Pattern of muscle involvement
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Left column: Visualization of mean degree of fatty infiltration in leg muscles in patients with increasing duration 
of symptoms. 
Middle column: Heatmap of fat fraction per muscle for each patient individually. Each row represents a patient 
ordered progressively by duration of symptoms. Each column represents a muscle ordered progressively by 
degree of fatty infiltration. 
Right column: Heatmap of TIRM positive muscles per patient. 
TP: Tibialis posterior; GL: Gastrocnemius lateralis; P: Peroneus; VL: Vastus lateralis; VI: Vastus intermedius; EDL: 
Extensor digitorum longus; S: Sartorius; VM: Vastus medialis; G: Gracilis; Sol: Soleus; BFB: Biceps femoris short 
head; TA: Tibialis anterior; BFL: Biceps femoris long head; AL: Adductor longus; ST: Semitendinosus; RF: Rectus 
femoris; GM: Gastrocnemius medialis; AM: Adductor magnus; SM: Semimembranosus
F2: FSHD2; F1+2: FSHD1 and 2 combined 
Out of 186 TIRM positive muscles, 29 (15.6%) had a normal fat fraction (< 10%) and 23 
(12.4%) a high fat fraction (> 60%). In 73.1% of TIRM positive muscles, the TIRM hyperin-
tense area was found directly adjacent to a fatty infiltrated area. TIRM positive muscles 
were most frequently found in patients with moderately severe disease (Ricci score 4-8). 
None were found in patients with severity scores of 0 or 1. 62.9% of TIRM positive muscles 
were found in the right leg, although the difference with the number in the left leg was 
non-significant (p = 0.157), except for the vastus lateralis (p = 0.001), tibialis anterior (p = 
0.000) and extensor digitorum longus (p = 0.012). Significantly more male patients had 
TIRM positive muscles than female patients: 45 males vs 23 females (χ² = 5.1, p = 0.024). In 
addition, the mean number of TIRM positive muscles was significantly higher in males than 
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in females (1.6 vs 0.9, p = 0.04). They did not significantly differ in age, disease duration, 
FSHD type, repeat fragment size, or scores on clinical outcome measures. 
Proximal-distal gradient 
Overall there was a mean decrease of fat fraction within muscles from distal to proximal of 
3.9%, ±3.7. A decrease from distal to proximal of > 10% was found in 33.2% of the muscles 
(711/2140). The adductor magnus, semimembranosus, tibialis anterior and rectus femoris 
showed the largest distal to proximal gradient (mean decreases 9.3% ±14.7, 7.2% ±18.4, 
6.9% ±12.4 and 4.9% ±14.8 respectively). 162/2140 (7.6%) individual muscles showed an 
increase of > 10% from distal to proximal. In some muscles we observed a gradient in fatty 
infiltration from distal to proximal, with a TIRM positive front in unaffected muscle tissue 
proximally adjacent to fatty infiltrated muscle tissue (Figure 4). 
Figure 4. Distal to proximal gradient in fatty infiltration with TIRM positive front in unaffected muscle tissue
Left column: DIXON fat images showing fatty infiltration of the m. vastus lateralis of the left leg with a distal to 
proximal decrease in fat fraction. Right column: corresponding TIRM images showing a front of TIRM hyperinten-
sity in normal appearing muscle tissue, adjacent to the fatty infiltrated muscle tissue.
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DISCUSSION
This study provides a thorough description of the relation of quantitative muscle MRI 
with clinical measures in a large cohort of FSHD patients comprising the entire clinical 
spectrum. It demonstrates that the mean total leg fat fraction on MRI correlates strongly 
with measurements of strength, clinical severity scores and measures of overall functional 
activity,and thus validates MRI as a biomarker of disease severity. MRI was able to detect 
muscle changes in patients without any loss of leg muscle function, especially in the ham-
string muscles, adductor muscles and rectus femoris. Possibly, we did not find a loss of 
leg muscle function in these patients because of compensation by other muscles (of the 
same group), compensation within the muscle on a molecular level or because limited 
fatty infiltration does not restrict the functional capacity of the muscle. Our finding of early 
MRI changes in individuals without leg muscle weakness suggests that MRI might be used 
to identify individuals and muscles at risk for clinical progression.
The hamstrings, the adductor muscles and gastrocnemius medialis were the most frequently 
affected muscles. Most often spared were the tibialis posterior, gastrocnemius lateralis and 
peroneus. The most frequently and most severely affected muscles were also the muscles 
that were affected in patients in early disease stages. Our findings support the hypothesis 
that muscles become affected in a sequential order, and that muscles that become affected 
in later stages progress at a similar pace as early affected muscles. The pattern of involve-
ment in fatty infiltration is in concordance with findings in a large qualitatively assessed FSHD 
cohort, although this cohort included only asymptomatic gene carriers or patients with a 
Ricci score of 5 and higher, indicating that no mildly affected patients were included.5 We 
found a similar frequency of asymmetric muscle involvement as previous studies5,16, but we 
did not find a clear right side predominance for fatty infiltration in the lower extremities. 
Recently, hyperintensities on TIRM sequence in FSHD muscles have been proposed to 
represent muscle edema which is sometimes interpreted as active muscle inflammation, 
and a marker for disease activity.24,15,25 The prevalence of TIRM hyperintense muscles in 
this study (3.5%) is comparable to prevalences in the literature (3-7%). In addition, we 
found a similar proportion of TIRM positive muscles without fatty infiltration. TIRM positive 
areas were often found near fatty infiltrated regions. In some muscles, there was a TIRM 
positive front located proximally to the fatty infiltration, supporting the hypothesis that 
in many muscles fatty infiltration starts distally in the muscle. However, the muscles that 
were most frequently TIRM positive, were not the same muscles as those that were most 
severely and/or frequently fatty infiltrated. In addition, in mildly affected patients fatty 
infiltrated muscles were more frequently observed than TIRM positive muscles. These find-
ings could indicate variation in the pathogenic mechanism, including different durations 
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of the TIRM positive phase, TIRM positive areas that reverse to normal muscle tissue, and 
the occurrence of fatty infiltration without preceding TIRM positivity. The proportion of 
TIRM positive muscles was higher in males than in females.5 This suggests that there are 
sex-specific disease differences, possibly related to differences inreproductive hormones. 
In all patients we found a combination of normal and fatty infiltrated muscles, and in some 
also TIRM positive muscles, supporting the hypothesis that FSHD is a ‘muscle per muscle’ 
disease with separate muscles affected in different stages of disease. Longitudinal studies 
are required to further explore this hypothesis and its underlying mechanisms. Muscles 
of the trunk and upper limb could also be included in future studies.
The unique value of this study lies in the use of quantitative analysis of muscle fat frac-
tions in a large genetically confirmed and clinically diverse cohort. For use as a biomarker, 
quantitative measurement is essential, since linear values can be used for parametric 
statistical analyses in contrast to ordinal scores.26 This might be more sensitive to change 
over time compared to functional measures in this slowly progressive disorder. A previous 
study showed that quantitative assessment has a larger sensitivity and better accuracy 
compared to a semi-quantitative visual score.16 Additionally, it can provide information on 
the pattern of involvement not only between but also within different muscles. The sin-
gle-center, single-evaluator design of this study avoids inter-rater variability and increases 
the reliability of correlations between fat fractions and clinical measures. However, a lim-
itation of this design is the decrease in the external validity. Results regarding disease 
duration, should be interpreted with caution since age at disease onset was collected 
retrospectively.
For clinical trials we propose quantitative muscle MRI assessment in addition to clinical 
outcome measures that directly measure patient functioning, like the motor function 
measure. The motor function measures, however, showed a ceiling effect in mildly affected 
patients. Although a good reliability and validity of the scale is suggested for patients with 
FSHD, its psychometric properties, including its target population, should be evaluated 
in more detail.27 Qualitative MRI evaluations will remain useful, for example in assessing 
the presence of TIRM hyperintensities and detecting subtle muscular changes that do not 
show in the clinical examination of the patient.
This study shows a strong correlation of quantitative muscle MRI with different clinical 
outcome measures, especially with the motor function measure. Since quantitative muscle 
MRI also has good clinimetric properties, it is a promising biomarker representative of 
disease severity. For clinical trials we propose to include quantitative muscle MRI in the 
‘FSHD trial toolbox’. 
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ABSTRACT
Objective: To assess the overlap of and differences between quantitative muscle MRI and 
ultrasound in characterizing structural changes in leg muscles of facioscapulohumeral 
muscular dystrophy (FSHD) patients. 
Methods: We performed quantitative MRI and quantitative ultrasound of ten leg muscles 
in 27 FSHD patients and assessed images, both quantitatively and visually, for fatty infil-
tration, fibrosis and edema. 
Results: The MRI fat-fraction and ultrasound echogenicity z-score correlated strongly (CC 
= 0.865, p < 0.05) and both correlated with clinical severity (MRI CC = 0.828, ultrasound 
CC = 0.767, p < 0.001). Ultrasound detected changes in muscle architecture in muscles 
that looked normal on MRI. MRI was better in detecting late stages of fatty infiltration 
and was more suitable to assess muscle edema. Correlations between quantitative and 
semi-quantitative scores were strong for MRI (CC 0.844-0.982, p < 0.05), and varied for 
ultrasound (CC 0.427-0.809, p = 0.026 – p < 0.001).
Conclusions: Quantitative muscle MRI and ultrasound are both promising imaging bio-
markers for differentiating between degrees of structural muscle changes. As ultrasound is 
more sensitive to detect subtle structural changes and MRI is more accurate in end stage 
muscles and detecting edema, the techniques are complementary. Hence, the choice for 
a particular technique should be considered in light of the trial design.
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INTRODUCTION
Muscle imaging complements the clinical assessment of muscle disorders. It reveals pat-
terns and severity of muscle involvement that can help guide diagnosis and track disease 
progression.1 Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive 
inherited muscle disorder.2 Recent insights in its pathogenic mechanism are expected to 
be translated into targeted therapies soon.3, 4 Clinical trials are expected in the upcom-
ing years, requiring (imaging) biomarkers for the assessment of muscle involvement and 
disease progression.5 Especially in early phase trials, the use of highly responsive bio-
markers would enable a smaller sample size or a shorter follow-up period and therefore 
a more efficient screening of potential therapies, compared to clinical outcome measures. 
In FSHD, muscle MRI is currently the most frequently used imaging technique in research 
studies. It is able to detect and quantify fatty infiltration of muscle tissue and visualize 
muscle edema. The degree of fatty infiltration on MRI correlates strongly to clinical mea-
sures and it is able to capture changes over time.6-8 
Muscle ultrasound may provide an alternative that is patient-friendly, safe, fast and can 
be performed at the bedside.9 Various structural changes in the muscle, such as fatty 
infiltration, fibrosis, or edema, produce an increase in echogenicity. Especially the pres-
ence of fibrosis is strongly correlated with an echogenicity increase.10-12 Increased muscle 
ultrasound echogenicity correlated strongly with decreased muscle strength in different 
neuromuscular disorders.13-15 In Duchenne muscular dystrophy it was shown to be sensi-
tive to disease progression.16, 17 A disadvantage is its inability to measure deeper layers of 
muscle. Limited work has been done comparing quantitative ultrasound and MRI head-
to-head. Measurements of muscle thickness, length and cross-sectional area were shown 
to yield similar results for both techniques.18-20 In a pilot-study on five male FSHD patients, 
ultrasound was shown to correlate with, but also complement MRI data.21 The promising 
results of this pilot, prompted us to evaluate the properties of both techniques and com-
pare them in a larger and clinically more diverse FSHD cohort. The aim of this study is to 
assess the overlap and the additional value of quantitative muscle MRI and ultrasound in 
leg muscles. This includes assessment of structural muscle changes, correlating imaging 
findings to clinical measures and comparing quantitative to semi-quantitative scores. 
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METHODS
Patients 
We included genetically confirmed FSHD patients of 18 years and older. A genetic diag-
nosis of FSHD1 was defined as a D4Z4 repeat array on chromosome 4 of 10 D4Z4 repeat 
units or less on a permissive haplotype, and for FSHD2 as an SMCHD1 pathogenic variant 
and hypomethylation of the D4Z4 repeat array on chromosome 4q35. This study was per-
formed in conjunction with a large MRI study on FSHD patients (n = 140).6 A random subset 
of patients participating in the last five months of the MRI study (between June-October 
2015) additionally underwent muscle ultrasound. The selection of patients was based on 
the availability of the ultrasound equipment. This study was conducted according to the 
principles of the Declaration of Helsinki (version October 2013) and in accordance with the 
Medical Research Involving Human Subjects Act (WMO). The study protocol was approved 
by the regional medical ethics committee (CMO region Arnhem-Nijmegen). All patients 
signed informed consent prior to their inclusion in the study. 
MRI acquisition and analysis
A detailed description of the MRI scanning protocol and quantitative analysis can be found 
elsewhere.6 The MRI exams were performed on a 3-Tesla MR system (TIM Trio; Siemens, 
Erlangen, Germany). In summary, we acquired scout images in three orthogonal direc-
tions for positioning of imaging slices. Next, both legs were scanned using a Dixon 2.0 
sequence and a TIRM sequence with a slice thickness of 5 mm.22 Regions of interest (ROI) 
were drawn on a fat fraction map of the Dixon sequence for the muscles of interest. We 
made a selection of frequently affected and spared muscles in FSHD that are suited for 
ultrasound measurement: the rectus femoris, vastus lateralis, peroneus tertius, tibialis 
anterior and medial gastrocnemius bilaterally. ROI’s were drawn at specific slices using the 
localizer sequences: rectus femoris halfway between anterior superior iliac spine (ASIS) 
and upper pole of patella, vastus lateralis at two thirds between ASIS and the upper lateral 
margin of patella, tibialis anterior at one third from the inferior border of the patella to 
the lateral malleolus, peroneus tertius at one fifth from the lateral malleolus to the fibular 
head and the medial head of gastrocnemius at one third from the popliteal fossa to the 
medial malleolus. A fish-oil capsule that could be visualized on the MRI images was placed 
on the skin to ensure that ultrasound images were obtained at the same level as the MRI 
images. Muscle fat fractions were calculated per ROI (fig 1). Fat fractions below 15% are 
considered normal.23 In addition, MRI images per muscle were visually scored by one 
investigator (KM) using the modified Lamminen scale. Fatty infiltration was scored as: 0 = 
normal; 1 = mild with only traces of fatty infiltration; 2 = moderate with fatty infiltration in 
less than 50% of the muscle tissue; 3 = severe with fatty infiltration in more than 50% of the 
muscle tissue; 4 = the entire muscle replaced by abnormal signal. 24, 25 TIRM images were 
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visually assessed for the presence of signal hyperintensity in each muscle at the location 
corresponding to the ultrasound images by a radiologist and one investigator (KM). The 
assessors of the MRI images were blinded for the ultrasound results and vice versa, but 
not for clinical status of the patient. 
Figure 1. MRI and ultrasound images of the rectus femoris muscle
A. MR image of left upper leg with a region of interest drawn for a normal looking rectus femoris muscle. B. 
Corresponding ultrasound image to A. 
C. MR image of left upper leg with a region of interest drawn for a dystrophic rectus femoris muscle. D. Corre-
sponding ultrasound image to C.
S: sartorius; G: gracilis; VM: vastus medialis; VI: vastus intermedius; VL; vastus lateralis; AL: adductor longus; AM: 
adductor magnus
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Ultrasound acquisition and analysis
Muscle ultrasound was performed using an Esaote MyLabTwice ultrasound scanner 
(Esaote SpA, Genoa, Italy) using an 8-14 MHz broadband linear transducer with a 53 mm 
footprint, that has an axial resolution of around 0.2 mm. The ultrasound protocol was 
previously reported elsewhere.21 In summary, a preset for system settings was used to 
ensure compatibility between measurements. Three consecutive measurements were 
performed to minimize variation in echo intensity. Results were averaged offline. Trans-
verse images were acquired at the same locations as described above for the MRI. Patients 
were in supine position with the legs in resting position. For correct echo intensity mea-
surements, oblique scanning angles were avoided by adjusting the angle of the probe to 
obtain optimal perpendicular imaging of the underlying bone. For every muscle, a ROI was 
drawn manually using custom software, developed at our center (fig 1). Raw muscle echo 
intensities were calculated per ROI and then converted to z-scores (the number of stan-
dard deviations from the mean score for sex, age and weight) using previously established 
reference values.26 These z-scores were used for statistical analyses. Z-scores below 2.0 
(i.e. below the population 95th percentile) are considered normal. 
A semi-quantitative assessment of the images was performed using the Heckmatt rating 
scale which ranges from one (normal echo-intensity) to four (severely increased echo-in-
tensity with absent bone reflection) by an experienced neuromuscular ultrasonographer 
(NvA).27 Ultrasound images were visually inspected for textural changes of muscle tissue. 
We assessed ultrasound images for the presence of edema by looking for the character-
istic pattern that is seen in inflammatory myopathies: a blurring of muscle architecture 
with “see through” echogenicity increase without decrease in echogenicity in the deeper 
part of the muscle.28
Clinical outcome measures
Disease severity was rated using the FSHD clinical score, a 15-point sum-score that eval-
uates different muscle groups, where zero indicates no muscle weakness and 15 severe 
muscle weakness in all muscle groups.29 The motor function measure (MFM) was chosen 
as a functional outcome measure. It assesses the severity of the motor deficit on a 32-item 
scale with outcomes ranging from 0-100% in which 100% implies no motor deficits.30 
Muscle strength was tested manually (MRC gradation31) for the knee extensors, foot dor-
siflexors and foot plantar flexors, and quantitatively (fixed dynamometry) for the knee 
extensors.
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Statistical analyses 
All statistical analyses were performed using IBM SPSS Statistics, version 22. Because of 
the skewed distribution of fat fractions and z-scores, a Spearman rho analysis was used 
to calculate bivariate correlations between MRI and ultrasound. The Spearman rho anal-
ysis was also used for correlations between quantitative and semi-quantitative scores. 
For correlations between clinical outcomes measures and fat fractions and z-score the 
Pearson correlation coefficient was used. To control for multiple testing we applied the 
Benjamini-Hochberg false discovery rate procedure, a less conservative method than the 
Bonferroni correction, in which we accepted the proportion of false discoveries to be 5%.32 
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RESULTS
Patients
We included 27 genetically confirmed FSHD patients comprising the full spectrum of dis-
ease severity. Of these, one was an asymptomatic gene carrier who only showed minimal 
signs of FSHD on examination, mainly abdominal muscle weakness. This resulted in ana-
lyzing 270 lower extremity muscles. Patient characteristics are presented in table 1. For 
each patient, muscle MRI and ultrasound were performed on the same day. There were 
no differences between FSHD1 and FSHD2 patients in either imaging or clinical outcomes. 
Table 1. Patient characteristics 
Characteristic N=27
Sex Male n= 17
Female n= 10
Age (mean ± SD [range]) 53.2 years ±12.7 [31-78]
BMI (mean ± SD [range]) 26.3 kg/m2 ±4.1 [21.0-35.3]
FSHD type FSHD1 n = 25
FSHD2 n = 2
FSHD clinical score (mean ± SD [range]) 5.5 ±3.8 [0-14]
Motor function measure (mean ± SD [range]) 86.6 ±17.7 [29.1-100]
Correlation between MRI and ultrasound
The mean MRI fat fraction of all muscles per patient correlated highly and significantly 
with the mean ultrasound z-score with a correlation coefficient of 0.865 (p < 0.001). When 
correlating MRI fat fraction and ultrasound z-score per muscle for both legs separately, 
all correlations were statistically significant (p < 0.05 after correction for multiple testing), 
but correlation coefficients varied widely from 0.514 to 0.873 (fig 2). As can be noted in 
figure 2, in all muscles measured except for the tibialis anterior, the ultrasound z-scores 
often decrease towards normal at muscle sites with the highest fat fractions on MRI. In 
approximately 15% of all muscles there was a high MRI fat-fraction but a normal ultra-
sound z-score, or vice versa.
Nineteen muscles appeared (nearly) normal on the MRI, but showed increased ultrasound 
z-scores. On visual inspection of these ultrasound images, the muscles showed tissue tex-
ture changes, consisting of an increased amount of short linear reflective structures that 
overall increased echogenicity. Such changes are consistent with intramuscular fibrosis, 
especially in the absence of fatty infiltration (fig 3A-B).10, 11
Twenty of the outliers were muscles that were severely fatty infiltrated on MRI, but had 
normal ultrasound z-scores (fig 3C-D). On visual inspection of these ultrasound images, the 
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muscle tissue appeared relatively hypoechogenic, but muscle architecture was disturbed 
on all these images. This was most often seen in the medial gastrocnemius muscle. 
Five of the outliers demonstrated heterogenous involvement of the muscle. The ultra-
sound measurement was performed at a site where only fatty infiltrated or only normal 
looking muscle tissue was present. In contrast, the MR image included the total cross-sec-
tional area of the muscle (fig 3E-F). 
Asymmetrical muscle involvement was found in 25/135 (18.5%) of all muscle pairs. In 14 
muscle pairs there was asymmetry both on MRI and on ultrasound images. In 11 muscle 
pairs there was asymmetry only on images of one of the two techniques and these were 
the muscles where MRI and ultrasound showed different results as described above. 
Muscle edema 
The MRI showed TIRM hyperintense areas, indicating muscle edema, in 22 (8%) of 270 
muscles. Two of these 22 TIRM positive muscles, both tibialis anterior muscles, also scored 
positively for inflammation on muscle ultrasound. Another 32 muscles were also scored 
positive for inflammation on muscle ultrasound, but were TIRM negative on MRI. These 32 
muscles all had a fat fraction below 15% except for one medial gastrocnemius (fat fraction 
18.2%). In 29 out of 32 muscles, this involved the vastus lateralis, rectus femoris or medial 
gastrocnemius muscles. The nineteen outliers mentioned above, showing an increased 
z-score on ultrasound images, but normal fat-fraction on MRI images, were all TIRM nega-
tive. TIRM hyperintense areas were found both in muscle with and without fatty infiltration. 
Correlation between imaging results and clinical outcome measures 
Both the mean MRI fat-fraction and mean ultrasound z-score of all muscles correlated 
strongly with the FSHD clinical score, a measure of disease severity (correlation coeffi-
cients 0.828 and 0.767 respectively, p < 0.001) and with the motor function measure, a 
functional outcome measure (correlation coefficients -0.826 and -0.674 respectively, p < 
0.001). Correlations of muscle strength testing with the MRI fat fraction and ultrasound 
z-score of the corresponding muscle group are shown in table 2. 
We separately evaluated the clinical involvement of the nineteen muscles showing an 
increased z-score on ultrasound images, but normal fat-fraction on MRI images. Manual 
muscle testing of the corresponding muscle group was normal in all but two patients. One 
patient with increased ultrasound z-score of the gastrocnemius medialis muscle had mild 
weakness of the plantar flexors (MRC 4), but also had a fatty infiltrated soleus muscle. One 
patient with a high z-score for the vastus lateralis muscle, scored MRC4 for knee extensors 
but additionally showed fatty infiltration of other parts of the quadriceps muscle. 
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TIRM hyperintense areas were found both in muscle with normal and with decreased 
strength. In muscles with decreased strength there was a combination of fatty infiltration 
and TIRM hyperintensity. 
Figure 2. Correlation between quantitative MRI (fat fraction) and ultrasound (z-score) for the mean values of 
all muscles and for each muscle separately
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The fat fractions and z-scores for the total legs were calculated by averaging the scores for the 10 muscles mea-
sured. Dotted lines indicate limits of values that are considered normal. CC: correlation coefficient.
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Figure 3. MRI and ultrasound images with different results in the same muscle
A&B. Images of the right vastus lateralis, appearing normal on MRI (fat fraction 6%) but showing textural changes 
tissue texture changes (an increased amount of short linear reflective structures) on ultrasound images, resulting 
in a high echo-intensity (z-score 3.4).
C&D. MRI of the left gastrocnemius medialis that is completely fatty infiltrated (fat fraction 74%) and the corre-
sponding ultrasound image, that shows a low echo-intensity (resulting in a normal z-score of 0.6), but a disturbed 
architecture of the muscle tissue. 
E&F. MRI of the right vastus lateralis with focal fatty infiltration (fat fraction 21%) and corresponding ultrasound 
image, capturing only the fatty infiltrated part of the muscle (z-score 7.1). 
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Table 2. Correlations between muscle strength testing and imaging outcomes of the corresponding muscle 
groups
Clinical outcome Muscle Side MRI fat-fraction Ultrasound z-score
CC p-value CC p-value
MMT dorsiflexors Tibialis anterior Right -0.882 0.01 -0.772 0.01
Left -0.886 0.01 -0.729 0.01
MMT plantar flexors Gastrocnemius medialis Right -0.323 0.16 -0.580 0.01
Left -0.378 0.08 -0.569 0.01
MMT knee extensors Vastus lateralis Right -0.823 0.01 -0.543 0.01
Left -0.828 0.01 -0.569 0.01
Rectus femoris Right -0.500 0.02 -0.335 0.14
Left -0.535 0.01 -0.230 0.30
QMT knee extensors Vastus lateralis Right -0.603 0.01 -0.492 0.03
Left -0.522 0.02 -0.232 0.32
Rectus femoris Right -0.385 0.08 -0.289 0.23
Left -0.123 0.57 -0.159 0.46
MMT: manual muscle testing; QMT: quantitative muscle testing; CC: correlation co-efficient; p-values corrected 
for multiple testing
Correlation between quantitative and semi-quantitative rating scales 
MRI quantitative muscle fat fractions correlated moderately to strongly with the semi-quan-
titative modified Lamminen score for all muscles (correlation coefficient ranging from 
0.641-0.891, p < 0.01 corrected for multiple testing). Correlations of quantitative ultra-
sound and the semi-quantitative Heckmatt score, were less strong, but still significant 
(range 0.418 – 0.840, p < 0.05 corrected for multiple testing) for all muscles. Moderate 
correlations were found for left gastrocnemius and vastus lateralis muscle. All correlation 
coefficients are presented in table 3.
Table 3. Correlations between quantitative and semi-quantitative scores per muscle for both MRI and ultra-
sound images
Muscle MRI 
fat fraction vs Lamminen score
Ultrasound 
z-score vs Heckmatt score
CC p-value CC p-value
Rectus femoris Right 0.865 0.01 0.717 0.01
Left 0.818 0.01 0.763 0.01
Vastus lateralis Right 0.795 0.01 0.651 0.01
Left 0.762 0.01 0.418 0.01
Tibialis anterior Right 0.835 0.01 0.840 0.01
Left 0.835 0.01 0.749 0.01
Gastrocnemius medialis Right 0.891 0.01 0.677 0.01
Left 0.745 0.01 0.582 0.01
Peroneus tertius Right 0.652 0.01 0.742 0.01
Left 0.641 0.01 0.805 0.01
p-values corrected for multiple testing 
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DISCUSSION
This study of 270 leg muscles of 27 patients with different stages of FSHD showed that 
both quantitative muscle MRI and quantitative ultrasound correlated strongly with clinical 
disease severity and with most of the manual muscle strength testing. There was a strong 
correlation between the degree of fatty infiltration on MRI and the ultrasound echo-in-
tensity. The head-to-head comparison provided unique insights into the strengths and 
pitfalls of both techniques. While for most muscles the techniques yielded similar results, 
there were differences between the two techniques in approximately 15% of the muscles 
measured. 
For some muscles ultrasound detected changes suggestive of intramuscular fibrosis, 
leading to increased echogenicity, while MR images were still normal both visually and 
quantitatively. Whereas MRI only detects fatty infiltration and edema, ultrasound also 
detects fibrosis. A study on FSHD patients using muscle biopsies from tibialis anterior and 
vastus lateralis muscles that appeared normal on MRI, showed mild to moderate fibrosis 
in 11 of 17 biopsies (65%) (unpublished data). Two animal studies have shown that fibro-
sis leads to increased muscle echo intensity.10, 12 However, as we did not perform muscle 
biopsies in this study, there is no direct pathological evidence to attribute the disturbed 
muscle architecture to fibrosis. Altogether, our findings suggest that muscle involvement 
in FSHD starts even before signs of fatty infiltration or edema become apparent on MRI, 
and that MRI is not able to detect all structural muscle changes. Whether these changes 
on ultrasound have an effect on muscle strength could not be determined, because the 
muscles involved perform their function as a part of a larger muscle group. Longitudinal 
data is necessary to determine the evolvement of these changes in muscle architec-
ture. For clinical trials on therapeutic agents intended to slow down disease progression, 
patients with early disease stage are an important target group. For this particular group 
quantitative ultrasound may be a more suitable biomarker than MRI. 
In contrast, in muscles that were nearly completely replaced by fat on MRI, ultrasound 
often failed to detect the degree of abnormality. This can be explained by the fact that in 
severely fatty infiltrated muscles, there will be few tissue transitions left to reflect the ultra-
sound beam, resulting in a relatively hypoechoic image. However, on visual inspection, the 
ultrasound images showed an abnormal muscle texture. Thus in these cases, new tech-
niques for texture analysis might provide an increased detection of muscle involvement 
over grayscale / echogenicity analysis.33 This difference between techniques was observed 
most frequently in the medial gastrocnemius muscle, that often shows early and severe 
involvement in FSHD 6. For the calf muscles, the misleading decrease in echogenicity in 
severely affected muscles has been described earlier34, but the current study shows that 
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this is also the case for other muscles, such as the rectus femoris, vastus lateralis and per-
oneus tertius. In longitudinal studies on severely affected muscles, quantitative ultrasound 
measurements bare the risk of false positive results, since a decrease in z-score could be 
due to the muscle becoming more fatty infiltrated. In this particular patient group, muscle 
MRI would be the preferred biomarker. 
A small proportion of all muscles (0.2%) showed inhomogeneous distribution of fatty infil-
tration within the muscle on MRI. Here, the smaller sampling area of the ultrasound images 
resulted in different results between the two techniques. For most muscles in FSHD the 
pattern of fatty infiltration is homogeneous, although it can vary along the length of a 
muscle.6, 35 For other muscle disorders with a more patchy distribution such as inflamma-
tory myopathies this poses a risk of sampling error when imaging these with ultrasound.36 
Quantitative ultrasound is currently only able to measure superficially located muscles 
and can often measure only a part of the muscle. So, in this case MRI has the advantage 
of depicting all leg muscles over their entire length. 
In the assessment of muscle edema, MRI and ultrasound yielded very disparate results, 
with a higher proportion of muscles scored positive for edema on ultrasound images. For 
MRI, different sequences can be applied to discriminate between signal changes due to 
fatty infiltration or muscle edema. With muscle ultrasound however, a variety of changes 
in the composition of the muscle tissue can produce increased echogenicity. For the 
assessment of edema on ultrasound images, we looked for signs that are typically seen in 
inflammatory myopathies. As these myopathies have a different pathogenic mechanism 
compared to FSHD, this definition for edema may not be suited to assess FSHD muscles. 
Additionally, a muscle can only be positive for edema when it is mildly fatty infiltrated, 
because in moderate or severely fatty infiltrated muscles there is always a decrease in 
echogenicity in the deeper layers of the muscle due to attenuation of the ultrasound beam, 
and hence no “see-through”. As there currently is no better method to discern increased 
echogenicity due to fat and/or fibrosis from edema, MRI remains the more suitable tech-
nique to assess muscle inflammation thus far.37
Finally, the suboptimal correlation between quantitative and semi-quantitative ultrasound 
scores in this study emphasizes the challenges in scoring ultrasound images visually. 
Even the use of a semi-quantitative rating such as the Heckmatt scale cannot capture all 
variables that influence the degree of abnormality. Additionally, qualitative measures are 
ordinal, non-linear, measures that are not suited for parametric statistical testing. For MRI 
quantitative and semi-quantitative assessments correlated strongly, but both failed to 
detect architectural changes in some muscles that were abnormal on ultrasound images. 
The main limitation of this study was the relative small sample size. Though we included 
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the full spectrum of disease severity, the population was limited in the sense that it did 
not include children or severely obese individuals. Longitudinal studies will be essential to 
assess evolvement of MRI and ultrasound abnormalities and their relation to one another.
 
In conclusion, quantitative muscle MRI and ultrasound were both able to differentiate 
between different degrees of muscle involvement and correlated strongly to clinical 
severity. At the ends of the severity spectrum, the two techniques complement each 
other in detecting structural muscle changes. The choice for a particular technique should 
therefore be carefully considered in light of the target population, the clinical or research 
question and muscles to be measured. 
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ABSTRACT 
Introduction: Electrical impedance myography (EIM) is a non-invasive technique for 
measuring muscle composition and a potential physiological biomarker for facioscapulo-
humeral muscular dystrophy (FSHD). 
Methods: Thirty-two genetically confirmed and clinically affected FSHD participants under-
went EIM in 7 muscles bilaterally. Correlations between EIM and baseline clinical measures 
were used to select EIM parameters of interest in FSHD, and EIM and clinical measures 
were followed for 1 year. 
Results: There were no significant changes in the EIM parameters. While fifty kHz reac-
tance correlated the strongest to clinical measures at baseline, the 50-211 kHz phase-ratio 
demonstrated lower within subject 12 month variability, potentially offering sample size 
savings for FSHD clinical trial planning.
Discussion: EIM did not identify significant disease progression over 12 months. It is 
currently unclear whether this is due to limitations of the technology, or the slow rate of 
disease progression in this cohort of FSHD patients over this period of time. 
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INTRODUCTION
Facioscapulohumeral muscular dystrophy is a hereditary muscle disorder.1,2 A unify-
ing model of the genetic mechanism for FSHD has been proposed and the increasing 
knowledge of the pathogenic mechanism provides opportunities to develop targeted ther-
apeutic strategies.3,4 Therefore, there is a high likelihood of clinical trials being initiated in 
the upcoming years. In preparation for these trials, there is a need to develop outcome 
measures.5 Development of biomarkers that are sensitive to change will be crucial espe-
cially for early phase clinical trials.
Electrical impedance myography (EIM) has been proposed as a biomarker for disease 
severity and progression in neuromuscular disorders.6,7 EIM is a non-invasive technique 
that measures changes in muscle composition through bio-impedance measures and thus 
provides a potential quantitative assessment of structural muscle changes.6 Electrodes 
are placed on the skin that produce multi-frequency, low intensity alternating electrical 
currents. These currents are applied to individual muscles or muscle groups and the 
resulting voltage is measured. Impedance is a measure of obstruction of the flow of the 
electrical current through the tissue, which differs between various body tissues such as 
muscle or fat. 
In FSHD, muscles undergo structural changes as the disease progresses, including atro-
phy, fatty infiltration, edema and fibrosis. These changes can all potentially influence the 
impedance across the muscle tissue.8,9 In a previous cross-sectional study on EIM in FSHD, 
we showed that EIM is a reliable measure of muscle composition in FSHD, that correlates 
with functional outcome measures.10 Studies on other neuromuscular disorder like amy-
otrophic lateral sclerosis, congenital myopathies and Duchenne muscular dystrophy, have 
shown that EIM is able to capture changes over time11-14, although research is ongoing on 
what parameters are most suitable to use in each different disorder. 
In this study we assessed the changes in EIM measurements in FSHD participants and 
the potential of EIM as a biomarker for clinical trials using a one year longitudinal study. 
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METHODS
Study design
This was a prospective, observational study. Participants were recruited at the University 
of Rochester Medical Center from 2012 to 2015. The study was approved by the human 
subjects committee, and written informed consent was obtained from all participants.
Participants
We included genetically confirmed participants aged 18-75 years, who had clinical symp-
toms while still being ambulatory.10 Data were obtained during 3 visits: one at baseline 
(and < 3 weeks later for reliability testing), one at 6 months and one at 12 months. Baseline 
and reliability data have previously been reported.10
EIM measurements
EIM measurements were obtained using a handheld EIM device from Skulpt, Inc. (Boston, 
Massachusetts) with a transverse sensor configuration (current passing across the 
myofibers), as previously described.10 Measurements were obtained utilizing standard 
positioning over the following muscles bilaterally: deltoid, biceps, triceps, abdominals, 
vastus lateralis, tibialis anterior, and thoracic paraspinals. Investigators underwent a single 
afternoon training session at the beginning of the study. Reactance, resistance and phase 
angle were recorded for 41 frequencies ranging from 1 kHz to 10 MHz. For each muscle, 
3 consecutive measurements were performed and the 2 most closely aligned measure-
ments were averaged. For analyses 4 different frequencies were chosen based on prior 
EIM studies in neuromuscular diseases: 50 kHz, 100 kHz, 211 kHz and 300 kHz. In addition, 
phase ratios were calculated for 50/211 kHz and 100/300 kHz.11,15
Clinical outcome measures 
Quantitative strength measurements were collected using fixed dynamometry (QMA 
system, Gainesville, GA). The maximum voluntary isometric contraction testing (MVICT) 
was recorded in kilogram-force for each muscle group and then standardized for sex, 
age and height as previously described.16 Composite MVICT scores were calculated by 
averaging the standardized scores across multiple muscle groups: shoulder abduction, 
elbow flexors and extensors, ankle dorsiflexors, knee flexors and extensors and hand-
grip. Regional composite scores were calculated by averaging upper and lower extremity 
muscle groups only. 
The FSHD clinical score assigns severity scores for different body regions, resulting in a 
total score that ranges from 0-15, in which zero indicates no symptoms and 15 indicates 
extremely severe symptoms (e.g. requiring a wheelchair for mobility). 
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The ‘timed up and go’ is a timed functional test that uses the time it takes for a patient to 
get up from a standard armchair, walk 3 meters, turn, walk back and sit down.17 
The domain delta questionnaire is a patient-reported anchor questionnaire that asks 
participants to indicate whether they got worse, remained stable or improved during the 
study period on the domains of overall health, mobility and ambulation and upper arm 
and shoulder function. There is one question for each domain with five answering options: 
much worse, a little worse, unchanged, a little better, or much better. 
Statistical analyses 
Statistical analyses were performed using SPSS version 22. Descriptive statistics were 
calculated for all parameters and are presented as mean and standard deviation unless 
stated otherwise. 
Outliers due to technical EIM errors, such as negative values at low frequencies or 
extremely high values far outside the normal range, were not included in analysis (the 
combination of deleted outliers and missing data, resulted in no more than 1.4% of total 
data being missing). Missing values were considered to be missing at random. For analy-
ses of average scores over multiple muscles, we used a last-observation carried forward 
approach for missing data. 
Spearman rho analyses were used to calculate bivariate correlations with p-values of < 
0.05 considered statistically significant. A one-way repeated measures ANOVA was used 
to test for changes in EIM and clinical results at baseline and after 6 and 12 months. To 
control for multiple testing we applied the Benjamini-Hochberg false discovery rate pro-
cedure, a less conservative method than the Bonferroni correction, in which we accepted 
the proportion of false discoveries to be 5%.18 
Differences in change in EIM outcomes between participants that subjectively did or did 
not progress over 6 months based on the domain delta questionnaire, was tested using 
a mixed ANOVA with time as a within-subject factor and outcome on the domain delta 
questionnaire as a between-subject factor. 
Sample size calculations were based on a hypothetical two-armed placebo-controlled 
clinical trial with an 80% power to detect a 5% difference. G*Power statistical software 
version 3.1 was used to calculate sample sizes based on the mean baseline EIM values 
and the standard deviation of the 12 month change.19 
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RESULTS
Participants
Out of the previously reported 35 participants in our cross-sectional EIM study10, 32 par-
ticipants had 12 month longitudinal data available for analysis. The majority of participants 
were male. Baseline characteristics are shown in table 1.
Table 1. Baseline patient characteristics
Parameter Value (n =32)
Sex (n) 25 male (78.1%)
Age (years, SD, [range]) 52.3 ±11.7 [22-68]
FSHD clinical score (mean, SD, [range]) 6.6 ±3.0 [1-11]
BMI (kg/m2, SD, [range]) 27.6 ±6.0 [17.2-43.3]
FSHD type (n) 30 FSHD1; 2 FSHD2 
Repeat length FSHD1 (kb, SD, [range]) 25.2 ±6.5 [13-41]
Time since first symptom (patient reported) (years, SD, [range]) 24.7 ±12.8 [4.2-47.0]
SD: standard deviation, BMI: body mass index 
Baseline correlations EIM and clinical measures
A comprehensive overview of correlations of EIM measurements to clinical measures is 
given in table 2. The 50 kHz reactance showed moderate, statistically significant correla-
tions to all clinical measures. Correlations between clinical measures and phase-ratios 
were stronger than correlations to single frequency phase values.
EIM changes
After 12 months of follow-up, no significant changes in EIM parameters were found for 
the average of all muscles measured, or the average of lower or upper extremity muscles. 
Mean changes over 12 months in 50 kHz reactance and 50-211 kHz phase-ratio, 2 of the 
Table 2. Baseline correlations between EIM and clinical outcome measures
50 kHz 100 kHz 211 kHz 300 kHz 50/211 kHz 100/300 kHz 
P X R P X R P X R P X R PR PR
FSHD Clinical Score -0.36 -0.64* 0.11 -0.34 -0.61* -0.09 -0.34 -0.53* -0.08 -0.34 -0.46† -0.07 -0.41 -0.38
Timed up and go test -0.37 -0.60* -0.08 -0.34 -0.54* -0.06 -0.32 -0.46† -0.05 -0.32 -0.40 -0.04 -0.56* -0.47†
Standardized QMT all muscles 0.43† 0.76* 0.17 0.42† 0.73* 0.14 0.42† 0.65* 0.13 0.42† 0.58* 0.12 0.46† 0.44†
Standardized QMT LEXT 0.39 0.67* 0.14 0.39 0.71* 0.11 0.41 0.46† 0.09 0.28 0.63* 0.01 0.31 0.34
Standardized QMT UEXT 0.43† 0.69* 0.05 0.41† 0.64* 0.02 0.39† 0.54* 0.01 0.38† 0.45† 0.00 0.61* 0.59*
BMI -0.69* -0.27 0.60* -0.68* -0.11 0.62* -0.68* 0.09 0.62* -0.67* 0.20 0.63* -0.63* -0.64*
QMT: quantitative muscle strength; LEXT: lower extremities; UEXT: upper extremities; BMI: body mass index;  P: phase; X: reactance; R: resistance; PR: phase-ratio. *p < 0.01; †p < 0.05 (false discovery rate corrected values)
525558-L-bw-Mul
Processed on: 30-11-2018 PDF page: 185
Electrical impedance myography in FSHD
185
9
EIM parameters that correlated the strongest with clinical measures at baseline, are shown 
in figure 1. The mean change of the 50 kHz reactance over all muscles measured was 0.001 
after 12 months (95%-CI -0.309 to 0.312), for the 50-211 kHz phase-ratio the mean 12 
month change was 0.009 (95%-CI -0.015 to 0.034). Additionally, we assessed changes in 50 
kHz reactance and 50-211 kHz phase-ratio over 12 months for all individual muscles and 
found no significant changes (table 3). We also assessed 12 months changes in individual 
muscles for the reactance and phase for 100, 211 and 300 kHz and for the 100-300 kHz 
phase-ratio and found no significant changes (data not reported). 
Figure 1. 50 kHz reactance (A) and 50-211 kHz phase-ratio (B) at baseline, 6 months and 12 months (whole 
body, upper extremity, and lower extremity averages)
Table 2. Baseline correlations between EIM and clinical outcome measures
50 kHz 100 kHz 211 kHz 300 kHz 50/211 kHz 100/300 kHz 
P X R P X R P X R P X R PR PR
FSHD Clinical Score -0.36 -0.64* 0.11 -0.34 -0.61* -0.09 -0.34 -0.53* -0.08 -0.34 -0.46† -0.07 -0.41 -0.38
Timed up and go test -0.37 -0.60* -0.08 -0.34 -0.54* -0.06 -0.32 -0.46† -0.05 -0.32 -0.40 -0.04 -0.56* -0.47†
Standardized QMT all muscles 0.43† 0.76* 0.17 0.42† 0.73* 0.14 0.42† 0.65* 0.13 0.42† 0.58* 0.12 0.46† 0.44†
Standardized QMT LEXT 0.39 0.67* 0.14 0.39 0.71* 0.11 0.41 0.46† 0.09 0.28 0.63* 0.01 0.31 0.34
Standardized QMT UEXT 0.43† 0.69* 0.05 0.41† 0.64* 0.02 0.39† 0.54* 0.01 0.38† 0.45† 0.00 0.61* 0.59*
BMI -0.69* -0.27 0.60* -0.68* -0.11 0.62* -0.68* 0.09 0.62* -0.67* 0.20 0.63* -0.63* -0.64*
QMT: quantitative muscle strength; LEXT: lower extremities; UEXT: upper extremities; BMI: body mass index;  P: phase; X: reactance; R: resistance; PR: phase-ratio. *p < 0.01; †p < 0.05 (false discovery rate corrected values)
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Changes in clinical outcomes
After 12 months there was a change in the composite MVICT for all muscles measured 
(mean change -0.48, 95%-CI -0.90 to -0.07, p = 0.042), but not in the raw quantitative 
strength results per muscle (table 4). The ‘timed up and go’ test did not significantly change 
over 12 months (mean change 0.11, 95%-CI -0.40 to 0.62, p = 0.663). 
Self-reported impression of change
Participants who reported worsening on the domains of overall health (n=12, 37.5%), 
mobility and ambulation (n=18, 56.3%), and arm and shoulder function (n=15, 46.9%), did 
not significantly change in their results on mean EIM measurements for the whole body, 
lower extremities and upper extremities, respectively (figure 2).
Clinical trial planning 
Estimates of variability of baseline values and changes over time are given in table 5. These 
estimates of variability were used to calculate the required sample sizes for a two-armed 
placebo-controlled clinical trial with an 80% power to detect a 5% difference over 12 
months. The variability across phase-ratio measures was smaller compared to reactance 
measures and to clinical measures, resulting in smaller sample sizes with the phase-ratio 
as a potential outcome parameter (table 5). 
Table 3. Changes in EIM parameters for individual muscle groups 
50 kHz Reactance 50-211 kHz Phase-ratio
6-month change 12-month change 6-month change 12-month change
Muscle Mean 95%-CI Mean 95%-CI Mean 95%-CI Mean 95%-CI
Deltoid Left 0.185 -0.34 to 0.71 0.083 -0.38 to 0.55 0.008 -0.03 to 0.05 0.007 -0.04 to 0.05
Right 0.305 -0.15 to 0.76 0.178 -0.34 to 0.70 0.046 -0.01 to 0.10 0.027 -0.02 to 0.08
Biceps brachii Left -0.080 -0.77 to 0.61 -0.544 -1.04 to -0.04* -0.008 -0.06 to 0.04 -0.008 -0.05 to 0.04
Right 0.011 -0.49 to 0.51 -0.208 -0.95 to 0.53 0.011 -0.04 to 0.07 0.020 -0.03 to 0.07
Triceps Left 0.030 -0.49 to 0.55 -0.230 -0.72 to 0.26 0.027 -0.03 to 0.08 -0.025 -0.08 to 0.03
Right 0.568 -0.01 to 1.15 0.043 -0.52 to 0.61 0.028 -0.03 to 0.09 0.026 -0.04 to 0.09
Abdominals Left 0.367 -0.28 to 1.02 0.006 -0.60 to 0.61 0.034 -0.05 to 0.12 0.019 -0.08 to 0.12
Right -0.018 -0.44 to 0.41 -0.048 -0.53 to 0.43 0.010 -0.06 to 0.08 0.038 -0.04 to 0.11
Vastus lateralis Left 0.062 -0.45 to 0.58 0.309 -0.37 to 0.98 -0.025 -0.10 to 0.05 -0.013 -0.07 to 0.04
Right 0.026 -0.61 to 0.67 0.285 -0.29 to 0.86 -0.023 -0.08 to 0.04 -0.014 -0.06 to 0.03
Tibialis anterior Left 0.116 -0.37 to 0.60 0.179 -0.26 to 0.62 -0.002 -0.07 to 0.06 -0.010 -0.07 to 0.05
Right 0.060 -0.39 to 0.51 -0.010 -0.51 to 0.49 0.017 -0.04 to 0.07 -0.003 -0.05 to 0.05
Thoracic paraspinal Left 0.030 -0.36 to 0.42 0.263 -0.21 to 0.73 0.002 -0.08 to 0.08 0.020 -0.05 to 0.08
Right 0.028 -0.43 to 0.49 0.096 -0.44 to 0.63 0.120 -0.02 to 0.26 0.055 -0.06 to 0.17
*non-significant after correction for multiple testing
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Table 4. Change in MVICT for individual muscle groups over 12 months in kgf 
Muscle group Mean 12 month change from baseline (kg) 95%-CI
Shoulder abductors Left -0.62 -1.40 to 0.16
Right -0.42 -1.13 to 0.29
Elbow flexors Left -0.54 -1.22 to 0.15
Right -0.70 -1.50 to 0.10
Elbow extensors Left -0.55 -1.16 to 0.06
Right -0.30 -0.86 to 0.26
Handgrip Left -0.25 -1.23 to 0.73
Right 0.20 -1.76 to 2.15
Knee flexors Left -0.25 -1.50 to 1.00
Right -1.12 -2.48 to 0.25
Knee extensors Left -0.34 -1.79 to 1.12
Right -1.54 -3.23 to 0.15
Ankle dorsiflexors Left 0.25 -0.64 to 1.14
Right -0.71 -1.65 to 0.23
Table 3. Changes in EIM parameters for individual muscle groups 
50 kHz Reactance 50-211 kHz Phase-ratio
6-month change 12-month change 6-month change 12-month change
Muscle Mean 95%-CI Mean 95%-CI Mean 95%-CI Mean 95%-CI
Deltoid Left 0.185 -0.34 to 0.71 0.083 -0.38 to 0.55 0.008 -0.03 to 0.05 0.007 -0.04 to 0.05
Right 0.305 -0.15 to 0.76 0.178 -0.34 to 0.70 0.046 -0.01 to 0.10 0.027 -0.02 to 0.08
Biceps brachii Left -0.080 -0.77 to 0.61 -0.544 -1.04 to -0.04* -0.008 -0.06 to 0.04 -0.008 -0.05 to 0.04
Right 0.011 -0.49 to 0.51 -0.208 -0.95 to 0.53 0.011 -0.04 to 0.07 0.020 -0.03 to 0.07
Triceps Left 0.030 -0.49 to 0.55 -0.230 -0.72 to 0.26 0.027 -0.03 to 0.08 -0.025 -0.08 to 0.03
Right 0.568 -0.01 to 1.15 0.043 -0.52 to 0.61 0.028 -0.03 to 0.09 0.026 -0.04 to 0.09
Abdominals Left 0.367 -0.28 to 1.02 0.006 -0.60 to 0.61 0.034 -0.05 to 0.12 0.019 -0.08 to 0.12
Right -0.018 -0.44 to 0.41 -0.048 -0.53 to 0.43 0.010 -0.06 to 0.08 0.038 -0.04 to 0.11
Vastus lateralis Left 0.062 -0.45 to 0.58 0.309 -0.37 to 0.98 -0.025 -0.10 to 0.05 -0.013 -0.07 to 0.04
Right 0.026 -0.61 to 0.67 0.285 -0.29 to 0.86 -0.023 -0.08 to 0.04 -0.014 -0.06 to 0.03
Tibialis anterior Left 0.116 -0.37 to 0.60 0.179 -0.26 to 0.62 -0.002 -0.07 to 0.06 -0.010 -0.07 to 0.05
Right 0.060 -0.39 to 0.51 -0.010 -0.51 to 0.49 0.017 -0.04 to 0.07 -0.003 -0.05 to 0.05
Thoracic paraspinal Left 0.030 -0.36 to 0.42 0.263 -0.21 to 0.73 0.002 -0.08 to 0.08 0.020 -0.05 to 0.08
Right 0.028 -0.43 to 0.49 0.096 -0.44 to 0.63 0.120 -0.02 to 0.26 0.055 -0.06 to 0.17
*non-significant after correction for multiple testing
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Figure 2. Change in EIM parameters (50 kHz reactance and 50-211 kHz phase-ratio) after 12 months for 
patients who reported to have remained stable and who reported subjective disease progression on different 
domains of the domain delta questionnaire
Table 5. Estimates of variability of baseline measurements and of changes over 12 months, and subsequent 
sample size requirements 
Baseline 12 months
change from baseline
Required sample size 
(per arm)
EIM measures SD SD
Reactance 50 kHz whole body 1.25 0.61 90
Reactance 50 kHz upper extremities 1.78 0.70 77
Reactance 50 kHz lower extremities 1.55 0.87 168
Phase-ratio 50-211 kHz whole body 0.09 0.06 29
Phase-ratio 50-211 kHz upper extremities 0.11 0.06 28
Phase-ratio 50-211 kHz lower extremities 0.11 0.07 33
Clinical measures
QMT whole body (kgf) 4.50 1.15 140
QMT upper extremities (kgf) 4.71 0.88 143
QMT lower extremities (kgf) 5.72 0.93 57
Timed up and go test (sec) 3.55 1.42 90
QMT: standardized quantitative muscle testing; kgf: kilogram-force; sec: seconds; SD: standard deviation 
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DISCUSSION 
In this 12 month follow-up study of 32 FSHD participants, EIM measurements did not 
change. The absence of change was consistent across all EIM parameters, all frequencies 
and all (individual) muscles measured. There was a small decrease in the composite MVICT 
for all muscles measured, and no change in the strength measurements for individual 
muscles and in the timed up and go test. This indicates that this select group of patients 
showed only minimal change over one year. This fits with the clinical picture of FSHD as a 
slowly progressive disorder with functional decline gradually evolving over many years.16 
Because of the small or even absent change in the clinical outcome measures, it is not 
possible to definitively conclude if the absence of change in EIM parameters was due 
to limitations of this technology as a longitudinal biomarker in this population over this 
period of time versus the possibility that EIM is a sufficient tool that detected no change 
in a clinically relatively static subset of patients.
On a cross-sectional level there is a moderate correlation of EIM measurements with 
clinical measures, especially for 50 kHz reactance, indicating that EIM is able to capture 
differences in the degree of muscle involvement.10 
We analyzed data both on individual muscles or muscle groups and on composite scores. 
While composite scores have the advantage of smaller variability, the addition of relatively 
unaffected muscles can decrease the chance of detecting a change. The muscles that were 
measured by EIM in this study, were all shown to be commonly affected in imaging studies 
on FSHD.20-22 For future studies, including the hamstrings could be a valuable addition, as 
these are affected frequently and early in the disease course.21 
This study only measured EIM parameters in the setting of a natural history study. There-
fore, EIM could potentially be a useful biomarker in clinical trials where therapeutic 
interventions may have a beneficial effect on the muscles. For example, in boys with 
Duchenne muscular dystrophy, a change in EIM values was seen shortly after initiating 
corticosteroid treatment.23 
It is still unclear which EIM parameters are best suited to measure changes and the choice 
for a specific parameter depends on the disease being studied. Consequently, multiple 
studies over the last years have all used different outcomes including, amongst others, 
single and multi-frequency measures, single muscle and composite measures, single 
phase values and phase-ratios.13,11,15,24,14 Prior studies have shown reactance is least sus-
ceptible to variability in subcutaneous fat content or electrode configuration.25 Despite 
this, several studies have used phase ratios as opposed to reactance – this value appears 
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to be optimized for function versus subcutaneous fat in muscle disease, and as a derived 
measure, utilizes both elements of reactance and resistance.23,26 For FSHD, the reactance 
correlated the strongest with clinical measures at baseline and seemed least affected by 
changes in body fat, which is also reflected in the weaker correlations to the body mass 
index. However, because of the smaller variability in phase-ratio outcomes, this parameter 
would require much smaller sample sizes to detect differences in a clinical trial. Therefore, 
the choice of the parameter to be used in FSHD, will depend on the clinical trial design in 
which a trade-off should be made between the stronger correlation to clinical measures 
of 50 kHz reactance, and the opportunity to use smaller sample sizes with the 50-211 kHz 
phase-ratio. In addition, the use of the 50-211 kHz EIM parameter would permit smaller 
sample sizes compared to the clinical measures. The required sample sizes for QMT are 
consistent with a natural history study on FSHD, that found sample sizes of 160 patients 
per group for a two-armed clinical trial with one year of follow-up.16
For future studies, there would be different ways to increase the chance of detecting 
changes using EIM measurements. First, a larger cohort, a longer follow-up period, or a 
subset of patients with a more rapid progression could potentially result in differences that 
can be picked up by EIM. Additionally, advances in the sensor technology make different 
electrode configurations possible using the same sensor (e.g. longitudinal versus cross 
sectional, or a combination of the two).27 
This was a single site study and for EIM to be used in future studies on FSHD, its results 
should be validated in a multicenter cohort. To assess changes over time we used a 
repeated measure ANOVA. Another commonly used option for longitudinal studies is a 
linear mixed effects model. Since the design of this study was simple and there were few 
data points missing, the results of both analyses including the sample size calculations 
are expected to be similar. We did not include a healthy control group, and therefore do 
not know how longitudinal EIM data would compare to healthy subjects. 
Although EIM did not identify statistically significant changes in this FSHD cohort, it is 
an easily applied, fast and non-invasive technique that provides quantitative measures 
of muscle composition that can possibly results in sample size savings for clinical trials. 
Therefore, assessment of its sensitivity to change in larger cohorts or over a longer fol-
low-up period should be considered. 
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ABSTRACT 
Objective: With upcoming clinical trials in the near future, there is a need for rigorous, 
scientifically sound and patient-relevant outcome measures for facioscapulohumeral mus-
cular dystrophy (FSHD). The motor function measure (MFM) is a widely used ordinal based 
generic outcome measure for neuromuscular disorders, but has not been examined in 
FSHD patients using modern clinimetric methods. This study reports on the clinimetric 
suitability of the MFM in FSHD patients through Rasch analyses. 
Participants: 194 FSHD patients
Main outcome measures: Rasch analyses were performed on the MFM and its three 
domains (D1: standing position and transfers; D2: axial and proximal motor function; D3: 
distal motor function). We assessed the fit to the Rasch model, sample-item targeting, 
individual item fit, threshold ordering, sex- and age-based differential item functioning, 
response dependency and unidimensionality.
Results: Rasch analysis revealed multiple limitations of the MFM for FSHD, the most 
important being a large ceiling effect and suboptimal sample-item targeting. The ceiling 
effect was most pronounced for domains D2 and D3. There were disordered thresholds 
for most items, often resulting in items functioning in a dichotomous fashion. It was not 
possible to remodel the MFM into a Rasch-built interval scale. We were able to provide 
suggestions for remodeling of domain D1 into an interval scale with adequate fit statistics, 
but sample-item targeting remained suboptimal.
Conclusions: The MFM should be used with caution in patients with FSHD, as it is not opti-
mally suited to measure functional abilities in this patient group. Although improvement 
of domain D1 could be achieved by remodeling it, other FSHD-specific interval scales will 
be required for future clinical trials.
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INTRODUCTION 
Facioscapulohumeral muscular dystrophy (FSHD) is a hereditary muscle disorder that 
affects the muscles of the face, shoulder girdle and upper extremity and often in later 
stages muscles of the trunk and lower extremities.1 Knowledge on the pathogenic mech-
anism of this disorder is progressing and clinical trials on therapeutic interventions are 
expected in the upcoming years.2 Therefore, valid, reliable, sensitive and clinically relevant 
outcome measures are warranted. A number of FSHD-specific measurement instruments 
is currently being developed3, but many other more generic clinical outcome measures 
are already in use. Before any of these outcome measures can be used in clinical trials 
for FSHD, evidence should be collected to support its accuracy and suitability to measure 
treatment effects in this specific population, fulfilling modern scientific requirements.4,5 
One widespread used functional outcome measure for neuromuscular disorders is the 
motor function measure (MFM).6 Although this scale was demonstrated to be valid and 
reliable according to the classical test theory methodology in a cohort comprising the 
most common neuromuscular diseases7,6, it was not specifically designed nor validated 
for FSHD patients. Consequently, not all items on the scale may be equally suited for this 
patient group because of the specific distribution of muscle weakness. Only limited work 
has been done so far to assess whether the scale captures the entire clinical spectrum of 
FSHD.8 In addition, the MFM has important limitations as has been reported for ordinal 
based classical test theory constructed metrics.9-11
Analysis according to the Rasch model can be used to evaluate the suitability of the MFM 
as a functional outcome measure for FSHD patients. The Rasch model is based on the 
assumption that a patient with a high ability (a less severely ill patient) will have a higher 
probability of fulfilling a task compared to a patient with a lower ability (a more severely 
affected patient).12 Through Rasch analyses, measurement properties of the MFM scale 
can be evaluated, and correct functioning of individual items can be assessed.13 Addition-
ally, Rasch analysis can be used to transform ordinal scores into interval scores. In contrast 
to ordinal scores, that only provide a structured order, interval scores provide a numerical 
value that enables the use of parametric statistical testing.14,11,9 
Rasch analysis has been applied successfully in the neuromuscular field. Rasch-built func-
tional outcome measures have been newly developed for, among others, Pompe’s disease15, 
myotonic dystrophy type 116 and inflammatory neuropathies17, and other scales have been 
successfully modified to create interval scales, like the MRC-gradation18, the North Star Ambula-
tory Assessment in Duchenne muscular dystrophy19, and the MFM in congenital myopathies.20 
In this study, we apply Rasch analysis to assess the measurement properties of the MFM 
as an outcome measure assessing functional ability in patients with FSHD.
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METHODS
Data collection
Data of 203 FSHD patients, collected in 2014 and 2015 for a large cohort study at the 
Neurology department of the Radboud University Medical Center (Nijmegen, the Neth-
erlands) were initially screened. The FSHD was genetically confirmed, and only patients 
18 years and older were included. Nine non-penetrant gene carriers (individuals without 
signs or symptoms of FSHD) were excluded from further participation, leading to a final 
group 194 patients for the purposes of the current study.
Ethical approval 
This study was conducted according to the principles of the Declaration of Helsinki (version 
October 2013) and in accordance with the Medical Research Involving Human Subjects 
Act (WMO). The study protocol was approved by the regional medical ethics committee. 
All patients signed informed consent.
Motor function measure 
The 32-item motor function measure (MFM) consists of three different domains: D1. 
Standing position and transfers (13 items); D2. Axial and proximal motor function (12 
items); D3. Distal motor function (7 items). Response categories per item are: 0 ‘does not 
initiate movement or starting position cannot be maintained’; 1 ‘partially completes the 
exercise’; 2 ‘completes the exercise with compensations, slowness or obvious clumsiness’; 
and 3 ‘completes the exercise with a standard pattern’. The total score is expressed as 
a percentage of the maximum possible score (a lower score indicating clinically more 
affected). The time required to complete the total test took approximately 10-45 minutes, 
depending on how severely a patient was affected. 
Clinical severity rating
The FSHD clinical score is a widely accepted scale to get an overall impression of the severity 
of muscle weakness.21 Scores are assigned to five different body regions (face, shoulders, 
arms, hips, lower legs and abdomen). A total score that ranges from 0-15 is calculated by 
summing all regional scores. Higher scores indicate more severe muscle weakness. 
Rasch analysis
Rasch analysis was performed using Rasch unidimensional measurement methods 
software (RUMM2030). A comprehensive description of Rasch analysis can be found else-
where.22 A sample size of approximately 200 is required to provide a stable model, with a 
99% confidence that the estimated item difficulty is within ±0.5 logits of its stable value.23 
There were no missing data. 
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In addition to the analysis of the total MFM, we also performed analyses of each of its 
three domains as these can be applied separately.6,24 The likelihood-ratio test was highly 
significant for the total MFM and for all three domains (p<0.001), excluding the use of the 
Rating Scale Model that assumes equivalent thresholds across all items. For further anal-
yses, the Partial Credit Model was therefore set as default. P-values corrected according 
to Bonferroni were considered statistically significant.25
For each analysis we first assessed the overall model fit which is given by a chi-square 
item-trait interaction statistic. A non-significant probability value indicates no substantial 
deviation from the model. Second, we assessed possible issues contributing to misfit in 
individual items. We checked the threshold ordering. The threshold is defined as the point 
between two adjacent response categories where either response is equally probable.26 
Disordered thresholds indicate inconsistent use of response options, which occurs when 
respondents have difficulty discriminating between response options within an item. 
Differential item functioning (DIF), a form of item bias, occurs when different groups of 
patients with an equal level of disability, respond in a different manner to an individ-
ual item. In our cohort we checked for DIF for sex (male and female) and different age 
groups (three groups with roughly the same number of participants per group: < 45 years, 
45-60 years, > 60 years). Individual item fit was checked by two statistics: fit residual value 
exceeding 2.5 and/or significant chi-square probability value after Bonferroni adjustments 
indicate deviation from the Rasch model expectations. Response dependency was also 
examined and indicated the correlation of residuals obtained of at least two items com-
pleted by patients, in essence measuring the same construct. This can potentially lead to 
inflation of the total score, contributing to potential false results. Inter-item residual cor-
relations of ≥0.3 indicate local dependency. Distribution of patients within class intervals, 
tests for unidimensionality and internal consistency reliability were monitored throughout 
the analyses.
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RESULTS
Study population
Ninety-five (49.0%) out of 194 participants were male and the mean age was 51.6 years 
(±15.7 years). Patient-reported mean disease duration was 26.8 years (±17.5 years). The 
total clinical spectrum of FSHD was represented in the cohort, from patients using a wheel-
chair (n= 46, 23.7%) to minimally affected individuals. The mean FSHD clinical score was 
7.2 ±4.4 (range 0-15). Mean score on the total MFM was 78.3% ±23.0 (range 13.5-100%). 
Mean scores on the three domains were 63.6% ±35.6 for domain D1, 86.3% ±20.3 for 
domain D2 and 91.8% ±11.4 for domain D3. 
Rasch analysis of the total MFM
The MFM did not meet the requirements to fit to the Rasch model for patients with 
FSHD (table 1) and inspection of individual item function revealed numerous poorly 
fitting items (table 2). A major concern was the poor targeting of items for this set of 
patients (figure 1). The mean person location was higher than the mean item location 
(3.525 vs 0.000), indicating that the person abilities were higher than the difficulty of 
the items. This fits with the person-item location distribution map showing a lack of 
more difficult items which are needed to evaluate patients with a high ability level 
(figure 1). It is also illustrated by high ceiling effects on the total score (14% of patients 
achieving the maximum score) as well as on multiple individual items (table 2). Another 
major concern was the high proportion of items with disordered thresholds (20/32 
items, 63%). For most of these items the examiner had difficulty discriminating between 
response categories and there was a relative infrequency of response option 1 ‘par-
tially completes the exercise’. 
Other violations of the Rasch model assumptions were DIF, response dependency and 
the multidimensionality of the scale. Only one item showed uniform DIF: item 30 (run 10 
meters) was scored differently in individuals with an equal level of disability but from dif-
ferent age groups. Eight item pairs showed response dependency (table 2). In all except 
one pair, both items were part of the same domain. 
We tried to remodel the total MFM according to the Rasch model to provide suggestions 
for scale improvement specifically for use in patients with FSHD. However, after numer-
ous attempts we did not succeed in remodeling the MFM to a scale that sufficiently fit all 
Rasch model requirements, and still being suitable for clinical application. Collapsing the 
response categories from four to three, taking into account the distribution of response 
options per catergory, did not restore the disordered thresholds for all items. Additionally, 
reducing the number of response categories increased the ceiling effect and the misfit in 
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sample-item targeting even more. Subsequently, this resulted in loss of information and 
a decreased discriminative power of the scale. 
Figure 1. Person-item location distribution of the total MFM
Upper part of the graph indicates distribution of person abilities (highest level of motor function on the right 
side), lower part indicates distribution of item difficulty (most difficult items on the right side).
Rasch analysis of the three domains
In addition to the analysis of the total MFM, we performed analyses of each of its three 
domains. Statistics for analyses of each of the three domains are shown in table 1. 
The D1 domain (standing position and transfers) did not fit the Rasch model. The mean 
person location was higher than the mean item location (1.020 vs 0.000) and there was a 
ceiling effect (18% of participants achieved the maximum score). There were six items with 
disordered thresholds. Items 8 (from supine, sit up) and item 30 (run 10 meters) showed 
individual items misfit. Item 30 also showed DIF on age, with lower scores for individuals 
> 60 years with an equal level of disability compared to younger individuals. No response 
dependency was found. 
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Table 1. Statistics for Rasch analysis of the total MFM and the three separate domains
Scale Item location (mean, 
SD)
Item fit residual
(mean, SD)
Person location
(mean, SD)
Person fit residual
(mean, SD)
Item trait interaction PSI Unidimensionality 
t-test % [95%-CI]
Ceiling effect*
df; p-value
Total MFM 0.000 ±2.957 -0.455 ±1.464 3.525 ±2.520 -0.258 ±0.668 64; 0.0000 0.94 18.1% [14.8-21.4] 14%
D1: standing position & transfers 0.000 ±2.184 -0.186 ±1.147 1.020 ±4.232 -0.351 ±0.558 26; <0.0001 0.96 4.1% [0.6-7.7] 18%
D2: axial & proximal motor function 0.000 ±1.886 -0.665 ±1.146 4.096 ±2.381 -0.435 ±0.646 24; 0.003 0.82 5.1% [1.5-8.8] 30%
D3: distal motor function 0.000 ±3.257 0.117 ±1.100 6.806 ±1.554 -0.098 ±0.336 14; 0.222 0.54 5.8% [1.6-10.0] 45%
PSI: person separation index; *Proportion of participants achieving the maximum score
Table 2. Individual item statistics ordered by item location 
Item Domain Location Fit residuals Chi2 prob Thresholds Ceiling effect* DIF Response dependency
22 place finger on 8 drawings 3 -6.76 -0.09 0.89 Disordered 98 Item 18: 0.390
18 go round edge of cd 3 -5.40 -0.74 0.37 Disordered 89 Item 22: 0.390
17 pick up and hold 10 coins 3 -4.67 0.27 0.10 93 Item 16: 0.537
20 tear sheet of folded paper 3 -3.90 0.86 0.09 82
16 extend the elbow 2 -3.86 -0.58 0.34 81 Item 17: 0.537
19 draw a series of loops 3 -3.76 3.29 0.00† 66
14 raise head from flexion 2 -3.48 -0.18 0.89 Disordered 98 Item 13: 0.301
23 place hands on table 2 -2.06 -0.24 0.77 87
15 place hands on head 2 -1.83 0.99 0.07 33 Item 9: 0.453
21 pick up ball and turn hand 3 -1.40 1.11 0.29 62
13 maintain seated position on chair 2 -1.03 -0.69 0.59 Disordered 88 Item 14: 0.301
1 hold head for 5 seconds 2 -0.31 1.29 0.000† Disordered 89 Item 2: 0.527
2 from supine, raise the head 2 -0.25 0.35 0.58 Disordered 86 Item 1: 0.527
3 flex hip and knee > 90° 2 -0.11 0.32 0.36 Disordered 82
25 maintain standing position 1 0.14 -2.22 0.02 Disordered 73
5 move hand to shoulder 2 0.39 0.49 0.32 49 Item 9: 0.353
10 lean forward and touch ball 2 1.17 1.41 0.00† Disordered 75
12 sit down from standing 1 1.18 -1.87 0.29 Disordered 57 Item 24: 0.393
9 maintain seated position on mat 2 1.35 -1.26 0.59 Disordered 39 Item 5: 0.353; item 15: 0.453
4 dorsiflex the foot 3 1.47 1.90 0.00† Disordered 59
24  stand up from the mat 1 1.60 -2.93† 0.02 Disordered 49 Item 12: 0.393
6 raise the pelvis 1 1.65 -1.89 0.47 56
27 touch the floor 1 1.73 -1.66 0.10 Disordered 63
7 roll to prone and free arms 2 1.91 -2.95† 0.15 Disordered 37
26 raise the foot 1 2.59 -2.05 0.02 Disordered 48
29 take 10 steps on a line 1 2.70 -0.99 0.10 Disordered 43
8 from supine, sit up 1 2.72 0.53 0.04 17
32 squat from standing 1 3.25 -1.03 0.11 Disordered 42
11 stand up from the mat 1 3.36 -1.47 0.70 20
28 10 steps on both heels 1 3.55 -1.24 0.04 Disordered 35
30 run 10 meters 1 3.93 -2.27 0.00† 27 Age Item 31: 0.314
31 hop 10 times in place 1 4.14 -1.03 0.13 Disordered 28 Item 30: 0.314
¶Disordered thresholds: at least one of the response options is never the most likely option to be chosen; *Proportion of participants achieving the maximum score on the item; †Significant deviation from the Rasch model
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Table 1. Statistics for Rasch analysis of the total MFM and the three separate domains
Scale Item location (mean, 
SD)
Item fit residual
(mean, SD)
Person location
(mean, SD)
Person fit residual
(mean, SD)
Item trait interaction PSI Unidimensionality 
t-test % [95%-CI]
Ceiling effect*
df; p-value
Total MFM 0.000 ±2.957 -0.455 ±1.464 3.525 ±2.520 -0.258 ±0.668 64; 0.0000 0.94 18.1% [14.8-21.4] 14%
D1: standing position & transfers 0.000 ±2.184 -0.186 ±1.147 1.020 ±4.232 -0.351 ±0.558 26; <0.0001 0.96 4.1% [0.6-7.7] 18%
D2: axial & proximal motor function 0.000 ±1.886 -0.665 ±1.146 4.096 ±2.381 -0.435 ±0.646 24; 0.003 0.82 5.1% [1.5-8.8] 30%
D3: distal motor function 0.000 ±3.257 0.117 ±1.100 6.806 ±1.554 -0.098 ±0.336 14; 0.222 0.54 5.8% [1.6-10.0] 45%
PSI: person separation index; *Proportion of participants achieving the maximum score
Table 2. Individual item statistics ordered by item location 
Item Domain Location Fit residuals Chi2 prob Thresholds Ceiling effect* DIF Response dependency
22 place finger on 8 drawings 3 -6.76 -0.09 0.89 Disordered 98 Item 18: 0.390
18 go round edge of cd 3 -5.40 -0.74 0.37 Disordered 89 Item 22: 0.390
17 pick up and hold 10 coins 3 -4.67 0.27 0.10 93 Item 16: 0.537
20 tear sheet of folded paper 3 -3.90 0.86 0.09 82
16 extend the elbow 2 -3.86 -0.58 0.34 81 Item 17: 0.537
19 draw a series of loops 3 -3.76 3.29 0.00† 66
14 raise head from flexion 2 -3.48 -0.18 0.89 Disordered 98 Item 13: 0.301
23 place hands on table 2 -2.06 -0.24 0.77 87
15 place hands on head 2 -1.83 0.99 0.07 33 Item 9: 0.453
21 pick up ball and turn hand 3 -1.40 1.11 0.29 62
13 maintain seated position on chair 2 -1.03 -0.69 0.59 Disordered 88 Item 14: 0.301
1 hold head for 5 seconds 2 -0.31 1.29 0.000† Disordered 89 Item 2: 0.527
2 from supine, raise the head 2 -0.25 0.35 0.58 Disordered 86 Item 1: 0.527
3 flex hip and knee > 90° 2 -0.11 0.32 0.36 Disordered 82
25 maintain standing position 1 0.14 -2.22 0.02 Disordered 73
5 move hand to shoulder 2 0.39 0.49 0.32 49 Item 9: 0.353
10 lean forward and touch ball 2 1.17 1.41 0.00† Disordered 75
12 sit down from standing 1 1.18 -1.87 0.29 Disordered 57 Item 24: 0.393
9 maintain seated position on mat 2 1.35 -1.26 0.59 Disordered 39 Item 5: 0.353; item 15: 0.453
4 dorsiflex the foot 3 1.47 1.90 0.00† Disordered 59
24  stand up from the mat 1 1.60 -2.93† 0.02 Disordered 49 Item 12: 0.393
6 raise the pelvis 1 1.65 -1.89 0.47 56
27 touch the floor 1 1.73 -1.66 0.10 Disordered 63
7 roll to prone and free arms 2 1.91 -2.95† 0.15 Disordered 37
26 raise the foot 1 2.59 -2.05 0.02 Disordered 48
29 take 10 steps on a line 1 2.70 -0.99 0.10 Disordered 43
8 from supine, sit up 1 2.72 0.53 0.04 17
32 squat from standing 1 3.25 -1.03 0.11 Disordered 42
11 stand up from the mat 1 3.36 -1.47 0.70 20
28 10 steps on both heels 1 3.55 -1.24 0.04 Disordered 35
30 run 10 meters 1 3.93 -2.27 0.00† 27 Age Item 31: 0.314
31 hop 10 times in place 1 4.14 -1.03 0.13 Disordered 28 Item 30: 0.314
¶Disordered thresholds: at least one of the response options is never the most likely option to be chosen; *Proportion of participants achieving the maximum score on the item; †Significant deviation from the Rasch model
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We were able to use Rasch analysis to remodel the D1 domain into an interval scale for 
FSHD patients. We first restored the disordered thresholds for items 27, 28, 29 and 32 
by collapsing the number of response categories from four to three (0-1-2-3 to 0-1-1-2), 
taking into account the frequency distribution of the categories as much as possible. One 
of the items that showed individual item misfit was removed (item 8, fit residuals 3.773 
and chi2 probability 0.0000). After removal of this item, no DIF was found for age or sex 
and there were no items with response dependency. There were two items left with dis-
ordered thresholds: items 24 and 31. For both items we assessed which rescoring option 
resulted in the best overall model, and subsequently decided to rescore both items from 
0-1-2-3 to 0-1-1-2. The new 12-item domain D1 was unidimensional and fitted the Rasch 
model expectations (table 3). However, fitting the D1 scale to the Rasch model, came at 
the cost of an increase in the mean person location from 1.020 on the original D1 domain 
to 1.445. Consequently, the ceiling effect also increased to 24% of patients achieving 
the maximum score. The limited number of items’thresholds resulted in a suboptimal 
sample-item targeting (figure 2). The range of patient abilities that could be measured by 
the items on domain D1 was too narrow and there were gaps between item locations of 
more than 1 logits. 
Both domain D2 (axial and proximal motor function) and domain D3 (distal motor function) 
had a very poor sample-item targeting with large ceiling effects (30% resp. 45% of partici-
pants achieved the maximum score) and very high mean person locations (4.096 and 6.806 
respectively). As such, nearly all items were too easy for most patients and these domains did 
not provide information on the actual abilities of these patients. Indeed, person separation 
indexes were low (0.82 and 0.54 respectively) indicating that domain D2 and D3 were not 
able to sufficiently discriminate between individuals with different ability levels. 
Both domains also did not fulfill some of the other Rasch model assumptions. There were 
many items with disordered thresholds (8/12 items in domain D2 and 3/7 items in domain 
D3). Domain D2 also had two items with individual item misfit (items 9 maintain seated 
position on mat and 16 extend the elbow). There was response dependency between 
items 1 and 2 (raise the head from supine and hold the head for 5 seconds), and between 
items 14 (maintain seated position on chair) and 2 and 9 (hold the head for 5 seconds, 
raise the head from flexion while seated). 
Table 3. Statistics for Rasch analysis of domain D1 after remodeling 
Scale Item location (mean, 
SD)
Item fit residual
(mean, SD)
Person location
(mean, SD)
Person fit residual
(mean, SD)
Item trait 
interaction
PSI Unidimensionality 
t-test % [95%-CI]
Ceiling effect*
df; p-value
Rasch-built D1: standing 
position & transfers
0.000 ±2.777 -0.250 ±0.581
1.445
±4.940
-0.271 ±0.502
24; 0.221
0.96 7.6% [3.9-11.3] 24%
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Domain D3 did not show any additional violations of Rasch model assumptions. 
As domains D3 and D2 both had a very large ceiling effect and therefore an inadequate 
item-person distribution, remodeling of these domains did not yield useful results for 
scale improvement. Remodeling of the scale by collapsing response categories to restore 
disordered thresholds and/or removing misfitting items, only reduced the score range and 
subsequently enlarged the ceiling effect and sample-item misfit. 
Figure 2. Person-item location distribution of the remodeled D1 domain (standing position and transfers)
Upper part of the graph indicates distribution of person abilities (highest level of motor function on the right 
side), lower part indicates distribution of item difficulty (most difficult items on the right side).
Table 3. Statistics for Rasch analysis of domain D1 after remodeling 
Scale Item location (mean, 
SD)
Item fit residual
(mean, SD)
Person location
(mean, SD)
Person fit residual
(mean, SD)
Item trait 
interaction
PSI Unidimensionality 
t-test % [95%-CI]
Ceiling effect*
df; p-value
Rasch-built D1: standing 
position & transfers
0.000 ±2.777 -0.250 ±0.581
1.445
±4.940
-0.271 ±0.502
24; 0.221
0.96 7.6% [3.9-11.3] 24%
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DISCUSSION
In this study we used Rasch analysis to evaluate the motor function measure as a func-
tional outcome measure in a large cohort of FSHD patients. The MFM was specifically 
designed to measure neuromuscular disorders including Duchenne, Becker, limb-girdle 
and congenital muscular dystrophy, myotonic dystrophy, congenital myopathy, spinal 
muscular atrophy, hereditary neuropathy and FSHD. It has the advantages of being reli-
able, easy to perform and suited to measure non-ambulatory patients, but our analyses 
revealed some important limitations for its use in FSHD patients.6 
The tasks of the total MFM and its three domains were relatively easy for FSHD patients. 
Especially domains D2 (axial and proximal motor function) and D3 (distal motor function) 
showed large ceiling effects. Considering the items on these scales, this is not completely 
surprising. More than half of the items on domain D2 focus on maintaining sitting posi-
tions, keeping the head upright and contractures and domain D3 contains many items 
on distal arm function. These functions are generally only limited in the most severely 
affected FSHD patients and contractures are rare. More items on shoulder function would 
be appropriate to measure FSHD patients. 
Rasch analysis revealed many items with disordered thresholds, indicating difficulty for the 
examiner to discriminate between different response options in FSHD patients. As a result, 
many of these items functioned as if it were dichotomous items: for easier items patients 
were able to complete the exercise either with or without compensatory movements, 
for difficult items patients were either able or not able to perform the exercise. Hence, 
for only few items patients showed a distribution among the four response categories. 
This fits with the clinical observation that FSHD patients often compensate their slowly 
progressive weakness for a long time, then cross a certain threshold and suddenly lose 
function. For some of the items collapsing from 4 to 3 response categories did not restore 
the disordered thresholds and we did not succeed in building a model for the total MFM 
or the separate domains. 
This study serves as an example of the importance of critically assessing the properties of 
an outcome measure in the light of the target population to optimize the design of clinical 
trials from modern clinimetric perspectives. We show that a scale that is validated in a 
cohort with patients with different diagnoses, is not necessarily optimally suited to mea-
sure each of the subgroups within the validation cohort separately. This also emphasizes 
the need for disease-specific outcome measures capturing subtle differences between 
patient groups, instead of more generic outcome measures. 
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Study limitations
Although this study included a very large FSHD cohort comprising the whole clinical sever-
ity spectrum, it was a single center study. For any analysis on the clinimetric properties of 
an outcome measure, the results will depend on the characteristics of the included cohort. 
Since the mean results on both the total scale and the three domains are similar to the 
results that have been described in the literature for FSHD patients, the group of patients 
included in this study seems representative of the total FSHD population.6,24 This is also 
supported by the percentage of patients using a wheelchair and the mean score on the 
FSHD clinical score.21,27 Because it was a cross-sectional study we were not able to assess 
the sensitivity to change of the MFM for FSHD patients. In general, a scale that has the 
most optimal person-item fit, will yield more information. Indeed, in longitudinal studies 
assessing the responsiveness of the MFM in FSHD domain D1 was the most sensitive of 
the 3 domains.7,8 Finally, the remodeled domain D1 scale still showed major limitations, 
most importantly the sample-item mistargeting. Consequently, there is still a need for a 
better functional outcome measure for FSHD patients. 
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CONCLUSIONS 
Rasch analysis revealed multiple limitations of the MFM for FSHD and should therefore 
be used with caution in this patient population. The detailed insights into the clinimetric 
abilities of the MFM are important for correct interpretation of test results, but can also 
be useful in developing new scales. For FSHD, there is a high need for the development of 
disease-specific cross-cultural interval scales on functional abilities for future clinical trials. 
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ABSTRACT
Introduction: Facial muscle weakness is a key symptom of facioscapulohumeral muscu-
lar dystrophy (FSHD). This study explores the use of quantitative data on strength and 
fatigability of orofacial muscles in FSHD patients. In addition, we assess the frequency 
of swallowing and communication difficulties, and their relationship to orofacial muscle 
involvement.
Methods: We included 43 FSHD patients and 35 healthy controls and used the Iowa 
Oral Performance Instrument (IOPI) to obtain quantitative measurements of strength and 
endurance of lip compression, cheek (buccodental) compression and tongue elevation. 
For the assessment of swallowing and communication difficulties, we used the dyspha-
gia-specific quality of life (SWAL-QOL) and Communicative Participation Item Bank (CPIB) 
questionnaires. 
Results: Cheek compression strength was reduced in FSHD patients compared to healthy 
controls. Dysphagia and difficulty with verbal communication were reported by 25% and 
35% of patients respectively, and correlated to cheek compression strength and endur-
ance, and to anterior tongue elevation endurance. Prolonged cheek compression and/or 
anterior tongue elevation endurance (decreased fatigability) made swallowing or speech 
problems less likely to occur.
Discussion: Cheek compression strength is the most sensitive IOPI measure for orofacial 
weakness in FSHD. Orofacial weakness contributes to dysphagia and speech difficulties 
in FSHD, which are both common though generally mild. Reduced fatigability of orofacial 
muscles was associated with a lower chance of dysphagia or speech problems. More 
research is required for further refinement of the pattern of facial muscle involvement 
in FSHD and to provide new insights for improvement of speech- and language therapy.
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INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) is a progressive inherited muscle disor-
der. One of the first and most characteristic symptoms for FSHD is weakness of the facial 
muscles, which is often asymmetrical and varies from minimal weakness that is barely 
notable to marked paresis of mimetic muscles.1 The circular muscles around the eyes and 
mouth (orbicularis oculi and orbicularis oris) and the muscle that raises the corners of the 
mouth (zygomaticus major) are frequently affected.1, 2 Weakness of the facial muscles limits 
facial expression and is identified by patients as a major impact of FSHD on their lives.3, 4 
Despite the frequency and relevance of facial weakness in FSHD, there are few studies on 
the severity, progression and functional and emotional consequences of facial weakness.
While studies report mild to moderate dysphagia and/or involvement of the tongue 
muscle in a subgroup of FSHD patients5-8, to the best of our knowledge, studies assessing 
the impact of facial weakness on speech or communication have not been reported in 
FSHD. Here we performed a cross-sectional multi-site study to obtain quantitative data on 
strength and fatigability of orofacial muscles in FSHD. In addition, we assess the frequency 
of self-reported swallowing and communication difficulties, and explore how these relate 
to orofacial muscle involvement. 
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METHODS
Participants 
Genetically confirmed FSHD patients aged 18 years and older were recruited in 2016-2017 
at the Kansas University Medical Center (Kansas City, KS) and at the University of Utah 
Hospital, (Salt Lake City, UT). Healthy controls were recruited in 2017 at the University 
of Utah Hospital. The study was approved by the human subjects committee. Written 
informed consent was obtained from all participants.
Disease severity rating
All FSHD patients underwent a standardized physical exam with a physician rating the 
severity of their FSHD symptoms. The FSHD clinical score rates muscle involvement in the 
face, shoulders and arms, core, and legs, and provides a combined score which ranges 
from 0 (unaffected) to 15 (severely affected). 
The physician also graded facial functioning for all FSHD patients (facial function score). 
The ability to furrow the brow, close the eyes and protrude the lips were each scored 
bilaterally, and the ability to puff out the cheeks was scored overall on a scale from 0-2 (0 
= normal; 1 = partial weakness; 2 = cannot perform). The total score ranges from 0-14 in 
which higher scores represent higher disease impact.
Quantitative measurements of orofacial muscles 
Quantitative strength measurements of orofacial muscles were obtained with the Iowa 
Oral Performance Instrument (IOPI, IOPI Medical, Redmond, WA, USA), a handheld device 
that attaches via tubing to an air-filled bulb to measure pressure.9 Measurements of 
strength and endurance for motions of lip compression, cheek compression, anterior 
and posterior tongue elevation were performed based on standardized procedures as 
described by Clark et al.9 with the following modification - lip compression measurements 
were performed by having the participants squeeze their lips with the bulb positioned 
between the lips at midline (without tongue depressors). Cheek (buccodental) compres-
sion measurements were obtained with the bulb placed inside the cheek next to the 
corner of the mouth and along the occlusal surface of the teeth and having the participants 
purse their lips, subsequently squeezing the bulb against the teeth. For tongue elevation 
measurements participants were instructed to elevate their tongue against the palate, 
with the bulb positioned on the anterior or posterior tongue. For strength measurements 
participants were asked to exert maximum pressure on the bulb and peak strength was 
recorded in kPa. Three trials were recorded with 10 seconds of rest in between. For 
endurance measurements, an indicator of muscle fatigability, participants were asked to 
maintain 50% of their maximum pressure for as many seconds as possible and timing 
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ceased when participants demonstrated a decrease from target pressure that was sus-
tained for longer than 1 second. Two trials were performed with a rest period of 2 minutes 
in between each trial. For analyses of both strength and endurance, the maximum score 
out of the different trials was used. 
Swallowing questionnaire 
All FSHD patients completed the dysphagia-specific quality of life (SWAL-QOL) ques-
tionnaire to capture symptoms related to dysphagia and to assess how they perceive 
swallowing problems affecting day-to-day quality of life.10 This questionnaire contains 44 
items with 5 response options, divided into 10 domains (burden, eating duration, eating 
desire, food selection, communication, fear of choking, mental health, social, sleep, and 
fatigue). Both the total score and the scores for the domains are scored as a percentage 
of the maximum achievable score, in which higher scores indicate less difficulty. Normative 
data were taken from the study by Ginocchio et al.11 
Communication questionnaire 
The Communicative Participation Item Bank (CPIB), a patient-reported instrument, was 
used to measure communicative participation in the FSHD patients.12 The total score 
from 10 items ranges from 0-30 in which higher scores are more favorable. As the CPIB 
is a Rasch-built scale, raw ordinal summary scores (0-30) are converted to an interval 
scale in which scores are expressed as ‘logits’. The logits range from -2.58 to 2.10 logits, 
with 0 logits representing the mean for the calibration sample.12 High, positive scores are 
preferable. This questionnaire was not filled out by the healthy controls. 
Statistical analyses 
Statistical analyses were performed using SPSS version 22. Descriptive statistics were 
calculated for all parameters and are presented as mean, standard deviation and range 
unless stated otherwise. To compare strength measurements between FSHD patients and 
healthy controls we performed independent-samples t-tests. For correlations of strength 
measurements with other outcome measures the Pearson correlation coefficient was 
used. For correlations of endurance measurements we used a Spearman rho analysis, 
because of the non-normal distribution. For the assessment of same day reproducibility 
(test-retest reliability) of the quantitative strength and endurance measurements, the 
intraclass coefficient (ICC) was used. P-values of < 0.05 were considered statistically signifi-
cant. Because of the exploratory nature of the study we did not adjust for multiple testing 
when testing subcategories of the questionnaires. 
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RESULTS 
Participants
We included 43 FSHD patients comprising the entire clinical spectrum and 35 healthy 
controls. Demographics are presented in table 1. The controls were significantly younger 
than the patients (40.2 vs 52.5 years, p = 0.000). 
Table 1. Demographics
Characteristic Patients n = 43 Controls n = 35
Age (mean ±SD [range]) 52.5 years ±13.1 [23-83] 40.2 years ±13.2 [23-65]
Sex 55.8% male 48.6% male 
Disease duration (mean ±SD [range]) 29.9 years ±15.2 [5-64] n/a
FSHD clinical score (mean ±SD [range]) 8.2 ±3.6 [2-14] n/a
Facial function score (mean ±SD [range]) 5.0 ±3.0 [0-10] n/a
SWAL-QOL score (mean ±SD [range]) 80.5% ±14.3 [45.7-100%] n/a
CPIB score (mean ±SD [range]) 1.1 logits ±1.0 [-0.67-2.1] n/a
Quantitative measurements of orofacial muscles
Results of the quantitative strength and endurance measurements are given in table 2. 
Cheek compression strength was significantly reduced in FSHD patients compared to 
healthy controls (figure 1). Both anterior and posterior tongue elevation strength was 
significantly reduced in male participants only. Cheek compression strength was the only 
quantitative measure that correlated to disease duration and overall disease severity 
(r = -0.494, p = 0.001 and r = -0.454, p = 0.003 respectively). In addition, it was the only 
quantitative measure that correlated to the physician-reported facial function score (r = 
-0.533, p < 0.001). 
Test-retest reliability between the different trials in patients was good to excellent for all 
quantitative measurements with intraclass correlation coefficients of 0.947, 0.972, 0.951 
and 0.945 for lip compression, cheek compression, anterior tongue and posterior tongue 
strength respectively and 0.955, 0.923, 0.853 and 0.888 for endurance measures respec-
tively. The lower ICC’s for the tongue elevation endurance measurements were probably 
due to fatiguing although the differences between the trials was non-significant. Strength 
and endurance measurements did not significantly correlate to each other, except for lip 
compression measurements (r = 0.375, p = 0.032). 
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Figure 1. Difference in strength measurements between FSHD patients and healthy controls
*p < 0.05
Table 2. IOPI strength and endurance measurements for orofacial muscles
Lip 
compression
Cheek 
compression
Anterior tongue 
elevation
Posterior tongue 
elevation
Strength (kPa)
Males Patients n=24 17.3 ±13.7 17.9 ±6.1 49.2 ±17.1 45.7 ±13.0
Controls n=17 18.6 ±3.4 28.5 ±4.7* 63.2 ±10.9* 56.0 ±16.5*
Females Patients n=19 11.8 ±11.4 12.9 ±7.8 51.7 ±14.2 48.7 ±12.4
Controls n=18 15.8 ±4.5 22.2 ±5.5* 59.7 ±10.5 53.9 ±8.0
Endurance (sec)
Males Patients n=24 45.6 ±43.6 55.9 ±33.3 25.3 ±11.8 21.0 ±11.0
Controls n=17 28.0 ±14.3 59.9 ±20.2 32.7 ±16.9 20.8 ±12.7
Females Patients n=19 56.3 ±46.7 55.2 ±38.3 25.5 ±17.8 24.5 ±21.1
Controls n=18 35.5 ±28.0 67.04 ±30.9 25.3 ±12.5 21.5 ±13.9
*Controls significantly stronger than patients (p < 0.05)
Swallowing
On the SWAL-QOL questionnaire, only one patient achieved the maximum total score, 
while scores of less than 75% of the maximum score were obtained by 11 (25.6%) patients. 
The SWAL-QOL scores were lower in FSHD patients compared to normative values from 
the literature on all 10 domains (range of differences 6-36%, all p < 0.001).11 The largest 
differences between patients and normative values were found in the domains on fatigue 
and sleep (scores of 43% and 56% respectively; normal values 79% and 81%). Of the 
domains related to swallowing, the largest differences were found in ‘eating duration’ 
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and ‘fear of choking’ (scores of 82.4% and 86.8% respectively, normative values 98% and 
99%). Although patients reported a fear of choking, only 2 (4.7%) patients reported actually 
choking often when eating foods and 3 (7.0%) when taking liquids. 
Communication
On the CPIB 18/43 (42%) of the patients had a maximum score, indicating no communi-
cation difficulties. Scores of less than 75% of the maximum score were obtained by 15 
(34.9%) of the patients. Items that FSHD patients scored the lowest on were ‘say something 
quickly’ and ‘getting your turn in a fast-moving conversation’, both with 22/43 patients 
(46.5%) reporting difficulty. 
Relation of orofacial muscle involvement to swallowing and communication
The SWAL-QOL scores decreased with lower cheek compression strength (r = 0.382, p = 
0.011). The correlation of the total SWAL-QOL score to cheek compression strength was 
driven by correlations on four domains: eating duration, eating desire, communication and 
fatigue (range r 0.378 – 0.400, all p < 0.05). No significant correlations were found between 
SWAL-QOL scores and lip compression or tongue elevation strength. 
There were moderate, positive correlations between total SWAL-QOL scores and cheek 
compression endurance and anterior tongue elevation endurance (r = 0.345, p = 0.029 
and r = 0.439, p = 0.004 respectively), but not lip compression and posterior tongue 
elevation endurance. Both significant correlations were mainly driven by patients who 
demonstrated extended lingual endurance (> 40 seconds) and additionally all of these 
patients, save one patient, self-reported little to no dysphagia on the SWAL-QOL. The one 
patient that did report dysphagia (SWAL-QOL score of 68%) demonstrated long cheek 
compression endurance of 126 seconds, but had the lowest cheek compression strength 
of all participants (2.5 kPa). 
The CPIB total score decreased with lower cheek compression strength (r = 0.398, p < 
0.01). No significant correlations were found between CPIB total scores and lip compres-
sion and tongue elevation strength. Significant correlations were found between CPIB 
scores and cheek compression endurance and anterior tongue elevation endurance, but 
not lip compression and posterior tongue elevation endurance. Again, there was a subset 
of patients with long endurance (>75 seconds for cheek compression endurance and >40 
seconds for anterior tongue elevation endurance), who all performed well on the CPIB 
(score > 1.4 logits), except for one patient with very low cheek compression strength (6.0 
kPa). There was a partial overlap in patients who reported swallowing problems and com-
munication difficulty and the SWAL-QOL and CPIB showed a moderate, positive correlation 
(r = 0.61; p = 0.000) (figure 2).
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Figure 2. Correlation between SWAL-QOL and CPIB scores
CPIB total score (logits)
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DISCUSSION 
This study reports a systematic approach to assess strength and fatigability of orofacial 
muscles in FSHD. To the best of our knowledge, this is this the first report of quantita-
tive strength measurements on orofacial muscles in FSHD patients. We show that cheek 
compression strength is significantly reduced compared to healthy controls. Cheek com-
pression is a motion that is caused by the contraction of various facial muscles, including 
the circumferential muscle complex that surrounds the mouth, in particular the orbicularis 
oris. The orbicularis oris muscle is known to be frequently affected in FSHD.1 Lip compres-
sion strength was not reduced compared to healthy controls even though that is also a 
motion driven by the orbicularis oris. This could suggest that weakness of the lips and 
mouth is not simply caused by weakness of the orbicularis oris, but in fact is caused by a 
more complex interplay with other facial muscles like the buccinators or risorius muscles. 
Indeed, the orbicularis oris is not a simple circular sphincter muscle, but is formed by 
muscle fibers running in different directions and originating from various facial muscles 
including the buccinator muscles. This hypothesis is also supported by the reduced cheek 
compression strength in FSHD patients. Additional research is required to study involve-
ment of various facial muscle in more detail. 
Twenty-five percent of the patients in our study had low scores on the SWAL-QOL ques-
tionnaire indicating swallowing difficulties. In the literature the reported prevalence of 
dysphagia in FSHD ranges from 2-25%.5, 6, 8, 13 Scores on the SWAL-QOL domains of fatigue 
and sleep were the lowest scores, but these findings might be unrelated to swallowing 
problems and more related to overall disease severity. However, also on all domains 
regarding more specific swallowing difficulties, FSHD patients scored significantly lower 
compared to the normative values. In concordance with two previous studies, our study 
shows that swallowing problems in FSHD do occur, but are generally mild.5, 6 
Low scores on the CPIB questionnaire indicating communication difficulties were found 
in approximately 35% of the patients in this study. This is in line with a previous study 
reporting 35% of FSHD patients having difficulty pronouncing words.13 Possibly, our study 
underestimates the prevalence of communication difficulties, because the questions 
asked were nearly all focused on verbal communication, i.e. speech. Though speech can 
be affected due to orofacial weakness, the lack of facial expression may hinder social 
communication more than problems with speech. In addition, emotional consequences 
of facial weakness were not studied, though they may be very relevant to patients. 
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Cheek compression strength and endurance and anterior tongue endurance correlated 
significantly to both dysphagia and communication difficulties. A previous study suggested 
that dysphagia in FSHD is caused by weakness of the lingual and orofacial muscles.6 The 
results of our study support this hypothesis, although the only moderately strong cor-
relations indicate that additional unidentified factors must be involved in swallowing and 
communication difficulties in FSHD. Whether the tongue muscles are involved in FSHD 
remains uncertain. Multiple studies report small series of FSHD patients with tongue 
atrophy and/or weakness, although the prevalence of tongue involvement seems much 
lower than the prevalence of dysphagia.6, 8, 14 In our study, dysphagia and communication 
difficulties were not related to weakness of the tongue muscles, but instead correlations 
were driven by a beneficial effect of an extended tongue elevation endurance. One could 
hypothesize that the longer endurance is in fact a compensatory mechanism to prevent 
dysphagia and communication difficulties, especially since endurance of the tongue mus-
cles can be improved by training.15 If this is the case, improvement through training of 
the endurance of facial muscles could potentially be used by speech therapists to teach 
patients a compensatory strategy. 
The most important limitation of this study was the significant age difference between 
FSHD patients and healthy controls for the quantitative strength measurements. Since 
younger individuals are expected to have a higher strength and endurance, this would 
potentially lead to an overestimation of the difference. However, for most of the quanti-
tative measures we did not find a difference. For cheek compression strength there is no 
association with age in the general population.9 The lip compression strength in healthy 
controls in this study was much lower than normative values that have been previously 
reported.9 We repeated the measurements in multiple healthy controls and found con-
sistent values. Therefore, it is currently unclear what is causing the differences between 
the two healthy control populations. 
In our study we used normative values from the literature for the SWAL-QOL, which were 
collected in an Italian cohort. Although cultural differences cannot be ruled out com-
pletely, we choose to use these normative data as the Italian study included a large cohort 
of healthy volunteers. A limited number of orofacial movements was assessed in this 
study. To increase knowledge on facial weakness and further refinement of the pattern of 
involvement, muscles in the upper part of the face should be studied as well. In addition, 
longitudinal studies could provide valuable information on disease progression over time, 
and on the correlation between changes in orofacial strength and endurance and changes 
in dysphagia or communication difficulties. 
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In conclusion, cheek compression strength is decreased in FSHD patients and correlates 
to dysphagia and communication difficulties. Decreased fatigability of cheek compression 
and tongue elevation make dysphagia or speech problems unlikely to occur. Additional 
research is required to confirm and extend these findings, which may be of relevance to 
gain insights into the clinical phenotype of FSHD, counseling and potentially treatment of 
patients with FSHD regarding swallowing and speech.
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SUMMARY
Facioscapulohumeral muscular dystrophy (FSHD) is an inherited chronic progressive 
muscle disorder. Although knowledge on the pathogenic mechanism is increasing, we 
still cannot adequately explain the variability in disease penetrance and symptom onset, 
progression and severity. A better understanding of this variability can lead to the identifi-
cation of disease modifying factors and thus provide new targets for therapy development. 
However, once these therapies are developed and need to be tested for efficacy, the 
clinical variability poses challenges in the design of clinical trials. The generally slow, yet 
highly variable rate of disease progression will likely result in high sample size require-
ments. Consequently, there is a need for a clinical trial toolbox including patient registries, 
biomarkers and clinical outcome measure, to optimize clinical trial designs. This thesis 
focused both on potential disease modifying factors and on the development of compo-
nents of the clinical trial toolbox. 
Part I provides a comprehensive overview of the clinical and genetic aspects of FSHD. 
Chapter 1 describes the clinical features of FSHD. Although there is a large variability in 
presenting symptoms, age at presentation, family history and disease course, there is also 
a number of (sometimes subtle) symptoms and signs that are highly characteristic for 
FSHD. As the name suggests, many of these symptoms and signs concern the facial- and 
shoulder girdle muscles, although involvement of the trunk and leg muscles is common. 
This chapter gives an overview of all characteristic features to facilitate the fast and cor-
rect recognition of this relatively common muscle disorder for the general neurologist to 
prevent diagnostic delay and unnecessary ancillary investigations. 
Chapter 2 connects clinical and (epi)genetic findings in FSHD, as it includes a description 
of the clinical findings, the pathogenic mechanism and phenotype-genotype relations. 
The clinical part of this chapter focuses on advances in muscle imaging techniques and 
lifestyle interventions for FSHD. Based on (mainly cross-sectional) muscle imaging studies, 
different stages of disease progression are proposed in which fatty infiltration of muscles 
is foregone by a phase of muscle inflammation, followed by accelerated fatty infiltration. 
As there is currently no cure for FSHD, there is a high interest in lifestyle interventions to 
slow down disease progression. Two clinical trials have shown a beneficial effect of aer-
obic exercise and an active lifestyle as both increased physical fitness. One preliminary 
clinical trial was conducted on supplementation of the antioxidants vitamin C, vitamin 
E, zinc gluconate and selenomethionine, but additional studies are required to assess a 
potential benefit of anti-oxidants.
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 Regarding phenotype-genotype relations, a rough inverse correlation between D4Z4 
repeat array size and disease severity is observed in FSHD1, although variability is large for 
all repeat sizes ranging from asymptomatic gene carriers to wheelchair bound individuals. 
This variability suggests that (epi)genetic factors influence disease severity. In FSHD2 the 
D4Z4 methylation level of the shortest permissive allele correlates with disease severity. 
All together, this suggests that for both FSHD1 and FSHD2, a combination of the D4Z4 
repeat size and its epigenetic state influences disease severity.
Part II focuses on potential disease modifying factors. 
Chapter 3 shows the results of a phenotype-genotype study. This study on 152 FSHD1 
mutations carriers confirms the rough inverse correlation between D4Z4 repeat array 
size and disease severity (age-corrected FSHD clinical score, R = 0.40; p = 0.000). As this 
study included various families with multiple participants, we were able to calculate that 
familial factors accounted for 50% of the variance in disease severity (FSHD clinical score). 
The explained variance by the D4Z4 repeat array size for disease severity was limited 
(approximately 10%), and varied per body region (facial muscles, upper extremities and 
lower extremities approximately 30%, 15% and 3%, respectively). The mean D4Z4 repeat 
array size was longer in symptomatic individuals compared to asymptomatic and non-pen-
etrant gene carriers (7.3 vs 6.0 units, p = 0.001). Sex and the Delta1 methylation score 
(D4Z4 methylation corrected for repeat array size) did not explain additional variance in 
disease severity. 
All together, clinical variability in FSHD1 can only be partially explained by our current (epi)
genetic knowledge. So although the D4Z4 repeat array size and D4Z4 methylation con-
tribute to differences in disease severity and penetrance, other disease modifying factors 
must be involved as well. These modifying factors could (epi)genetic as well as organ-
ismal, environmental or lifestyle factors. To illuminate these modifying factors detailed 
descriptions of phenotypic features will be required, as there are probably differences 
between body regions in the sensitivity to the influence of the D4Z4 locus itself and to 
various modifiers. 
In chapter 4 an extreme example of clinical variability is studied. Previous studies showed 
that identical missense mutations in the extended ATPase domain of SMCHD1 are associ-
ated with two seemingly unrelated disorders: FSHD2 and Bosma arhinia microphthalmia 
syndrome (BAMS). BAMS is characterized by congenital arhinia with co-morbid repro-
ductive and ocular defects. We examined and/or interviewed 14 FSHD2 patients and 4 
unaffected family members with BAMS-associated or BAMS-like SMCHD1 mutations to 
search for clinical features related to BAMS. None of the FSHD2 patients or family mem-
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bers demonstrated any congenital defects or dysmorphic features commonly found in 
patients with BAMS. These findings suggest that arhinia/BAMS and FSHD2 do not rep-
resent one phenotypic spectrum and that SMCHD1 mutations alone are insufficient to 
cause either of the two disorders. For FSHD2, a D4Z4 repeat array size in the range of 
1-20 D4Z4 repeat units, but not longer arrays, together with a permissive haplotype are 
known requirements to cause disease. For BAMS a second disease locus has not been 
identified. Both arhinia/BAMS and FSHD2 are most likely caused by complex oligogenic or 
multifactorial mechanisms which only partially overlap at the level of SMCHD1.
Chapter 5 investigates estrogen exposure as a potential disease modifying factor in 
female FSHD patients. Clinical observations and recent in vitro work have suggested a 
protective effect of estrogens on muscle pathology in FSHD. This study reports a clini-
cal approach to the influence of estrogen exposure on disease severity in female FSHD 
patients. We calculated the lifetime endogenous estrogen exposure by subtracting periods 
with high progesterone levels (in which estrogens are counteracted) from the reproduc-
tive life span. Multiple linear regression in 85 patients did not show a contribution of the 
lifetime endogenous estrogen exposure to disease severity (B = 0.063, p = 0.517, ΔR2 = 
0.003). To exclude the possibility that a small effect of estrogen exposure was obscured 
by the large effect of age or D4Z4 repeat array size on disease severity, we repeated the 
analyses with patients stratified in subgroups for age and different repeat array sizes. In 
none of the subgroups an effect of estrogen exposure on disease severity was found (ΔR2 
0.001 to 0.036, all p > 0.05). 
The majority of women reported an unchanged rate of disease progression through peri-
ods of hormonal changes, like menarche, pregnancy or menopause. Women that noticed 
differences reported accelerations as well as decelerations. These results indicate that dif-
ferences in estrogen exposure do not have a clinically relevant modifying effect on disease 
severity. However, a clinically relevant protective effect of greater differences in estrogen 
levels, or a protective effect caused by a more complex interplay with other reproductive 
hormones, cannot be ruled out.
Part III focuses on the development of components of the FSHD ‘clinical trial toolbox’: 
patient registries, biomarkers for structural muscle involvement, and clinical outcome 
measures.
Chapter 6 describes the outcomes of a European Neuromuscular Center workshop on 
‘A global FSHD registry framework’. This workshop emphasized the importance of patient 
registries as valuable instruments to efficiently recruit patients for clinical trials and to 
provide knowledge on many aspects of FSHD to doctors, researchers and patients. World-
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wide there are 13 different FSHD patient registries, including both clinician-centered and 
patient-driven registries, with a total of over 3,000 participants. Since no registry will be 
able to capture data on every aspect of the disease, a core dataset with optional additional 
data collection on specified topics is required. The existing common data set for FSHD by 
Treat-NMD was updated and two items concerning central nervous system involvement 
were added. This data set will aid in standardizing data collection for the various registries 
and thus enable assembly of data globally to create larger data sets. 
Chapter 7 displays the results of a cross-sectional study on quantitative muscle MRI of 
the leg muscles of 140 FSHD patients. We found a distinct pattern of muscle involvement, 
that was similar in patients with FSHD1 (n = 130) and FSHD2 (n = 10). The most often and 
most severely affected muscles were the hamstrings, the adductor muscles, the rectus 
femoris and the gastrocnemius medialis. In patients without any functional involvement 
of the leg muscles, these muscles already showed elevated fat fractions. The tibialis pos-
terior, peroneus and gastrocnemius lateralis were least frequently affected. Asymmetric 
involvement in at least one muscle pair was found in 80.7% (113/140) of all patients. The 
mean fat fraction of the total leg musculature correlated highly with various clinical out-
come measures (the Motor Function Measure ‘MFM’, FSHD clinical score, Ricci score and 
6-minute walking test, correlation coefficients -0.845; 0.835; 0.791; -0.701 respectively).
TIRM hyperintense areas, suggesting muscle inflammation, were found in 3.5% of all mus-
cles, with and without fatty infiltration. Although TIRM-positive areas were often found 
adjacent to fatty infiltrated regions, the muscles that were most frequently TIRM-positive 
were not the same muscles as those that were most severely or frequently fatty infil-
trated. The latter challenges the proposed concept of muscle inflammation preceding 
fatty infiltration.
As quantitative MRI was able to detect subclinical muscle pathology and correlates with 
clinical outcome measures, it is a promising biomarker for FSHD. 
Chapter 8 compares the outcomes of quantitative MRI and quantitative ultrasound as 
biomarkers for the assessment of muscle involvement in leg muscles of FSHD patients. 
Twenty-seven patients were included and ten muscles per patient were analyzed. Images 
were assessed, both quantitatively and visually, for fatty infiltration, fibrosis and edema. 
Both techniques were able to differentiate between degrees of structural muscle changes 
and correlated strongly to clinical severity (FSHD clinical score, MRI R = 0.828, ultrasound 
R = 0.767, p < 0.001).The MRI fat-fraction and ultrasound echogenicity z-score correlated 
strongly to each other (R = 0.865, p < 0.001), but showed different results in approximately 
15% of the muscles measured. Ultrasound detected changes in muscle architecture con-
sistent with intramuscular fibrosis in muscles that looked normal on MRI. In contrast, in 
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muscles that were nearly completely replaced by fat on MRI, ultrasound often failed to 
detect the degree of abnormality. Additionally, MRI was more suitable to assess muscle 
edema. Hence, muscle MRI and ultrasound are complementary and the choice for a par-
ticular technique should be considered in light of the trial design.
Chapter 9 reports a one-year follow-up study on electrical impedance myography (EIM) 
as a potential biomarker for muscle composition in 32 FSHD patients. EIM is a non-inva-
sive technique that measures changes in muscle composition through bio-impedance 
measures and thus provides a quantitative assessment of structural muscle changes. We 
collected EIM data on 7 muscles bilaterally and performed quantitative strength measure-
ments and the ‘timed up and go’ test. 
After 12 months of follow-up, there were no significant changes in the EIM parameters 
for the average of all muscles measured, nor for any of the single muscles. There was a 
small decrease in the quantitative strength measurements for the composite score of all 
muscles measured (composite voluntary isometric contraction strength mean change 
-0.48 kgf, 95%-CI -0.90 to -0.07, p = 0.042), and no change in the strength measurements 
for individual muscles and the timed up and go test. Because of the small or even absent 
change in the clinical outcome measures, it is not possible to definitively conclude if the 
absence of change in EIM parameters was due to limitations of this technology as a lon-
gitudinal biomarker in this population over this period of time versus the possibility that 
EIM is a sufficient tool that detected no change in a clinically relatively static subset of 
patients. One of the EIM parameters, the 50-211 kHz phase-ratio, showed the smallest 
variability of all outcomes used and would therefore potentially permit smaller sample 
sizes of approximately 30 patients per arm to detect a change in a two-armed clinical trial. 
Consequently, assessment of its sensitivity to change in larger cohorts or over a longer 
follow-up period could be considered. 
Chapter 10 assesses the suitability of the ‘Motor Function Measure (MFM)’, a widely used 
ordinal-based generic outcome measure for neuromuscular disorders, to measure FSHD 
patients using Rasch analysis. Ordinal scales only provide a structured order without a 
numerical value. Rasch analysis can be used to transform ordinal scores into interval 
scores with a numerical value. We applied Rasch analyses on the total MFM and its three 
domains (D1: standing position and transfers; D2: axial and proximal motor function; 
D3: distal motor function) and found multiple limitations of the MFM for FSHD, the most 
important being a large ceiling effect and suboptimal sample-item targeting. In general, 
items on the MFM were relatively easy for FSHD patients and there were few items on 
shoulder function, which is often most affected. Disordered thresholds were found for 
most items, indicating difficulty for the examiner to discriminate between the four different 
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response options. As a result, many of these items functioned as if it were dichotomous 
items: for easier items patients were able to complete the exercise either with or without 
compensatory movements, for difficult items patients were either able or not able to per-
form the exercise. We did not succeed in remodeling the MFM into a Rasch-built interval 
scale that sufficiently fit Rasch model requirements, and still being suitable for clinical 
application. As the MFM has multiple limitations for use in FSHD patients, it should be used 
with caution in this patient group. For FSHD, there is a high need for the development of 
disease-specific interval scales on functional abilities for future clinical trials.
Chapter 11 explores the use of quantitative data on strength and fatigability of orofacial 
muscles in FSHD patients. We included 43 FSHD patients and 35 healthy controls and 
used the Iowa Oral Performance Instrument (IOPI) to obtain quantitative measurements 
of strength and endurance of cheek (buccodental) compression and tongue elevation. 
Additionally, we used the dysphagia-specific quality of life (SWAL-QOL) and Communicative 
Participation Item Bank (CPIB) questionnaires to study swallowing and communication 
difficulties, respectively.
Cheek compression strength, a function of multiple facial muscles including the orbicu-
laris oris, was reduced in FSHD patients compared to healthy controls. Tongue elevation 
strength was reduced only in male patients. The endurance measures did not differ 
between patients and controls. Dysphagia and difficulty with verbal communication were 
reported by 25% and 35% of patients respectively, and correlated to cheek compression 
strength and endurance, and to anterior tongue elevation endurance. Therefore, orofacial 
weakness likely contributes to dysphagia and speech difficulties. Long cheek compression 
and tongue elevation endurance, indicating a decreased fatigability of these muscles, 
made swallowing or speech problems unlikely to occur. One could hypothesize that the 
longer endurance is in fact a compensatory mechanism to prevent dysphagia and com-
munication difficulties, especially since studies have shown that endurance of the tongue 
muscles can be improved by training. More research is required for further refinement of 
the pattern of facial muscle involvement in FSHD and to provide new insights for improve-
ment of speech- and language therapy.
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GENERAL DISCUSSION
The central theme in this thesis is the clinical and genetic variability in FSHD. The first 
aim was to identify factors that contribute to clinical variability to provide opportunities 
to increase the understanding of the disease mechanism. The other aim was to over-
come challenges in the design of clinical trials by capturing clinical variability through the 
development of the optimal ‘FSHD clinical trial toolbox’, consisting of patient registries, bio-
markers and outcome measures. Here, the results described in this thesis are discussed 
in the context of other earlier and recent studies. Additionally, the clinical relevance of the 
findings and future research perspectives are explored.
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A MULTIFACTORIAL DISEASE MODEL FOR FSHD 
The findings in this thesis show that with our current knowledge we can only partly explain 
the clinical variability (chapter 3). Additionally, genetic variability appeared to be even larger 
than anticipated (chapter 4). The combination of clinical and genetic variability provides 
arguments that the FSHD phenotype is the result of a complex interplay of many modifying 
factors resulting in a multifactorial disease model.
The increasing complexity in genetic mechanisms
The progress in the field of molecular biology and genetics has extended our knowledge 
on genetic disorders from single mutant genes causing disease to various complex disease 
mechanisms. There are known examples of a single phenotype caused by mutations in 
different genes1, single mutations causing multiple phenotypes2, different mutations in the 
same gene resulting in different phenotypes3, and incomplete penetrance for some muta-
tions suggesting an interplay with other (epi)genetic factors.4 For FSHD, the well-defined 
phenotype and mostly autosomal dominant pattern of inheritance first suggested that 
FSHD was a rare monogenic disorder. However, it has become clear that FSHD is subject to 
several of the complex genetic patterns described above. The FSHD phenotype is caused 
by at least two different genetic mechanisms (FSHD1 and FSHD2)5,6, identical mutations in 
the SMCHD1 gene can cause different phenotypes (FSHD2 and congenital arhinia/Bosma 
arhinia microphthalmia syndrome)7,6, and disease penetrance is incomplete.8,9 Therefore, 
the model of FSHD as a monogenic disorder falls short, and recent findings, including the 
results described in this thesis, favor a complex polygenic model.10 
A polygenic model for FSHD1 
A first clue for a complex pathogenic mechanism was the clinical variability that was 
observed both between and within families long before the FSHD1 locus was mapped 
and genetically defined.11,12 Once genetic testing became available, family studies revealed 
FSHD1 mutation carriers without any sign of the disease at an old age. Thus, disease pen-
etrance was shown to be incomplete. Moreover, over the last few years it became clear 
that FSHD-sized D4Z4 repeat arrays (especially with 7-10 D4Z4 units) on a disease-per-
missive haplotype are carried by 1-2% of the general population.13-15 This high frequency 
suggests that the molecular signature of FSHD1 is merely a precondition for the disease to 
become manifest, rather than a rare highly pathogenic mutation, especially for the D4Z4 
repeat arrays of 7-10 units (figure 1). This fits with the finding in chapter 3 of this thesis 
that the size of the D4Z4 repeat array only accounts for approximately 10% of the clinical 
variability. Thus, although the D4Z4 repeat array that encodes for the DUX4 gene remains 
a key factor in the pathogenic mechanism of FSHD, there must be an interplay with other 
modifying factors that determine the phenotype on an individual level.10 
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This hypothesis is supported by the differences in the degree of influence of the D4Z4 
repeat array on clinical severity and penetrance in various settings. Only symptomatic 
individuals with 7-10 D4Z4 repeat units, and not asymptomatic gene carriers with 7-10 
repeat units or individuals with 1-6 repeat units, were shown to have a greater reduction 
of D4Z4 methylation than could be expected based on the size of the repeat array.16,17 
Therefore, it was hypothesized that the effect of the activity of (D4Z4 chromatin) mod-
ifiers is most relevant in individuals with 7-10 repeat units. However, these studies did 
not include asymptomatic or non-penetrant gene carriers with 5-6 D4Z4 repeat units. In 
chapter 3 of this thesis, it is shown that also for these shorter repeat sizes of 5-6 units, 
the D4Z4 methylation was reduced in symptomatic individuals compared to asymptom-
atic and non-penetrant individuals. Consequently, chromatin modifiers may play a role 
in determining disease penetrance. Still, non-penetrant gene carriers are rare in families 
with D4Z4 repeat arrays of 1-4 units, suggesting that the influence of the D4Z4 locus itself 
may be larger for these short repeat array sizes. Indeed, phenotype-genotype studies 
that showed the strongest correlation between disease severity and repeat length, were 
performed in patients with 1-6 repeat units.18-21,8 
Additionally, we show in this thesis that the influence of the D4Z4 repeat array on clinical 
severity varies across different body regions (chapter 3). The D4Z4 repeat array size had 
a stronger influence on the degree of facial weakness than on upper extremity weakness. 
Leg muscle weakness was hardly influenced by the D4Z4 repeat array size. This suggests 
that the facial muscles might be more sensitive to the influence of the FSHD1 locus itself, 
whereas involvement of the leg muscles seems highly dependent on modifying factors. 
Recent studies suggest a functional relationship between DUX4 and the myogenic Pax3 
and Pax7 homeodomain transcription factors, but not with Pitx2 and Tbx1, and provide a 
theory that facial muscles, that are derived in embryogenesis from Pax3-negative progen-
itors, may be more susceptible to DUX4 damage during development due to the interplay 
with these genes.22,23 Other studies showed that a reduction of FAT1 gene expression, 
one of the largest cadherin molecules in human species, may render individuals more 
susceptible to develop symptoms of FSHD.24,25 As the lowest FAT1 levels were found in 
the earliest and most severely affected muscles, this might indicate that these muscles 
are more sensitive to increased DUX4 levels.24 Although all these findings need to be 
confirmed in additional studies, it is tempting to hypothesize that many genetic variants 
contribute to the FSHD phenotype and its clinical variability (figure 1).
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Figure 1. A polygenic model for FSHD1 
An FSHD-sized D4Z4 repeat array, especially of 7-10 D4Z4 units, on a disease-permissive chromosome 4 has a 
high prevalence (1-2%) in the general population, and its effect on clinical variability is small and differs per body 
region. These findings favor a polygenic disease model, especially for the longer-sized D4Z4 repeat contractions. 
A polygenic mechanism for FSHD2 
The current genetic model for FSHD2 is a digenic model, which requires both a permissive 
4q35 haplotype and a mutation in the SMCHD1 or DNMT3B gene working in trans to modify 
the chromatin structure of the D4Z4 repeat array.6,26 Subsequently, FSHD2 has a digenic 
mode of inheritance, instead of an autosomal dominant mode. 
The recent discovery that SMCHD1 mutations also have a critical role in the pathogenesis 
of Bosma arhinia microphthalmia syndrome (BAMS), sets an argument for the involvement 
of additional disease modifying factors in FSHD2 (and BAMS).7,27 Chapter 4 of this thesis 
shows that identical mutations can give rise to both FSHD2 and BAMS and thus indicates 
that the SMCHD1 mutation by itself is insufficient to cause either of the two disorders. In 
the case of FSHD2, a D4Z4 repeat array size in the range of 1-20 D4Z4 repeat units, but 
not longer arrays, together with a permissive haplotype are known requirements to cause 
disease. For arhinia/BAMS a second disease locus has not been identified. However, both 
525558-L-bw-Mul
Processed on: 30-11-2018 PDF page: 245
General discussion and future perspectives
245
in FSHD2 and in BAMS there is a wide spectrum of disease severity.7,16,28 The nature of the 
SMCHD1 mutation (preserving or disrupting the open reading frame; or the effect on the 
ATPase activity of SMCHD1) may in part explain variability in clinical severity in FSHD2.29 
Mutations with a preserved open reading frame result in lower D4Z4 methylation, which 
was associated with a more severe phenotype.16 Additionally, the size of the D4Z4 repeat 
array is likely to contribute to differences in disease severity.30 Exactly how much of the 
clinical variability in FSHD2 can be explained by these factors, is currently unknown. 
Environmental disease modifiers
While the disease mechanism for both FSHD1 and FSHD2 is likely to include multiple 
genetic factors, the contribution of environmental, lifestyle or organismal factors may be 
an underappreciated aspect of the pathogenic mechanism of FSHD. Because of the lim-
ited influence on clinical variability of the genetic factors known so far, FSHD is probably 
caused by a multifactorial disease model in which additive contributions of genes vary with 
environmental influences.31 The result described in chapter 3 of this thesis that familial 
factors accounted for only 50% of the variance in disease severity, indirectly hints that 
non-genetic factors are likely to play a role in clinical variability. A more direct argument for 
the role of environmental factors is the observed discordance in the disease phenotype 
in monozygotic twins with FSHD.32-35 
FSHD is an epigenetic disease.36 Epigenetics is the study of heritable changes in gene 
expression that do not involve changes to the underlying DNA sequence. For FSHD, 
changes in the D4Z4 chromatin structure control the expression of the DUX4. In contrast 
to the DNA sequence or genomic code that is determined from the moment of concep-
tion, epigenetic changes are dynamic and may change over life under the influence of 
environmental factors.37 Many different environmental exposures have been shown to 
exert an influence on gene regulation, including amongst others pharmaceuticals, toxins 
and pollutants, nutrition, hormones, parental care and exercise.38 
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For FSHD, aerobic exercise may be a disease modifier that causes epigenetic changes. 
Exercise has been shown to cause changes in DNA methylation in healthy individuals.39,40 
A clinical trial on aerobic exercise and cognitive behavioral therapy (promoting an active 
lifestyle) showed that physical activity can decelerate fatty infiltration of leg muscles in 
FSHD patients.41 Although this suggests that exercise may have a beneficial epigenetic 
effect, the effect of exercise on epigenetic changes in FSHD patients, for example D4Z4 
methylation, has not been studied. However, one study found that D4Z4 methylation in 
patients and healthy controls is stable over several years of time.42 This finding has to be 
confirmed by additional studies. 
In this thesis we studied the effect of the lifetime endogenous estrogen exposure on 
disease severity in female FSHD patients (chapter 5). Clinical observations reported in the 
literature and in vitro work suggested a protective effect of estrogens in FSHD.43-45 How-
ever, we did not find an effect of estrogen exposure on disease severity, nor did women 
report decelerations or accelerations of disease progression through periods of hormonal 
changes. It is difficult to determine whether estrogens truly do not have any effect on 
disease severity, or whether there is an effect that only becomes clinically relevant in a 
complex interplay with other factors, for example other reproductive hormones. Addi-
tionally, hormone levels in the human body constantly change over time and a temporary 
effect on disease progression cannot be ruled out. 
The challenges we faced in studying the effect of estrogens will be encountered in nearly 
every study on environmental or physiological disease modifying factors. For factors like 
smoking, nutrition, co morbidities and pharmaceuticals effects may be small, interact with 
other factors and change over time. Although identification of environmental or physio-
logical disease modifying factors may be hard, research on this topic should be continued 
as these factors provide opportunities for potential therapeutic targets. 
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THE FSHD CLINICAL TRIAL TOOLBOX 
In the upcoming years, newly developed drugs are expected to proceed from preclinical 
planning into human trials. Therefore, there is an urgent need for a ‘FSHD clinical trial 
toolbox’, consisting of patient registries, biomarkers and outcome measures. These tools 
are required for the clinical testing of newly developed drugs, which is composed of mul-
tiple phases that each have their own objectives and challenges (box 1). Evaluating the 
usefulness of various available tools for clinical trials on FSHD yields valuable information 
to overcome challenges in clinical trial design, and additionally leads to a deeper under-
standing of the pattern of muscle involvement in FSHD. 
Patient registries
The inability to recruit a sufficient number of participants is an important cause for the 
failure of clinical trials.48 A study from 2015 showed that 481 (19%) out of 2579 trials were 
terminated because of failed accrual or were completed but achieved less than 85% of 
the expected enrolment.48 Although enrolment of patients into clinical trials has not yet 
been an issue in FSHD, researchers agree on the importance of patient registries to effi-
ciently recruit participants for future clinical studies.49 FSHD is relatively rare and especially 
if multiple clinical trials would be initiated simultaneously or within a short time frame, 
insufficient accrual is a potential threat. Additionally, strict eligibility criteria may compli-
cate patient enrolment. Chapter 6 of this thesis shows that only a small proportion of all 
patients is included in one of the 13 FSHD patient registries worldwide. Furthermore, of 
those registered, data are not uniformly collected. Consequently, the value of FSHD patient 
registries could be enlarged by including more patients and using a common dataset as 
proposed in chapter 6. 
Biomarkers
Highly responsive biomarkers that objectively measure a pathogenic process and/or 
response to therapy are required for early phase trials (phase I/II) to accelerate the drug 
development process. A suitable biomarker does not only measure a biological or patho-
genic process, but also correlates strongly to the clinical outcome of interest.50 While 
molecular biomarkers for DUX4 activity in skeletal muscle have been identified51, this thesis 
provides an important step in the validation of three non-invasive biomarkers: quantitative 
muscle MRI, quantitative muscle ultrasound and electrical impedance myography.
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BOX 1 
The drug development process
The drug development process is a time-consuming and expensive process. After a drug-discovery and 
preclinical testing phase that takes approximately 5 years, a limited number of potential compounds is 
selected for clinical testing in humans.46 The clinical testing process is composed of three phases that 
together take approximately 8-9 years, followed by the drug approval and registration process by the 
health authorities.47 Drugs that are found to be unsafe or ineffective during development will not progress 
through all four phases. A less time-consuming approach is to test new uses for existing drugs, a process 
referred to as drug repurposing or repositioning.
Clinical trial phases 
Phase Objectives Dose Participants
I Exploratory: safety, tolerability, 
pharmacological actions
Ascending doses ± 20 healthy volunteers or 
sometimes patients
II Exploratory: short-term safety, side 
effects, and therapeutic efficacy
Therapeutic doses ± 100 patients
III Confirmatory: efficacy and safety 
compared to other therapy or placebo
Therapeutic doses > 100 patients
Drug approval and registration
IV Post-marketing surveillance, long-term 
efficacy and safety
Regular patient care
Together, phase I and II trials are often referred to as ‘early phase trials’. In these phases, biomarkers are 
especially valuable to detect that the drug in development is active on the pathogenic process. When 
these biomarkers are sensitive, they enable a more efficient screening of potential therapies and facilitate 
decisions which therapies should (or should not) proceed to phase III. 
Phase III trials intent to provide the necessary information for evaluating whether the drug can be 
approved and licensed. In most cases, the efficacy and safety of the new drug will be compared to 
placebo or to the current standard treatment using a randomized controlled trial. Clinically meaningful 
outcome measures are required, that reflect the benefit that a therapy has on a patient’s life. As phase 
III trials often include large numbers of participants, patient registries can be especially valuable for 
recruitment of participants.
Once a beneficial effect of the drug is established, data is submitted to the health authorities (EMA in 
Europe; FDA in the United States) to request approval and licensing of the drug. This process can take 
up to 1.5 years, although for some promising therapies that treat a serious or life-threatening condition 
accelerated approval can be applied. 
Phase IV trials take place once the drug has been licensed to evaluate the long-term effects of new 
drugs and treatments over a lengthy period for a greater number of patients, and possibly subgroups 
of patients within the population.
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For quantitative muscle MRI and ultrasound, we established a strong correlation to clinical 
measures at a cross-sectional level (chapters 7 and 8). A head-to-head comparison of MRI 
and ultrasound (chapter 8) showed that the two techniques differ in their ability to detect 
specific structural muscle changes. MRI was better in detecting late stages of fatty infiltra-
tion and was more suitable to assess muscle edema, while ultrasound was able to detect 
changes in muscles that appeared normal on MRI.52,53 Thus, quantitative muscle MRI and 
ultrasound complement each other. These findings not only emphasize that the choice for 
a particular biomarker should depend on the research question and clinical trial design, 
but also led to new hypotheses on the disease process in FSHD muscles. The ultrasound 
changes in muscles that looked normal on MRI were tissue texture changes consistent 
with intramuscular fibrosis.54,55 Muscle biopsies from FSHD muscles that appeared normal 
on MRI indeed frequently showed mild to moderate fibrosis (unpublished data). Although 
the data is cross-sectional, these findings indicate that muscle involvement in FSHD may 
start even before signs of fatty infiltration or edema become apparent on MRI. Additionally, 
the results of the MRI study show that the proposed model in chapter 2 of this thesis in 
which muscle edema precedes fatty infiltration of muscle tissue, is probably more com-
plex. The muscles in which muscle edema was most frequently found, were not the same 
muscles that were most severely or frequently fatty infiltrated. In mildly affected patients, 
fatty infiltrated muscles were more frequently observed than muscle edema. These find-
ings could indicate variation in the pathogenic mechanism, including different durations 
of the phase with muscle edema, areas with edema that reverse to normal muscle tissue, 
and the occurrence of fatty infiltration without preceding edema. Finally, muscle edema 
was found more frequently in male patients, suggesting sex-specific disease differences 
and thus a more complex pathogenic mechanism. 
Electrical impedance myography (EIM) is a different kind of biomarker that uses bioimped-
ance measures to provide a quantitative assessment of structural muscle changes.56 The 
results of a longitudinal EIM study in chapter 9 of this thesis emphasize the slow yet vari-
able disease progression of FSHD and subsequently the need for sensitive biomarkers. 
More importantly, the results show that decreasing the variability of a biomarker or clinical 
outcome measure can dramatically lower the sample size requirements for clinical trials. 
So in the development of biomarkers, attention should be paid not only to sensitivity to 
change, but also to variability. 
Clinical outcome measures
For late phase clinical trials and drug approval clinical outcome measures are required 
that are reliable, valid, highly responsive, easy to use and clinically meaningful. The results 
of a literature search on all non-invasive clinical outcome measures applied in clinical 
research on FSHD, showed that in 125 papers 130 different primary and secondary out-
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come measures were used (unpublished data). When including all variants and modified 
versions of the outcome measures the number increased to over 200 different outcome 
measures. The majority of these outcome measures had not been validated in general 
and almost none had been validated specifically for use in FSHD patients. Consequently, 
there is a lack of uniformity in the use of clinical outcome measures for FSHD and clinical 
researchers tend to chose existing outcome measures which they feel would best suit 
their study. The scales that were used were nearly exclusively ordinal based scales that 
have important clinimetric limitations. Ordinal scores only provide a structured order, but 
do not provide a numerical value as linear scales do. As such, they should not be used for 
parametrical statistical testing.57-60
In chapter 10 of this thesis, we evaluated the measurement properties of the Motor 
Function Measure (MFM) in FSHD patients using Rasch analysis. The Rasch model analyses 
categorical or ordinal data as a function of the trade-off between the patient’s abilities 
and the task difficulty, and can be used to transform the data into an interval scale. The 
MFM was already tested for its validity and reliability according to the classical test theory 
methodology in a cohort comprising the most common neuromuscular disorders, and 
we considered it a potentially suitable scale for use in FSHD patients.61,62 At first glance, 
the scale seemed to adequately capture disease severity as it strongly correlated to other 
outcome measures and biomarkers (chapters 7 and 8). However, a thorough evalua-
tion of the MFM using Rasch analysis revealed important limitations for its use in FSHD 
patients, the most important being a large ceiling effect (chapter 10). Although Rasch 
analysis cannot always solve these limitations (as was the case for the MFM for FSHD), it 
can provide detailed insights into the clinimetric abilities of a scale. The optimal choice 
of outcome measures for a clinical trial is of critical importance to generate meaningful 
data to determine whether a newly developed therapy has a beneficial effect. Therefore, 
each outcome measure should be thoroughly evaluated before it is used. It will never be 
possible to find a single scale that is suited for all studies and all cohorts, irrespective of 
age, sex and many other variables. Instead, the choice for particular outcome measures 
should be driven by the clinical trial design, the research question and the targeted patient 
group. To make this choice, deeper knowledge on nearly all outcome measures used in 
FSHD research will be required. 
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RELEVANT INSIGHTS FOR 
PATIENT COUNSELING AND MANAGEMENT 
The progress in our knowledge on FSHD has also yielded relevant information for patient 
counseling and information provided to patients and their family should be updated and 
refined.
Inheritance 
While in most cases FSHD has an autosomal dominant mode of inheritance, the chance 
for a patient’s offspring to develop (symptomatic) muscle weakness is often less than 50%. 
In FSHD1, especially for the longer sized repeat arrays of 7-10 units, disease penetrance 
is incomplete and up to 30% of family members may remain asymptomatic.8,9 Therefore, 
the finding of an FSHD-sized D4Z4 repeat array in a family member without signs of FSHD 
merely indicates that this individual has a genetic predisposition for FSHD and not neces-
sarily that he/she will develop symptomatic muscle weakness. 
FSHD2 has a digenic mode of inheritance, instead of an autosomal dominant mode, 
which means that two independent genetic changes are necessary to cause muscle weak-
ness.6 Consequently, the chance of passing on the disease depends on the exact genetic 
make-up of both parents.
Clinical variability
Because of the large clinical variability in FSHD both between and within families, the age 
at symptom onset and the severity and progression of muscle weakness cannot be pre-
dicted on an individual level. Approximately 10% of all FSHD patients has an early age at 
onset (facial weakness before the age of five years and scapulohumeral weakness before 
the age of ten years) with severe muscle weakness and frequent extramuscular manifes-
tations including sensorineural hearing loss, retinal vasculopathy, chestwall deformities 
and restrictive lung disease.63 These patients often carry a very short D4Z4 repeat array 
of 1-3 units and have a higher chance of becoming wheelchair dependent at a young age 
(< 30 years).64,65
On the other end of the spectrum, there is a group of patients that is mildly affected and 
not or only minimally limited in their daily activities. Both in the large Dutch FSHD cohort 
described in various chapters of this thesis and in a large Italian cohort, approximately 
30% of symptomatic patients fall into this mildly affected group.66
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In general, disease progression is slow and muscle function gradually declines over multi-
ple years. Both in a natural history study and in the one-year follow-up study described in 
this thesis (chapter 9), progression was hardly notable over one year for most patients.67,68 
Knowledge is currently lacking on the progression of facial weakness, which may be slower 
than progression of limb muscle weakness based on clinical observations. There is still 
a high need for prognostic factors for disease course and severity to facilitate patient 
counseling and clinical management.
Management
Currently, there is no pharmacological treatment available for FSHD. However, interest 
has grown in optimizing symptomatic treatment and improving quality of life. An evi-
dence-based FSHD care guideline was developed by the American Academy of Neurology 
(AAN).69 This guideline focuses on improvement of care for FSHD by providing recom-
mendations regarding diagnostics, predictors of severity, surveillance of extramuscular 
complications and (non-pharmacological) treatments. The main recommendation regard-
ing treatments is to encourage patients with FSHD to engage in low-intensity aerobic 
exercise.69 
Recently, a Dutch FSHD guideline was presented that complements the AAN guideline.70 
For the Dutch guideline, FSHD patients selected the topics with most impact on their lives. 
The guideline focuses on uniform multidisciplinary care to optimize daily functioning and 
quality of life by improving pain, fatigue, and difficulties with mobility and communication.
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FUTURE PERSPECTIVES
The main goals in FSHD research for the upcoming years will be therapy development 
and clinical trial preparedness to efficiently test newly developed therapies.49,71,72 At least 
two pharmaceutical companies have active preclinical programs for targeted treatments 
in FSHD and basic scientists continue to search for potential therapeutic targets. 
While this thesis mainly describes the results of cross-sectional studies, longitudinal data 
will be essential for clinical trial preparedness. Therefore, the data collected on 203 FSHD 
patients at the Radboud University Medical Center will serve as a baseline measurement 
for a 5-year follow-up study. The longitudinal data will reveal the natural history of FSHD. 
The longest clinical FSHD natural history study so far dates from 1997.67 It assessed 81 
patients initially with a follow-up of one (n=50) to three years (n=9) and focused on mea-
suring muscle strength. The American FSHD patient registry includes over 800 patients 
and contains patient-reported longitudinal data up to 14 years of follow-up. Because of 
the extensive data collection at baseline in our current study, disease progression can be 
studied in much more detail including progression on clinical severity scores, functional 
abilities, strength per muscle group or body region, and individual muscles using imaging 
techniques. Additionally, patients can be stratified according to their rate of disease pro-
gression to search for genetic variants that influence disease progression. 
Another major goal of the follow-up study will be to assess the changes over time in bio-
markers and clinical outcome measures. Longitudinal MRI data will be correlated to clinical 
data to determine what increase in muscle fat fraction represents a clinically relevant 
change. Information will be provided on whether muscle inflammation (TIRM hyperinten-
sities) precedes fatty infiltration and if it can be used as a prognostic marker for muscle 
degeneration. Evolvement of muscle ultrasound abnormalities will be assessed as well 
and correlated to clinical measures and MRI. The question will be answered whether the 
muscles that showed abnormalities on ultrasound consistent with intramuscular fibrosis 
progress to fatty infiltration and/or muscle weakness. This will improve our understanding 
of the pathogenic mechanism of FSHD.
The sensitivity to change of all clinical outcome measures that were collected at baseline 
will be assessed, including questionnaires, muscle strength testing, functional tests and 
spirometry. Additionally, based on the baseline data we are developing a questionnaire 
on activity and participation using Rasch analysis. This project is a collaboration with the 
French and United Kingdom FSHD patient registries and subsequently, the questionnaire 
will be available in three languages. The longitudinal study can be used to (further) validate 
this new questionnaire and assess its sensitivity to change.
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Additionally, intensifying international collaborations will be required as clinical trials are 
likely to be conducted as international multicenter studies. Therefore, we will collaborate 
with an international network of 8 academic centers with considerable experience in 
neuromuscular diseases in the USA and Italy on a large natural history study, including 
200 participants with an 18-month follow-up. This study will validate some additional 
clinical outcome measures and test the multisite reliability of various outcome measures. 
Instead of muscle imaging, electrical impedance myography will be included in this study. 
Together with our Dutch 5-year follow-up study this will lead to a wealth of information on 
FSHD including the natural history, clinical outcome measures, biomarkers and disease 
modifying factors. 
Finally, for both therapy development and clinical trial preparedness integrating knowl-
edge of clinical features and the (epi)genetic mechanism will be essential. Because of the 
large clinical and genetic variability of FSHD, it will most likely be necessary to select specific 
patient groups for (testing of) specific therapies. Moreover, because of the different dis-
ease stages in various muscles, the timing of a treatment in the disease course could be of 
great importance. Consequently, researchers will need to integrate clinical and molecular 
research to successfully complete the road to therapies. 
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NEDERLANDSE SAMENVATTING
Facioscapulohumerale spierdystrofie (FSHD) is een erfelijke progressieve spierziekte. 
Hoewel de kennis over het pathogenetisch mechanisme van FSHD de laatste jaren sterk 
is toegenomen, is de variatie in penetrantie van de ziekte, en in beginleeftijd, progressie 
en ernst van de symptomen nog onvoldoende verklaard. Een beter begrip van factoren 
die bijdragen aan deze variatie, zogeheten ziektemodificerende factoren, kan aanleiding 
geven tot nieuwe aangrijpingspunten voor de ontwikkeling van therapieën.
Wanneer er nieuwe therapieën ontwikkeld worden, zullen deze getest moeten worden 
op hun effectiviteit in klinische trials. De klinische variatie is een grote uitdaging bij het 
ontwerpen van klinische trials bij FSHD. Door de meestal langzame doch sterk variabele 
ziekteprogressie zullen naar verwachting grote aantallen patiënten noodzakelijk zijn om 
een effect van een behandeling aan te kunnen tonen. Daarom is een ‘FSHD clinical trial 
toolbox’, bestaande uit patiëntenregistraties, biomarkers en klinische uitkomstmaten, 
nodig om klinische trials zo optimaal mogelijk op te zetten en uit te voeren. Dit proefschrift 
is gericht op het identificeren van ziektemodificerende factoren en op het ontwerpen van 
onderdelen van de FSHD clinical trial toolbox. 
Deel I geeft een uitvoerig overzicht van de klinische en genetische aspecten van FSHD. 
Hoofdstuk 1 beschrijft de klinische karakteristieken van FSHD. Ondanks de grote variatie 
in leeftijd en symptomen ten tijde van manifestatie van de ziekte, familieanamnese en 
ziekteprogressie, is er een aantal (soms subtiele) symptomen en kenmerken die zeer 
karakteristiek zijn voor FSHD. Zoals de naam al suggereert betreft dit veelal symptomen 
van de gelaats- en schoudergordel musculatuur, hoewel ook zwakte van de romp- en 
beenspieren veel voorkomt. Dit hoofdstuk geeft een overzicht van alle karakteristieke 
klinische kenmerken van FSHD om goede en snelle herkenning van deze relatief zeldzame 
ziekte te vergemakkelijken voor de algemeen neuroloog, zodat onnodige aanvullende 
onderzoeken en vertraging in het stellen van de diagnose voorkomen kunnen worden. 
Hoofdstuk 2 verbindt klinische en (epi)genetische bevindingen bij FSHD en beschrijft 
klinische karakteristieken, het pathogenetisch mechanisme en fenotype-genotype relaties. 
Het klinische deel van dit hoofdstuk is gericht op de vooruitgang in beeldvormend 
onderzoek van de spieren en leefstijlinterventies bij FSHD patiënten. Op basis van 
(voornamelijk transversale) onderzoeken naar spier-MRI bij FSHD is een hypothetisch 
model opgesteld waarin vervetting van de spieren voorafgegaan wordt door een fase met 
inflammatie in de spier, waarna er versnelde vervetting van het spierweefsel optreedt. 
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Omdat er op dit moment geen behandeling beschikbaar is voor FSHD, is er grote 
belangstelling voor leefstijlinterventies om de ziekteprogressie te remmen. Twee klinische 
trials hebben een gunstig effect aangetoond van aerobe inspanning en een actieve leefstijl 
op fysieke fitheid. Eén klinische trial is verricht naar antioxidant supplementen (vitamine C 
en E, zink, en selenomethionine), maar er is meer onderzoek noodzakelijk om te kunnen 
bepalen of deze middelen een positief effect op de spieren hebben. 
Ten aanzien van fenotype-genotype relaties bestaat er voor FSHD1 patiënten een grove 
correlatie tussen een kortere D4Z4 repeat lengte en ernstiger symptomen. De variatie 
in ziekte-ernst is echter groot voor alle repeatlengtes en varieert van asymptomatische 
gendragers tot rolstoelgebonden patiënten. Deze grote variatie suggereert dat er 
bijkomende (epi)genetische factoren moeten zijn die de ziekte-ernst mede bepalen. Voor 
FSHD2 is een relatie aangetoond tussen de ziekte-ernst en de mate van methylatie van 
het kortste ziekte-permissieve allel op chromosoom 4. Zowel voor FSHD1 als voor FSHD2 
wordt de ziekte-ernst waarschijnlijk bepaald door een combinatie van de D4Z4 repeat 
lengte in combinatie met de epigenetische status van het D4Z4 fragment. 
Deel II is gericht op potentiële ziektemodificerende factoren. 
Hoofdstuk 3 toont de resultaten van een fenotype-genotype onderzoek. Dit onderzoek 
bij 152 FSHD1 gendragers bevestigt de grove correlatie tussen de D4Z4 repeat lengte en 
de ziekte-ernst (leeftijdsgecorrigeerde ‘FSHD clinical score’, R = 0.40; p = 0.000). Doordat 
diverse deelnemers afkomstig waren uit dezelfde families konden we berekenen dat 
familiaire factoren ongeveer 50% van de variatie in ziekt-ernst (FSHD clinical score) 
bepalen. De verklaarde variatie voor de D4Z4 repeat lengte was beperkt (ongeveer 10%) 
en varieerde per lichaamsregio (gelaatsspieren, bovenste en onderste extremiteiten 
respectievelijk ongeveer 30%, 15% en 3%). Symptomatische patiënten hadden gemiddeld 
een langere D4Z4 repeat lengte dan asymptomatische en non-penetrante gendragers 
(7.3 vs 6.0 units, p = 0.001). Geslacht en de Delta1 methylatie score (D4Z4 methylatie 
gecorrigeerd voor repeat lengte) droegen beiden niet bij aan de variatie in ziekte-ernst. 
Deze resultaten tonen dat we met de huidige (epi)genetische kennis de variatie in ziekte-
ernst bij FSHD1 maar deels kunnen verklaren. Hoewel de D4Z4 repeat lengte en D4Z4 
methylatie bijdragen aan verschillen in ziekte-ernst en penetrantie, zullen er ook andere 
ziektemodificerende factoren betrokken moeten zijn. Deze factoren kunnen (epi)genetische 
factoren betreffen, maar ook fysiologische, omgevings- en leefstijlfactoren. Om deze factoren 
te kunnen identificeren zullen gedetailleerde beschrijvingen van de klinische kenmerken 
noodzakelijk zijn, omdat er waarschijnlijk verschillen bestaan tussen lichaamsregio’s in de 
gevoeligheid voor de invloed van de D4Z4 locus en diverse modificerende factoren. 
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In hoofdstuk 4 wordt een extreem voorbeeld van klinische variabiliteit bestudeerd. Eerder 
onderzoek heeft aangetoond dat identieke missense mutaties in het verlengde ATPase 
domein van het SMCHD1 gen geassocieerd zijn met twee ogenschijnlijk ongerelateerde 
aandoeningen: FSHD2 en Bosma arhinie microphthalmie syndroom (BAMS). BAMS wordt 
gekenmerkt door congenitale arhinie vaak gecombineerd met oogafwijkingen en een 
tekort aan geslachtshormonen (hypogonadotroop hypogonadisme). We onderzochten 
en/of interviewden 14 FSHD2 patiënten en 4 niet-aangedane familieleden met BAMS-
geassocieerde of BAMS-verwante SMCHD1 mutaties op klinische kenmerken van BAMS. 
Geen van de FSHD2 patiënten of familieleden had congenitale afwijkingen of dysmorfe 
kenmerken die passen bij BAMS. Deze resultaten suggereren dat FSHD2 en arhinie/BAMS 
niet twee uiteinden van één fenotypisch spectrum betreffen en dat SMCHD1 mutaties op 
zichzelf onvoldoende zijn om deze ziektebeelden te veroorzaken. In het geval van FSHD2 
is een D4Z4 repeat lengte van 1-20 D4Z4 repeat units op een permissief haplotype een 
voorwaarde om symptomen van FSHD2 te krijgen. Voor BAMS is nog geen tweede locus 
bekend. Waarschijnlijk worden zowel FSHD2 als arhinie/BAMS veroorzaakt door complexe 
oligogene of multifactoriële ziektemechanismen die slechts den dele overlappen op het 
niveau van SMCHD1. 
Hoofdstuk 5 onderzoekt oestrogeenexpositie als een potentiële ziektemodificerende 
factor bij vrouwen met FSHD. Op basis van klinische observaties en recent beschreven 
in vitro experimenten wordt een mogelijk beschermend effect vermoed van oestrogenen 
op spierpathologie bij FSHD. In hoofdstuk 5 wordt een klinische benadering gebruikt 
om de invloed van oestrogeenexpositie op de ziekte-ernst bij vrouwelijke patiënten te 
onderzoeken. We berekenden de levenslange endogene oestrogeenexpositie door 
perioden met hoge progesteronspiegels (waarin progesteron de effecten van oestrogeen 
tegen gaat) af te trekken van de reproductieve periode (menarche tot huidige leeftijd of 
menopauze). Multipele lineaire regressie analyse bij 85 patiënten liet geen effect zien van 
de levenslange oestrogeenexpositie op de ziekte-ernst (B = 0.063, p = 0.517, ΔR2 = 0.003). 
Om uit te sluiten dat een klein effect van de oestrogeenexpositie werd overschaduwd 
door een groot effect van leeftijd of D4Z4 repeat lengte herhaalden we de analyses voor 
subgroepen ingedeeld op leeftijd of repeat lengte. In geen van de subgroepen had de 
oestrogeenexpositie een effect op de ziekte-ernst (ΔR2 0.001 tot 0.036, allen p > 0.05). 
De meerderheid van de vrouwen gaf aan dat de snelheid van de ziekteprogressie 
niet veranderde tijdens periodes met hormonale veranderingen zoals de menarche, 
zwangerschappen of menopauze. Vrouwen die wel een verandering in de mate van 
progressie bemerkten, meldden zowel toename als afname in de snelheid van progressie. 
Deze resultaten laten zien dat verschillen in de mate van oestrogeenexpositie geen 
klinische relevant modificerend effect hebben op de ziekte-ernst. Een klinisch relevant 
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effect van grotere verschillen in de oestrogeenexpositie of een beschermend effect door 
een complex samenspel met andere geslachtshormonen kan op basis van deze studie 
niet worden uitgesloten. 
Deel III is gericht op de ontwikkeling van onderdelen van de FSHD ‘clinical trial toolbox’: 
patiënten registraties, biomarkers voor spieraantasting en klinische uitkomstmaten. 
Hoofdstuk 6 beschrijft de uitkomsten van een werkgroepbijeenkomst van het European 
Neuromuscular Center getiteld ‘A global FSHD registry framework’. Tijdens de werkgroep 
is het belang besproken van patiëntenregistraties als waardevolle instrumenten bij het 
rekruteren van patiënten voor klinische trials en bij het verzamelen van kennis over diverse 
aspecten van FSHD voor dokters, onderzoekers en patiënten. Er bestaan wereldwijd 13 
verschillende FSHD patiëntenregistraties met een totaal aantal deelnemers van meer dan 
3,000. Sommige registraties worden gevuld met data door dokters, andere door patiënten. 
Omdat geen van deze registraties in staat zal zijn om data te verzamelen over alle aspecten 
van de ziekte is een basis dataset noodzakelijk met optionele extra dataverzameling over 
specifieke onderwerpen. De bestaande basis dataset voor FSHD van Treat-NMD is door de 
werkgroep geactualiseerd en twee vragen over centraal zenuwstelsel betrokkenheid zijn 
toegevoegd. Deze basis dataset kan bijdragen aan gestandaardiseerde dataverzameling 
in de diverse registraties en daarmee het combineren van data van meerdere registraties 
wereldwijd mogelijk maken. 
Hoofdstuk 7 toont de resultaten van een transversale studie naar kwantitatieve spier-
MRI van de beenspieren van 140 FSHD patiënten. We vonden een specifiek patroon van 
spieraantasting, dat vergelijkbaar was voor patiënten met FSHD1 (n = 130) en FSHD2 (n 
= 10). De meeste frequent en meest ernstig aangedane spieren waren de hamstrings, 
adductoren, rectus femoris en gastrocnemius medialis. Bij patiënten zonder functionele 
beperkingen van de beenspieren werden in deze spieren regelmatig al verhoogde 
vetfracties gevonden. Het minst frequent aangedaan waren de tibialis posterior, peroneus 
en gastrocnemius lateralis. Asymmetrie in de vervetting van minstens één paar spieren 
werd gezien bij 80.7% (113/140) van de patiënten. De gemiddelde vetfractie van alle 
beenspieren correleerde sterk met diverse klinische uitkomstmaten (Motor Function 
Measure ‘MFM’, FSHD clinical score, Ricci score en 6-minuten wandel test, correlatie 
coëfficiënten -0.845; 0.835; 0.791; -0.701 respectievelijk).
Gebieden met een TIRM hyperintens signaal, passend bij spierinflammatie, werden 
gevonden in 3.5% van alle spieren, met en zonder vervetting. Hoewel TIRM-positieve 
gebieden vaak werden gevonden aangrenzend aan gebieden met vervetting, waren de 
spieren die het meest frequent TIRM-positief waren andere spieren dan degenen die het 
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meest frequent of meest ernstig vervet waren. Deze bevinding pleit tegen de theorie dat 
spierinflammatie altijd voorafgaat aan vervetting. Omdat kwantitatieve MRI in staat is om 
subklinische aantasting van spieren te meten en correleert met klinische uitkomstmaten 
is het potentieel een geschikte biomarker voor FSHD. 
Hoofdstuk 8 vergelijkt de uitkomsten van kwantitatieve MRI en kwantitatieve echografie 
als biomarkers voor het meten van spieraantasting in beenspieren van FSHD patiënten. 
Bij 27 patiënten werden 10 beenspieren per patiënt geanalyseerd. De beelden werden 
zowel kwantitatief als ook visueel gescoord op vervetting, fibrose en oedeem (inflammatie). 
Beide technieken waren goed in staat te differentiëren tussen verschillen in de ernst van 
spieraantasting en correleerden sterk met de ziekte-ernst (FSHD clinical score, MRI R = 
0.828, echografie R = 0.767, p < 0.001). De vetfractie op de MRI en de echogeniciteit z-score 
correleerden sterk met elkaar (R = 0.865, p < 0.001), maar verschilden in hun uitkomst 
bij ongeveer 15% van de gemeten spieren. Echografie detecteerde veranderingen in de 
architectuur van het spierweefsel passend bij intramusculaire fibrose in spieren die er 
normaal uitzagen op de MRI beelden. Echter bij spieren die bijna geheel vervet waren op 
de MRI, onderschatte de echo vaak de mate van vervetting. De MRI was daarnaast meer 
geschikt om oedeem te detecteren. MRI en echografie zijn complementaire technieken 
en de keuze voor één van beiden technieken moet afhangen van de vraagstelling en het 
ontwerp van de klinische trial. 
Hoofdstuk 9 beschrijft een longitudinale studie met een follow-up van 12 maanden naar 
elektrische impedantie myografie (EIM) als een biomarker voor spiersamenstelling bij 
32 FSHD patiënten. EIM is een non-invasieve techniek die de spiersamenstelling meet 
met behulp van bio-impedantie metingen en is daarmee een kwantitatieve maat voor 
structurele veranderingen in de spier. We verzamelden EIM data van 7 spieren bilateraal 
en voerden daarnaast kwantitatieve krachtmetingen en de ‘timed up and go’ test uit. 
Na 12 maanden follow-up waren er geen significante verschillen in de gemiddelde EIM 
parameters over alle gemeten spieren, noch voor de individuele spieren. Er was een 
kleine afname in de kwantitatieve krachtmetingen voor de samengestelde score van alle 
gemeten spieren (verandering in gemiddelde maximale isometrische contractie kracht 
-0.48 kgf, 95%-CI -0.90 tot -0.07, p = 0.042), en geen verandering in de krachtmetingen 
voor individuele spieren of in de ‘timed up and go’ test. Vanwege de kleine of zelfs afwezige 
veranderingen in de klinische uitkomsten is het niet mogelijk om met zekerheid te bepalen 
of het ontbreken van veranderingen in de EIM parameters te wijten is aan de beperkingen 
van deze techniek als longitudinale biomarker of dat EIM een accuraat meetinstrument is 
dat geen verschil mat in een klinisch stabiele subgroep van patiënten. 
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Eén van de EIM parameters, de 50-211 kHz fase-ratio, had de kleinste variabiliteit van 
alle gebruikte uitkomsten waardoor bij gebruik van deze parameter in een klinische trial 
potentieel een kleiner aantal patiënten nodig is om een effect van een behandeling aan te 
kunnen tonen (ongeveer 30 patiënten per behandelarm). Deze bevinding is reden om te 
overwegen de gevoeligheid van EIM als een biomarker om veranderingen te meten over 
tijd nader te onderzoeken in grotere groepen patiënten of over een langere follow-up 
periode. 
In hoofdstuk 10 wordt Rasch analyse gebruikt om de ‘Motor Function Measure (MFM)’, een 
wijd verbruikte ordinale generieke uitkomstmaat voor neuromusculaire aandoeningen, 
te beoordelen op de geschiktheid om patiënten met FSHD te meten. Ordinale schalen 
zoals de MFM geven een rangorde aan zonder een numerieke waarde. Door middel van 
Rasch analyse kunnen ordinale scores getransformeerd worden in interval scores mét 
een numerieke waarde. We voerden Rasch analyses uit op de gehele MFM en op de drie 
afzonderlijke domeinen (D1: staande positie en transfers; D2: axiale en proximale motore 
functie; D3: distale motore functie) en vonden diverse beperkingen van de MFM voor 
FSHD. De belangrijkste beperkingen waren een groot ceiling effect en een onvermogen 
om verschillen in ziekte-ernst met voldoende precisie te kunnen onderscheiden. 
De taken van de MFM waren over het algemeen relatief gemakkelijk voor FSHD patiënten 
en er waren slechts enkele items over de schouderfunctie, die vaak aangedaan is bij 
FSHD. Daarnaast was de onderzoeker bij veel taken bij het scoren niet in staat om een 
onderscheid te maken tussen de 4 antwoordcategorieën. Hierdoor functioneerden 
diverse taken alsof deze dichotoom gescoord werden: voor gemakkelijker taken waren 
patiënten in staat deze uit te voeren met of zonder compensatoire bewegingen, voor 
moeilijker taken waren patiënten wel of niet in staat om deze uit te voeren. 
Het bleek niet mogelijk om de MFM te transformeren tot een Rasch-ontwikkelde schaal die 
voldoet aan de voorwaarden van het Rasch model en tegelijkertijd nog klinisch bruikbaar is. 
Omdat de MFM diverse beperkingen heeft voor het meten van FSHD patiënten moet deze 
uitkomstmaat met de nodige voorzichtigheid gebruikt worden in deze patiëntengroep. Voor 
toekomstige klinische trials is er een grote behoefte aan ziektespecifieke uitkomstmaten 
om functionele beperkingen te meten bij FSHD patiënten. 
Hoofdstuk 11 onderzoekt het gebruik van kwantitatieve metingen van kracht en 
vermoeibaarheid van de orofaciale spieren bij FSHD patiënten. We includeerden 43 FSHD 
patiënten en 35 gezonde controles en gebruikten de Iowa Oral Performance Instrument 
(IOPI) voor kwantitatieve metingen van de kracht en het uithoudingsvermogen van 
compressie van de wang (buccodentale compressie) en elevatie van de tong. Daarnaast 
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gebruikten we de dysfagie-specifieke kwaliteit van leven vragenlijst (SWAL-QOL) en de 
Communicatieve Participatie Item Bank vragenlijst (CPIB) om problemen met slikken en 
communicatie te onderzoeken. 
De kracht van de wangcompressie, een beweging gedreven door diverse faciale spieren 
waaronder de orbicularis oris, was verlaagd bij FSHD patiënten ten opzichte van 
gezonde controles. De tongelevatie was alleen verlaagd bij mannelijke patiënten. Het 
uithoudingsvermogen van de spieren verschillende niet tussen patiënten en controles. 
Dysfagie en problemen met verbale communicatie werden gerapporteerd door 
respectievelijk 25% en 35% van de patiënten en correleerden met wang compressie 
kracht en uithoudingsvermogen, en met het uithoudingsvermogen van de anterieure 
tong elevatie. Het is daarom waarschijnlijk dat orofaciale zwakte bijdraagt aan dysfagie 
en problemen met spreken. Een lang uithoudingsvermogen van wangcompressie en 
tongelevatie, wijzend op een verminderde vermoeibaarheid van deze spieren, maakte 
slik- of spraakproblemen onwaarschijnlijk. Mogelijk is dit lange uithoudingsvermogen een 
compensatiemechanisme waarmee dysfagie en spraakproblemen voorkomen kunnen 
worden, ook gezien de bevindingen in eerdere studies dat het uithoudingsvermogen de 
tongspieren trainbaar is. Er is meer onderzoek nodig om het patroon van betrokkenheid 
van de faciale spieren bij FSHD te verfijnen en om nieuwe inzichten te verkrijgen om 
logopedische behandeling bij FSHD patiënten te verbeteren. 
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